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SUMMARY 
 
 The major hurdle in the development of transdermal route as a versatile drug 
delivery method is the formidable transport barrier provided by the stratum corneum. 
Despite decades of research to overcome the stratum corneum barrier, limited success 
has been achieved. The objectives of this research were to develop and characterize 
two different strategies to overcome the stratum corneum barrier for transdermal delivery 
of biopharmaceuticals and vaccines. In the first strategy, coated microneedles (sharp-
tipped, micron-sized structures) were developed to enable delivery of drugs directly into 
the skin by bypassing the stratum corneum barrier. In the second strategy, instead of 
bypassing the barrier, microdermabrasion was used to selectively abrade stratum 
corneum with sharp microparticles for topical drug application.  
 
Coated microneedles 
 For developing painless microneedles, the first detailed study was performed to 
characterize the effect of microneedle geometry on pain caused by microneedle 
insertions in human volunteers. This study demonstrated that microneedles are 
significantly less painful than a 26-gage hypodermic needle and that decreasing 
microneedle length and numbers reduces pain. 
 Next, the first in-depth study of microneedle coating methods and formulations 
was performed to (i) develop a novel micron-scale dip-coating process, (ii) test the 
breadth of compounds that can be coated onto microneedles, and (iii) develop a rational 
basis to design novel coating formulations based on the physics of dip-coating. 
 Finally, a plasmid DNA-vaccine was coated onto microneedles to immunize mice, 
to provide the first evidence that microneedle-based skin immunization can generate a 
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robust in vivo antigen-specific cytotoxic-T-lymphocyte response using similar, or lower, 
DNA doses on microneedles as when using the gene gun or intramuscular injection. 
 
Microdermabrasion 
 We demonstrated for the first time that microdermabrasion in monkeys and 
humans can selectively, yet completely remove the stratum corneum layer. Using a 
mobile mode of microdermabrasion, an increase in the number of treatment passes led 
to greater tissue removal.  Furthermore, topical application of Modified Vaccinia Ankara 
virus after microdermabrasion induced virus-specific antibodies in monkeys. 
 
 In conclusion, both coated microneedles and microdermabrasion were developed 
to enable delivery of biomolecules into the skin, indicating their potential for transdermal 










CHAPTER 1: INTRODUCTION 
 
1.1 SPECIFIC AIMS 
 Delivery of drugs into the body is often achieved through passive diffusion or 
active transport across body surfaces. The oral route utilizes the gastrointestinal surface 
for this purpose. While the oral route is convenient and relatively safe, in many instances 
it is ineffective, for example due to poor drug absorption or when the patient is 
unconscious and therefore is unable to ingest the medication (Ansel, Allen et al. 1999). 
As an alternative, hypodermic needles, which are more versatile are often used to inject 
drugs into the body. However, the pain (Hamilton 1995; Hanas 2004; Deacon and 
Abramowitz 2006) and safety risks due to transmission of blood borne pathogens like 
HIV and hepatitis B virus from accidental needle pricks or unsafe injection practices 
(Kane, Lloyd et al.; Hauri, Armstrong et al. 2004; Pruss-Ustun, Rapiti et al. 2005), make 
hypodermic needles unpopular. 
 The skin is another body surface that can be used to transport drugs into the 
body for both systemic delivery and immunizations. The bed of capillaries located just 
beneath the epidermal layer is conducive to systemic drug delivery (Braverman 1997; 
Cevc and Vierl 2007) from topically applied drugs. Furthermore, the epidermal dendritic 
cells (Langerhans cells), dermal dendritic cells and the epidermal keratinocytes (Babiuk, 
Baca-Estrada et al. 2000) provide immunological capability to the skin to enable 
generation of robust immune responses. However, only small and lipophilic molecules 
have been effectively delivered across the skin via transdermal patches because the 
skin’s top most layer called the stratum corneum provides a formidable transport barrier 
(Naik, Kalia et al. 2000; Prausnitz, Mitragotri et al. 2004). Many physical and chemical 
approaches have been tested to enhance transdermal drug delivery, but limited clinical 
impact has been achieved from these methods (Prausnitz, Mitragotri et al. 2004). 
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 Recently, micron-sized sharp-tipped structures called microneedles have been 
developed  to enhance transdermal drug delivery by creating micro-pores in the stratum 
corneum (Henry, McAllister et al. 1998). Other variations of microneedles like drug 
coated, drug encapsulated or hollow microneedle configurations have also been tested 
(Prausnitz 2004). Despite the attractiveness of coated microneedles, a detailed 
investigation of the coating process has not been performed. 
 Another approach to deliver biopharmaceuticals into the skin may involve the full-
thickness removal of stratum corneum so that topically applied drugs may easily diffuse 
into the skin. Microdermabrasion is an FDA approved method currently used to treat 
scars and acne by partially abrading the stratum corneum (Spencer 2005). The 
microdermabrasion process has potential to remove the full-thickness of the stratum 
corneum layer, yet no study has demonstrated this. 
 Accordingly, the objectives of this research were to develop and characterize (i) 
drug coated microneedles and (ii) microdermabrasion for transdermal drug delivery. The 
following specific aims were designed to achieve these objectives. 
  
Specific Aim 1: Determine the effect of microneedle design and geometry on pain in 
human volunteers. 
Specific Aim 2: Design, develop and characterize microneedle coating process and 
formulations.  
Specific Aim 3: Determine the ability of DNA vaccine-coated microneedles to generate 
a cellular immune response in vivo.  
Specific Aim 4: Investigate the effect of microdermabrasion parameters on the ability of 




 The outcomes of this doctoral research have potential to significantly impact 
mass immunizations by providing safer and less painful alternatives to hypodermic 
needle-based immunizations. On a broader scale, this research will advance the field of 
transdermal drug delivery by enabling delivery of hydrophilic molecules and large 
molecular weight compounds including proteins, DNA and other biotherapeutics through 
the skin. At a more basic level, results from this research will promote understanding of 
coatings of micro-structures and the effects of microdermabrasion on skin. 
 
1.2 THESIS OUTLINE 
 Background information relevant to this research can be found in Chapter 2. 
Each specific aim is then described in its own separate chapter: Chapter 3 (Specific Aim 
1), Chapter 4 (Specific Aim 2), Chapter 5 (Specific Aim 2, continued), Chapter 6 
(Specific Aim 3) and Chapter 7 (Specific Aim 4). Each chapter on the specific aims is 
complete in itself and the relevant materials and methods pertaining to the specific aim 
are included in the chapter. Overall conclusions of this research are presented in 
Chapter 8 and the recommendations for future work are provided in Chapter 9. 









CHAPTER 2: BACKGROUND 
  
2.1 SKIN ANATOMY AND VASCULATURE 
 Skin is the largest organ in the human body covering about 18,000 cm2 of 
surface area. Its primary function is to prevent entry of harmful substances into the 
human body and to reduce loss of internal body-water to the surroundings. Structurally, 
the skin consists of three main layers, the outermost stratum corneum, the middle viable 
epidermis and the innermost dermis (Figure 2.1). The stratum corneum is about 10-20 
μm in thickness and is made of dead, polyhedral, non-nucleated, protein-rich cells called 
corneocytes. The corneocytes are about 0.5 μm thick and 40 μm in diameter, and about 
15 layers of corneocytes stack one above the other in a staggered arrangement to 
produce a compact layer. The space between the corneocytes is filled with lipids forming 
a tortuous path in between the protein rich corneocytes. Thus, two domains exist in the 
stratum corneum, the protein-rich corneocyte domain embedded in an intercellular lipid-
rich domain (Figure 2.2) (Schaefer and Redelmeier 1996). 
 The viable epidermal layer is 50-100 μm thick and is primarily made up of live 
keratinocytes, which continuously differentiate into corneocytes and replenish the 
stratum corneum layer above. In addition pigmented melanocytes and special dendritic 
cells called the Langerhans cells are also found in the epidermis. Langerhans cells are 
potent antigen presenting cells and are believed to initiate the immune response upon 
the entry of pathogens through the skin (Babiuk, Baca-Estrada et al. 2000; Partidos, 
Beignon et al. 2002; Partidos, Beignon et al. 2003). Vascular network is absent in the 
epidermis. Nutrient exchange occurs by passive diffusion from the lower dermal layer 
through the interstitial fluid, which constitutes about 15% of the total volume of the 
epidermis (Schaefer and Redelmeier 1996). 
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 The dermis is 1-2 mm thick and forms the major bulk of the skin. Dermis is made 








Figure 2.1. Skin anatomy. Histological section of monkey skin stained with hematoxylin and eosin showing 
the three layers of the skin: outermost stratum corneum (SC), middle viable epidermis (Ep) and the 






Figure 2.2. Protein and lipid rich domains of stratum corneum. A schematic of the stratum corneum 
layer showing the protein-rich corneocyte domain and the lipid-rich intercellular domain. 
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cellular components of dermis include fibroblasts, dermal dendritic cells and 
macrophages. The fibroblasts regulate collagen production while the dendritic cells and 
macrophages mediate immune responses. 
 The dermis has a dense vasculature to facilitate nutritional and heat exchange, 
and to regulate the immune response. This vasculature is organized into two major 
horizontal plexus (i.e. networks), one situated at the dermal-subcutaneous junction, and 
the other in the papillary dermis near the epidermal-dermal junction. The two horizontal 
networks are connected by ascending arterioles and descending venules. The upper 
plexus gives rise to dermal capillary loops that form a hairpin loop in the dermal-
epidermal papillae (Figure 2.3). Majority of the vasculature resides in the upper plexus 
about 0.1 mm deep into the skin. This network provides an attractive target for systemic 
transdermal drug delivery, and also plays a role in the clearance characteristic of 




Figure 2.3. Vascular layout of skin. A schematic showing the upper and the lower vascular plexus of the 
skin interconnected with ascending arterioles and descending venules. The capillary loops of the dermal 
papillae arise from the upper plexus. SC: stratum corneum; E: epidermis; A: arteriole; V: venule; F: 
subcutaneous fat. Modified from (Braverman 2000) 
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2.2 BARRIER PROPERTY OF THE SKIN 
 Majority of the skin’s permeability barrier comes from just the top 10-20 μm thick 
stratum corneum layer. The stratum corneum’s unique lipid-rich and protein-rich domain 
structure forms the basis of this tough barrier property. To understand the nature of this 
barrier to transport, the stratum corneum structure may be considered analogous to a 
‘mortar and brick’ structure, with the intercellular lipids mimicking the mortar and the 
corneocytes the bricks. Only the lipid-rich domain forms a continuous phase. To 
permeate through the stratum corneum, any substance must generally either diffuse 
through the tortuous lipid-rich phase taking the intercellular diffusion pathway, or must 
take the transcellular route and diffuse through both the protein-rich corneocyte domains 
and the intervening lipid-rich domains (Figure 2.4). Because the lipid-rich phase forms 
the continuous phase, it is expected to be the preferred route of diffusion. Available 
evidence supports this hypothesis because lipophilic molecules with octanol-water 
partition coefficients between 10 and 1000 show higher permeability through the skin, 
while the hydrophilic molecules show very poor permeability. In addition, extraction of 
the lipid phase from mouse skin by acetone treatment has shown an increase in 
transepidermal water loss, supporting the hypothesis that the lipid phase is a major 
contributor of skin permeability barrier (Schaefer and Redelmeier 1996). 
 The protein-rich phase of corneocytes is also important in maintaining the barrier 
function. The presence of corneocytes disrupts the otherwise continuous lipid-rich phase 
and creates a tortuous path for diffusion by increasing the diffusive path length by 50-







2.3 TRANSDERMAL DRUG DELIVERY 
 The goal of transdermal drug delivery is to enable transport of drugs into the 
systemic circulation through the skin surface. Because of the unique nature of stratum 
corneum’s barrier to transport, compounds with the following physicochemical and 
formulation characteristics have been experimentally found to be favorable for passive 
diffusion through the stratum corneum (Naik, Kalia et al. 2000):  
(i) Aqueous solubility: > 1 mg/ml 
(ii) Lipophilicity : 10 < Ko/w < 1000 , where Ko/w is the octanol-water partition 
coefficient 
(iii) Molecular weight: < 500 Da 
(iv) Dose deliverable: < 10 mg/day 
Because of the narrow class of drugs that can passively diffuse through the stratum 
corneum, currently there are just close to 16 drugs available in the form of transdermal 
patches from the whole compendium of therapeutic drugs (Center for Drug Evaluation 
and Research 2007) . 
 To increase the range of drugs that can be delivered through the skin, a number 








Figure 2.4. Diffusion pathways through the stratum corneum. A schematic showing the intercellular and 
the transcellular diffusion pathways through the stratum corneum. 
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surfactants have been used as chemical enhancers to increase drug permeabilities 
through the stratum corneum either by improving solubility, fluidizing the lipid-rich 
domain or by disrupting the lipid-rich domain (Karande, Jain et al. 2005) . Skin irritation 
limits the use of strong chemical enhancers, and this method has only shown limited 
successes. Physical enhancement methods like iontophoresis (Nair, Pillai et al. 1999; 
Pillai, Nair et al. 1999) and electroporation (Prausnitz, Edelman et al. 1995; Banga and 
Prausnitz 1998; Prausnitz 1999) based on electrical energy, sonoporation based on 
ultrasound effects (Mitragotri and Kost 2004), thermoporation based on radiofrequency 
excitation (Sintov, Krymberk et al. 2003; Birchall, Coulman et al. 2006), and high velocity 
jets based on kinetic energy (Schramm and Mitragotri 2002) have also been investigated. 
These methods are generally limited to a special class of substances, for example, 
iontophoresis is applicable only to charged species; and/or require the use of power and 
equipment, which generally adds expense and complexity to the method (Prausnitz, 
Mitragotri et al. 2004). 
  
2.4 MICRONEEDLES FOR TRANSDERMAL DRUG DELIVERY 
 Micron-sized needles – microneedles - were developed as a hybrid between 
hypodermic needles and transdermal patches to eliminate the pain associated with 
hypodermic needles, and yet, facilitate delivery of a wide range of therapeutic agents 
through the skin, including proteins, DNA and other biopharmaceuticals. 
 Microneedles have been used in four different ways for transdermal drug delivery 
(Prausnitz, Mikszta et al. 2005):  
(i) “poke-and-patch”: creation of micron-sized holes in the stratum corneum by 
piercing solid microneedles into the skin to allow topical application of drugs. 
(ii) “coat-and-poke”: insertion of drug coated microneedles into the skin for drug 
dissolution into the skin. 
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(iii) “poke-and-release”: encapsulation of drug within solid microneedles to enable 
rapid or controlled release upon microneedle insertion into the skin. 
(iv) “poke-and-flow": injection of drug through hollow microneedles into the skin. 
 
2.4.1 Poke-and-patch 
 The first demonstration of the ability of microneedles to enhance permeability of 
the skin was done by poking solid, silicon microneedles into skin in vitro (Henry, 
McAllister et al. 1998). Delivery of compounds including calcein, insulin, bovine serum 
albumin (BSA) and latex nanoparticles as big as 100 nm in diameter has been 
demonstrated with up to 10,000 fold permeability enhancement of the skin (McAllister, 
Wang et al. 2003; Park, Allen et al. 2005; Teo, Shearwood et al. 2005) (Figure 2.5 A-C). 
In addition, delivery of plasmid DNA and lipid-polycation-plasmid DNA has also been 
shown in vitro. Bioactivity was shown using β-galactosidase after delivering it into ex-
vivo human skin kept viable in culture (Chabri, Bouris et al. 2004; Birchall, Coulman et al. 
2005) (Figure 2.5 D). 
 Blood glucose reduction was shown in hairless rats, demonstrating bioavailability 
of insulin after its topical application on skin treated with stainless steel microneedles 
(Martanto, Davis et al. 2004) (Figure 2.5 E). Similarly, delivery of antisense-
oligonuletides has also been shown in hairless guinea pigs. Combination of 
iontophoresis with microneedle pretreatment resulted in 100 fold enhancement of 
antisense-oligonucleotide delivery over iontophoresis alone (Lin, Cormier et al. 2001). 
 Using a related blunt-tipped device called the microenhancer array, strong 
immune response has been generated in vivo against hepatitis B, anthrax and Japanese 
encephalitis (Mikszta, Alarcon et al. 2002; Dean, Alarcon et al. 2005) (Figure 2.5 F). In 
all cases the antigen was first applied on the skin and the microenhancer array was 
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rubbed on the skin to mechanically scrape the stratum corneum and perturb the barrier 
to allow the uptake of the antigen. 
 
 
Figure 2.5. Representative solid microneedles used in poke-and-patch approach. (A) Sharp tipped, 
conical, silicon microneedles 150 μm long with a base diameter of 80 μm (Kaushik, Hord et al. 2001; 
Mikszta, Sullivan et al. 2005). (B) Blunt tipped, cylindrical, silicon microneedles 150 μm long with a base 
diameter of 80 μm (Teo, Shearwood et al. 2005). (C) Bevel tipped, cylindrical, polyglycolic acid microneedles 
600 μm long with a base diameter of 100 μm and a tip diameter of 10 μm (Park, Allen et al. 2005). (D) Sharp 
tipped, cylindrical, silicon microneedles 150 μm long with a base diameter of about 50 μm (Chabri, Bouris et 
al. 2004). (E) Sharp tipped, tapered, stainless steel microneedles 1000 μm long with a base width of 200 μm 
and a thickness of 50 μm (Martanto, Davis et al. 2004). (F) Blunt tipped, pyramidal, silicon microenhancers 




 Drug coated microneedles have been used to deliver drugs and antigens in vivo. 
Desmopressin coated microneedles were used in hairless guinea pigs to show up to 
85% bioavailability (Cormier, Johnson et al. 2004) (Figure 2.6 A-B). In the same animal 
model, strong immune response against ovalbumin has also been generated after 
delivery of ovalbumin from coated microneedle arrays made of titanium (Matriano, 
Cormier et al. 2002; Widera, Johnson et al. 2006). 
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 In another approach, microporous calcium phosphate was coated onto 
acupuncture needle tips and filled with trehalose to help stabilize proteins 
(Shirkhanzadeh 2005). 
 In a different approach, the microneedle substrate was coated rather than the 
microneedles. The substrate coating functioned as a drug reservoir to deliver drug 
through the pores created in the skin by the microneedles. Using this method, in vitro 
delivery of calcein and BSA was shown from chitosan coatings on the microneedle 
substrate (Xie, Xu et al. 2005) (Figure 2.6 C). This method may also be considered a 
variation of the poke-and-patch approach with the drug reservoir attached to the 
substrate of the microneedle array. 
 Coated microneedles have also been used to deliver pilocarpine and other model 
compounds into rabbit eye in vivo (Jiang, Gill et al.). 
 
Figure 2.6. Representative solid microneedles used in coat-and-poke approach. (A,B) Desmopressin 
coated, sharp tipped, arrow-head shaped, titanium microneedles 200 µm long, 170 µm wide at the arrow 
head and 35 µm thick (Cormier, Johnson et al. 2004). (C) Sharp tipped, cylindrical, silicon microneedles 130 




2.4.3 Poke-and release 
 Instead of coating drugs onto microneedles, the drug can also be encapsulated 
in the matrix of the microneedles, and released by its dissolution or degradation in the 
skin. Based on this approach, sodium salicylate and ascorbate-2-glicoside was 
encapsulated in maltose needles. Rapid dissolution of maltose microneedle in less than 
5 min was shown in human skin in vivo (Miyano, Tobinaga et al. 2005) (Figure 2.7 A). 
Similarly, erythropoietin (Ito, Yoshimitsu et al. 2006) and insulin delivery (Ito, Hagiwara et 
al. 2006) was shown in mice skin in vivo with millimeter scale needles made of a 
dissolvable matrix of dextrin. 
 Instead of rapid release, the matrix can be designed to provide a controlled 
release. Microneedles made from a biodegradable polymer, polylactic-co-glycolic acid 
(PLGA) have been fabricated to encapsulate calcein, BSA and microparticles (Figure 2.7 
B-C). Controlled release over hours to months was demonstrated in vitro depending on 
the encapsulation formulation (Park, Allen et al. 2006). These needles can be easily 





Figure 2.7. Representative solid microneedles used in poke-and-release approach. (A) Maltose 
microneedles 500 μm long encapsulating 10 wt% calcein as a model drug (Miyano, Tobinaga et al. 2005). 
(B) Bevel tipped, cylindrical PLGA microneedles 600 μm long encapsulating calcein within their tips (Park, 
Allen et al. 2006). (C) PLGA microneedle with its tip chipped to expose microparticles encapsulated inside 
the microneedle (Park, Allen et al. 2006). (D) A complete 20 × 10 array of polymer microneedles made of 




 Hollow microneedles have been fabricated using silicon, metal and glass as the 
materials of construction. Using hollow microneedles, insulin and diclofenac was 
delivered to rats in vivo (Gardeniers, Luttge et al. 2003; McAllister, Wang et al. 2003) 
(Figure 2.8 A). Another study demonstrated microneedle injection of methyl nicotinate in 
human subjects using silicon hollow microneedles (Sivamani, Stoeber et al. 2005) 
(Figure 2.8 B). Microneedle injections have been precisely made in the epidermis and 
into the dermis at controlled depths, which can be useful dermatological, vaccine and 
research purposes (Wang, Cornwell et al. 2006).  
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 Additional research into the fluid dynamics of injection into the skin has helped to 
show that the primary resistance to microinjection into the skin does not reside in the 
microneedles, but it is offered by the tissue (Martanto, Baisch et al. 2005). Partial 
retraction of inserted microneedles has been shown to increase the injection flow rates 
by up to 10 fold (Martanto, Moore et al. 2006b) (Figure 2.8 C). Mechanistically, retraction 
allowed the skin to regain its uncompressed state and increased the skin fluid 
conductivity as compared to its compressed state that was created during microneedle 
insertion (Martanto, Moore et al. 2006a). Insulin delivery has also been shown in vivo 
using passive diffusion through hollow microneedles (Davis, Martanto et al. 2005) 
(Figure 2.8 D). 
 Using small hypodermic needles measuring 1 – 3 mm in length, mice and rabbits 
have been vaccinated against anthrax (Mikszta, Sullivan et al. 2005) and non-human 
primates against Japanese encephalitis (Dean, Alarcon et al. 2005). Dose sparing of 
vaccine for influenza virus and strong immune response has been shown in rats upon 
delivery of either a whole inactivated influenza virus, a trivalent split-virion human 
vaccine, or a plasmid DNA encoding the influenza virus hemagglutinin (Alarcon, Hartley 
et al. 2007)  (Figure 2.8 E-F). 
 Hollow microneedles have also been used for diagnostic applications like 
withdrawing blood (Tsuchiya, Nakanishi et al. 2005) and extracting interstitial fluid for 
glucose monitoring (Smart and Subramanian 2000). Microneedles have also been 






Figure 2.8. Representative hollow microneedles used in poke-and-flow approach. (A) Hollow, silicon 
microneedles 350 µm long with a 70 µm-wide bore (Gardeniers, Luttge et al. 2003). (B) Hollow, silicon 
microneedles 200 µm long with a lumen diameter of 40 µm (Sivamani, Stoeber et al. 2005). (C) Hollow, 
glass microneedle with a tip opening effective radius of 30 µm (Martanto, Moore et al. 2006b). (D) Hollow, 
metal microneedles 500 µm long shown next to a 27-gauge hypodermic needle (Davis, Martanto et al. 
2005). (E) Hollow, metal microneedle 2 mm long assembled onto a hypodermic syringe and (F) pierced 







 Because microneedles are often made of metals and have micron sized 
dimensions, mechanical methods of polishing will not be suitable to clean the surfaces. 
Therefore, electropolishing is of interest for metal microneedle fabrication. Anodic 
dissolution of metal to produce deburred, bright and passivated metal surfaces is called 
electropolishing. Electropolishing can clean and polish the microneedle surfaces and 
sharpen the microneedle tips. To electropolish a metal, a direct positive current is 
applied to it with an appropriate cathode and an electropolishing solution (Landolt 1987). 
Cardiovascular stent is an example of a medical device that is electropolished to 
improve its surface finish (Figure 2.9). 
 
 
Figure 2.9. Electropolished cardiovascular stent. Example of a cardiovascular stent electropolished to 
produce a smooth and bright surface: (A) entire stent and (B) outer surface (Raval, Choubey et al. 2004). 
 
 
Electropolishing is thought to occur because of mass transfer limited anodic dissolution 
of the metal. As the applied voltage across the anode and the cathode increases, the 
current flowing through the cell increases. However, at a limiting current density the rate 
of metal ion formation exceeds the rate at which the metal ions can diffuse into the bulk 
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of the solution and causes the current density to plateau (Figure 2.10 A). At this diffusion 
controlled stage, an anodic film gets formed, comprising of a saturated metal ion layer 
and a thin salt film adjacent to the metal surface. This anodic film has a higher electrical 
resistance than the bulk of the solution and can therefore control the erosion of the 
anodic metal surface. Because the anodic film has a regular thickness, the raised peaks 
of the surface roughness features of the metal protrude more into the anodic film and 
provide a path of lower resistance to the flow of current (Figure 2.10 B). Thus, the peaks 
get eroded faster than the valleys and lead to the electropolishing effects of deburring 
and a bright finish of the metal surface (Hahn and Marder 1988; Datta, Vega et al. 1992). 
 
 
Figure 2.10. Mechanism of electropolishing. (A) Polarization curve of a standard electropolishing system 
showing the current plateau at the limiting current – Ilimiting when the anodic film is formed because of 
diffusion controlled rate of reaction. (B) A schematic of an anodic surface showing the peaks and valleys of 
the surface roughness, the anodic film, the bulk solution and the diffusion distances Y1, Y2 and Y3 that the 
ions have to travel to reach the bulk solution. Lower diffusion distances of the peaks cause them to erode 






 Different coating methods are practiced to form solid coatings on surfaces on a 
macro scale, for example, roll coating, spin coating, slot coating and dip coating 
(Weinstein and Ruschak 2004). To form drug coatings on microneedles, dip coating is 
an attractive method because it is a relatively simple method of forming liquid films on a 
solid substrate for solidification into solid coatings. Conventional batch dip coating 
processes consist of the following steps (Scriven 1988) (Figure 2.11 A-C ) : 
(i) Immersion: A solid substrate to be coated is immersed into a container filled 
with the coating solution. 
(ii) Withdrawal: The solid substrate is removed from the coating solution at a 
constant speed. Because of the viscous drag, the withdrawal of the substrate 
initiates an upward flow in the coating solution at the substrate boundary. The 
thickness of the liquid film carried by the substrate depends on the balance 
between the viscous drag force, gravity and surface tension. A high 
withdrawal velocity and coating solution viscosity and low surface tension 
lead to thicker liquid films on the substrate. 
(iii) Drainage and evaporation: After withdrawal, the excess liquid from the 
substrate is allowed to drain away under gravity. The solvent from the liquid 
film is then allowed to evaporate to form a solid coating on the substrate. 
Depending upon the volatility of the solvent, evaporation may begin as soon 





Figure 2.11. Dip-coating process. A schematic showing the steps involved in dip coating: (A) immersion of 
a substrate into a container containing the coating solution, (B) startup of substrate withdrawal from the 
coating solution, and (C) drainage of excess liquid film and evaporation of the volatile solvent to eventually 
result in a solid coating. 
 
 
2.6.1 Thermodynamic wetting 
 To form a uniform solid coating on the substrate, the liquid film must in turn 
uniformly spread on the solid substrate. Based on the thermodynamics of wetting, the 
condition for a liquid to completely wet a solid surface can be determined from the 
Young’s equation. The Young’s equation reflects a balance of the surface forces acting 









 Young’s equation : cos(θ) = (γs,v - γs,l) / γl,v 
 
θ = contact angle
γs,v = solid-vapor surface energy
γs,l = solid-liquid surface energy








Figure 2.12. Static thermodynamic wetting. A schematic of a liquid drop stationary over a solid surface 




For a liquid to completely wet the solid, the contact angle must be zero. Therefore, 
based on the Young’s equation, the liquid surface tension must be equal or less than the 
solid surface energy (Stokes, Evans et al. 1997). 
 
2.6.2 Dynamic wetting 
 The thermodynamic criterion of wetting is applicable only to systems at 
equilibrium. Because the dip coating process is a dynamic process, a uniform liquid film 
can still be formed on the substrate from liquids that do not completely wet the substrate. 
This can be achieved by relying on the viscous drag and the inertia of withdrawal of the 
substrate. Thus, a high velocity of the substrate and a high solution viscosity, which 
increase the viscous drag force and the inertia of the substrate, can be used to form a 
uniform liquid film on the substrate even from partially wetting liquids.  
 Using this method, a solid coating can be formed even from partially wetting 
liquids by first forming a liquid film on the substrate, and then accelerating the solvent 
evaporation to solidify it into a solid coating before thermodynamic dewetting can occur. 
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 Instead of bypassing the stratum corneum layer to deliver drugs across it, the 
stratum corneum layer can alternatively be selectively removed to deliver drugs topically, 
to the epidermis beneath it. Microdermabrasion, which uses microparticles to abrade the 
skin for cosmetic applications like improvement of acne, scars and photoaging (Spencer 
2005) has the potential to perform the selective removal of just the stratum corneum. In 
microdermabrasion, the abrasive action is achieved by impinging aluminum oxide or 
other abrasive particles on the skin and removing them under vacuum. The particles are 
irregularly shaped and have sharp edges that can mechanically damage the surface of 
the skin using the kinetic energy of their motion. Microdermabrasion procedure is 
performed manually by moving a handpiece on the skin surface. Abrasive particles enter 
the handpiece under vacuum through a tubing connected to a container filled with clean 
abrasive particles, and exit through a separate tubing connected to a waste container 
(Figure 2.13). 
 Microdermabrasion is used to remodel the skin through a partially known 
mechanism. Studies have shown that microdermabrasion causes partial abrasion of the 
stratum corneum, though complete stratum corneum removal is not typically achieved 
(Spencer 2005). Biological effects like erythema, dermal edema, vasodilation and 
perivascular inflammation have been reported after microdermabrasion (Freedman, 
Rueda-Pedraza et al. 2001). 
 Microdermabrasion also has potential for transdermal drug delivery. 
Transepidermal water loss in human subjects has been shown to increase significantly 
24 h after microdermabrasion (30 g/m2/h) as compared to the baseline value (20 g/m2/h), 
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which returned to normal levels 7 days later (Rajan and Grimes 2002). A similar result 


















Figure 2.13. Principle of microdermabrasion. A schematic of a microdermabrasion handpiece in contact 
with the stratum corneum (SC) showing the impingement of abrasive particles on to the skin surface leading 
to its mechanical damage and removal. Ep: epidermis, De: dermis. 
 
 
in another human study, though the recovery was observed just 1 day later (Song, Kang 
et al. 2004). Delivery of estradiol was shown through through freshly excised hairless 
mouse sking using diffusion cells experiments (Fujimoto, Shirakami et al. 2005). In this 
study majority of microdermabrasion conditions led to only a partial removal of the 
stratum corneum, and yet demonstrated enhanced delivery as compared to normal skin.  
 In a related approach called microscission, microparticles were accelerated on to 
the skin under pressure instead of a vacuum, to create microconduits in the skin of 
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human subjects. Lidocaine delivery and blood glucose measurement was demonstrated 








 The purpose of this study was to design microneedles that minimize pain. This 
study tested the hypothesis that microneedles cause significantly less pain than a 26-
gage hypodermic needle, and that decreasing microneedle length and the number of 
microneedles reduces pain in normal human subjects. Single microneedles with lengths 
ranging from 480 to 1450 μm, widths from 160 to 465 μm, thicknesses from 30 to 100 
μm and tip angles from 20° to 90°; and arrays containing 5 or 50 microneedles were 
inserted into the volar forearms of ten healthy, human subjects in a double-blinded, 
randomized study. Visual analog scale pain scores were recorded and compared to 
each other and to the pain from a 26-gage hypodermic needle. All microneedles 
investigated were significantly less painful than the hypodermic needle with microneedle 
pain scores varying from 5 to 40% of the hypodermic needle.  Microneedle length had 
the strongest effect on pain, where a three-fold increase in length increased the pain 
score by seven fold. The number of microneedles also affected the pain score, where a 
10-fold increase in the number of microneedles increased pain just over two-fold. 
Microneedle tip angle, thickness and width did not significantly influence pain. In 
conclusion, this study demonstrated that microneedles are significantly less painful than 
a 26-gage hypodermic needle over the range of dimensions investigated, and that 
decreasing microneedle length and number of microneedles reduces pain. 
                                                 
1 This work was done in collaboration with Dr. Donald Denson at the Center for Pain Medicine, 




 Micron-scaled needles, i.e., microneedles, have been developed as a hybrid 
approach between transdermal patches and hypodermic needles to overcome the 
individual limitations of injections and patches, and to create a minimally invasive and 
less painful method of transdermal drug and vaccine delivery (Prausnitz 2004). A major 
limitation of hypodermic needles is the pain and risk of infection from bloodborne 
pathogens. Pain from needle insertion leads to distress and poor patient compliance 
(Hanas 2004), and in extreme cases can produce needle phobia, which is characterized 
by fear, anxiety and vasovagal reaction that can lead to fainting or sometimes even 
death (Hamilton 1995; Nir, Paz et al. 2003; Deacon and Abramowitz 2006). Furthermore, 
the hazardous practice of needle reuse found predominantly in developing countries 
puts millions of people at risk. In the year 2000, an estimated 40% of the 16 billion 
injections administered worldwide were from reused needles, which led to an estimated 
21 million, 2 million and 260,000 new cases of hepatitis B, hepatitis C and HIV infections, 
respectively (Hauri, Armstrong et al. 2004). 
 To eliminate the pain and risk associated with hypodermic needles, transdermal 
drug patches have been developed (Prausnitz, Mitragotri et al. 2004). However, 
transdermal delivery is currently limited in scope because of the formidable transport 
barrier provided by the stratum corneum (Prausnitz, Mitragotri et al. 2004).  Because of 
this barrier, the 16 drugs that exist as transdermal patches are all small and lipophilic 
molecules with low dose requirements (Prausnitz, Mitragotri et al. 2004). 
 In a synergistic approach, microneedles assembled on a patch have been 
successfully used to deliver a variety of large and hydrophilic compounds into the skin. 
In vitro delivery of small molecules like calcein and large compounds like proteins, DNA 
and  nanoparticles has been shown (McAllister, Wang et al. 2003; Chabri, Bouris et al. 
2004; Gill and Prausnitz 2007b). In vivo delivery has been shown for insulin (Martanto, 
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Davis et al. 2004) and vaccines, for example, against influenza and hepatitis B (Mikszta, 
Alarcon et al. 2002; Alarcon, Hartley et al. 2007). 
 Excitement about microneedles is based in part on the expectation that they 
cause less pain than hypodermic needles. However, this expectation has not been fully 
validated. Only one study has formally measured the pain caused by microneedles in 
human subjects. It found that insertion of 400 microneedles measuring 150 μm in length 
was painless as compared to a 2-mm deep insertion of a 26-gage hypodermic needle 
(Kaushik, Hord et al. 2001). In a related study, scraping the skin with microneedle-like 
structures measuring 50-200 μm in length was similarly found to be painless (Mikszta, 
Alarcon et al. 2002). However, no study has examined the pain caused by microneedles 
in detail or determined how microneedle geometry influences pain. Addressing this issue 
is important because larger microneedles are stronger, can deliver more drug, and are 
generally easier to handle, but are expected to cause more pain. Design of an effective 
microneedle drug delivery system that minimizes pain requires a quantitative 
understanding of the dependence of pain on microneedle geometry. 
 Therefore, as the first study to examine the relationship between pain and 
micron-scale trauma to the skin, this study investigated the influence of microneedle 
design on pain by fabricating microneedles over a broad range of dimensions by varying 
microneedle length, width, thickness, tip angle and number of microneedles in an array; 








3.2 MATERIALS AND METHODS 
 
3.2.1 Fabrication and assembly of stainless steel microneedles 
 Using methods described in detail previously (Gill and Prausnitz 2007a), 
microneedle geometries were first drafted in AutoCAD software (Autodesk, Cupertino, 
CA, USA) and then cut into 50, 75 or 125 μm thick stainless steel sheets (Trinity Brand 
Industries, SS 304; McMaster-Carr, Atlanta, GA, USA) using an infrared laser 
(Resonetics Maestro, Nashua, NH, USA). Single, in-plane microneedles (microneedle 
shafts oriented parallel to the base substrate) were fabricated in different geometries and 
thicknesses. ‘Out-of-plane’ microneedles (shafts bent at 90° to the base substrate) were 
fabricated as two-dimensional arrays after manually bending microneedles 
perpendicularly out of the plane of their base substrate. To deburr and clean 
microneedle edges and to make the tips sharp, microneedles were electropolished, 
washed under running water, dried using compressed air, and stored in air-tight 
containers until further use. 
 For insertion into skin, single microneedles were firmly held in slots axially cut 
through the flat ends of teflon rods (3 mm diameter, McMaster-Carr) and clamped using 
a one-piece shaft collar (McMaster-Carr). Out-of-plane microneedles were assembled 
into adhesive patches using methods described in detail previously (Gill and Prausnitz 
2007a). Briefly, out-of-plane microneedle arrays were attached to a single-sided medical 
foam tape (TM9942, MACtac, Stow, OH, USA) and a perforated, double-sided, poly-
ethylene-terephthalate carrier tape (63.5 μm thick; T04314A, MACtac) was then 
attached on top of the array with the microneedles passing through the perforations. The 
final patch had an adhesive layer surrounding the microneedles to hold the microneedles 
firmly against the skin after insertion. All the microneedles were assembled in a laminar 
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flow hood for cleanliness. The final microneedle-teflon rod assemblies were autoclaved 
and the microneedle adhesive patches were ethylene oxide sterilized (AN 74j, Andersen 
Sterilizers, Haw River, NC, USA) before use. 
 
3.2.2 Pain study design 
 
3.2.2.1 Range of microneedle dimensions 
 Microneedle length, width, thickness, tip angle (Figure 3.1) and the number of 
microneedles were independently varied over a wide range to determine their influence 
on pain in human subjects. The following microneedle dimensions were investigated. 
Microneedle length: 480, 700, 960 and 1450 μm; microneedle tip angle: 20°, 55° and 
90°; microneedle width: 160, 245 and 465 μm; microneedle thickness: 30, 45 and 100 
m; and the number of microneedles: 5 and 50. A 5-mm deep insertion of a 26-gage 
(outer diameter: 460 μm) hypodermic needle was used as a positive control for 
comparison with all the different microneedle insertions. The flat tip of a teflon rod 
pressed against the skin served as a negative control to account for possible pain 













Figure 3.1.  Schematic of microneedle dimensions. Typical geometry and characteristic dimensions of 
length, width, thickness and tip angle investigated during the pain study. 
 
  
 Because microneedle dimensions decrease from their AutoCAD design values 
during the laser cutting and electropolishing steps of the fabrication process, the final 
dimensions of the microneedles after fabrication were visually measured (n=5 for each 
dimension configuration) using a stereomicroscope (SZX12, Olympus America, Melville, 
NY, USA) and a precision micropositioning stage that was equipped with a digital 
readout display (Boeckeler Instruments, Tucson, AZ, USA). On average, the variability in 
the dimensions of the fabricated microneedles was low with a mean standard deviation 
of about 5% (range: 1 to 15%) for all the microneedle geometric parameters. 
 
3.2.2.2 Statistical design 
 The study was carried out using the within-subject repeated measures design. In 
this design, all the subjects in a study received identical treatments, which allows for 
comparisons within the subjects, such that every subject acts as his or her own control 
(Neter, Kutner et al. 1996). To avoid carryover effects (i.e. influence of previous 
insertions) caused by too many insertions on a subject during a single session, the study 
was conducted in two stages. Each stage consisted of 10 subjects. The different 
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microneedle dimensions to be studied were divided between the two stages. In stage I, 
the effects of microneedle length and microneedle tip angle were investigated (Table 
3.1); and in stage II, the effects of microneedle numbers, thickness and width were 
investigated (Table 3.1). All insertions were performed in triplicate for every subject. 
 
3.2.2.3 Randomization for bias reduction 
 To reduce investigator bias and subject preconceived bias to hypodermic needle 
pain, the subjects and the two investigators performing the study were blinded to the 
type of microneedle being inserted. Further, the location of insertions on the forearms 
was also randomized. This was done by stamping rectangular grids of dots onto the 
subjects’ volar forearms using a custom-designed rubber stamp (Dixie Seals and 
Stamps, Atlanta, GA, USA) to demarcate 40 treatment sites, and then randomly 









3.2.2.4 Volunteer recruitment  
 Normal human subjects were recruited from the student and staff population at 
the Georgia Institute of Technology (Atlanta, GA, USA). Allergy to stainless steel was 
used as the subject exclusion criteria. In addition, individuals conducting research with 
microneedles were excluded from the study to reduce subject bias. The use of human 
subjects in the pain study was approved by the Institutional Review Boards at the 
Georgia Institute of Technology and Emory University. There were three males and 
seven females (18 to 40 years of age) in each stage of the pain study, with four subjects 
common to both stages of the study. 
 





















* Positive control used in both the stages of the pain study.
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700 ± 20 45 ± 5
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5 mm deep insertion of a 26 gage hypodermic needle
55°160 ± 10 45 ± 5




3.2.2.5 Insertion protocol 
 Upon receiving written consent of the subjects, the forearms of the subjects were 
cleaned using isopropanol swabs (Becton and Dickinson, Franklin Lakes, NJ, USA). 
Next, the rubber stamp was stamped on the forearms of the subjects. Subjects were 
then introduced to the use of the visual analog scale (VAS). Throughout the study, the 
same investigator performed the insertions and the same second investigator performed 
the pain score measurement. 
 Insertions were performed manually on the volar forearms of the subjects with a 
gap of at least 30 s between insertions. All treatment sessions began with the insertion 
of a microneedle (55° tip angle, 700 μm long, 160 μm wide and 45 μm thick), a negative 
control teflon rod and a positive control hypodermic needle, in that order, to help the 
subjects understand the use of the VAS and calibrate their responses to the range of 
sensations to be encountered. The remaining insertions were then performed according 
to the randomized sequence for each subject, and pain scores were recorded. Insertion 
sites were visually examined to note signs of skin reaction. If bleeding was observed 
after hypodermic needle insertions, a cotton swab dipped in isopropanol was 
immediately applied to stop the blood flow. 
 Upon completion of the insertions, the dot-grid was removed using isopropanol 
swabs. The subjects were contacted after 24 h to check for any adverse sensations or 
reactions during that period. 
 
3.2.2.6 Measurement of visual analogue pain scores 
 Each subject was presented with a ruler containing a 100-mm slot with “No Pain” 
written at the left end and “Worst Pain” at the right end. There were no other markings 
visible to the subject.  Immediately after each insertion, the blinded subjects were asked 
to move the slider to the place along the slot that best described his or her pain.  The 
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blinded observer recorded the location of the slider along the slot in millimeters, which 
was visible on the back side of the ruler. 
 
3.2.2.7 Staining of insertion sites 
 To validate penetration of microneedles into the skin after insertion, three 
randomly-selected microneedle insertion sites on each subject of stage II of the pain 
study were stained with gentian violet (2% solution, Humco, Texarkana, TX, USA), a 
violet-colored topical antifungal agent that preferentially stains sites of microneedle 
penetration into skin, even after cleaning the skin with isopropanol.  To prevent bias 
during insertion for sites to be stained, the investigator performing the insertions was 
blinded to the random sites requiring staining. Upon completion of all insertions, images 
of the stained sites were collected using a digital camera (DMC-TZ3S, Panasonic, 
Secaucus, NJ, USA). 
 
3.2.3 Statistical analysis  
 VAS pain scores were analyzed for statistical significance using parametric tests 
on the basis of a previous study, which found no significant differences in conclusions 
between parametric and non-parametric tests analyzing VAS pain scores, even when 
the data were not normally distributed (Dexter and Chestnut 1995). 
 For each subject, average raw VAS pain scores (based on triplicate 
measurements) for each microneedle geometry were calculated and then normalized to 
the average raw hypodermic needle pain score to account for the variability in a 
subject’s perception of hypodermic needle pain and thereby provide a common 
reference point. Because all the negative controls had a VAS score of zero (no pain), no 
adjustment to the raw VAS scores was necessary to account for pain caused by the 
microneedle insertion device.  The percentage of subjects reporting painless insertions 
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(i.e., VAS = 0) for each microneedle geometry was also reported. Box plots for raw and 
normalized VAS pain scores were plotted to show the range and variation of the pain 
scores across the subjects (Minitab, ver. 15, State College, PA, USA). 
 To identify if the microneedles and the 26 gage hypodermic needle produce 
significantly different pain sensations, an omnibus F-test was conducted for each stage 
of the pain study using the raw (unaveraged) VAS pain scores of all the microneedle 
configurations and the 26 gage hypodermic needle (repeated measures ANOVA test, 
NCSS, Kaysville, Utah, USA), where p<0.05 was considered statistically significant. 
When Mauchly’s test indicated that the compound symmetry assumption used in this 
test was invalid, the lower bound F-statistic was calculated and the corresponding 
corrected p-value was reported. Finally, Tukey’s multiple comparison test was used to 
identify microneedle configurations significantly different in pain level from the 
hypodermic needle. 
 To compare pain levels amongst different microneedle designs, the normalized 
VAS pain scores for each microneedle geometry were statistically tested using the 
repeated measures ANOVA method (NCSS), where p<0.05 was considered statistically 





3.3.1 Microneedle fabrication and insertion into skin 
 Microneedles were fabricated with a range of geometries in order to compare 
pain between microneedles and a hypodermic needle, and to quantify differences in pain 
resulting from different microneedle designs. To determine the effect of microneedle 
geometry, single microneedles of different lengths (Figure 3.2 A), widths (Figure 3.2 B), 
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tip angles (Figure 3.2 C) and thicknesses (Figure 3.2 D) were fabricated. To study the 
influence of the number of microneedles, arrays of microneedles with 5 or 50 
microneedles were also fabricated (Figure 3.2 E). To facilitate handling, single 
microneedles (Figure 3.3 A) and arrays of microneedles (Figure 3.3 B and 3.3C) were 
mounted onto holders.  
 To verify that microneedles penetrated into the skin, three randomly selected 
sites on each subject of stage II were stained with gentian violet as described in the 
Materials and Methods section. This protocol selectively stained sites of skin perforation, 
as shown in the representative images for a single microneedle (Figure 3.3 D), a 
microneedle array with 5 microneedles (Figure 3.3 E) and a microneedle array with 50 
microneedles (Figure 3.3 F). Analysis of images from all of the stained sites on all 






Figure 3.2.  Representative microneedles used for insertion. Scanning electron microscopy images of 
microneedles used in the length study (A), tip-angle study (B), width study (C), thickness study (side view) 
(D) and number of microneedles study (E). A 5 mm-long, 26-gage hypodermic needle was used as a 
positive control (F). All images are at the same magnification. 
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Figure 3.3. Microneedle devices and stained skin penetration sites. Brightfield microscopy images of 
microneedles assembled into devices: a single microneedle affixed to a teflon rod holder (A), a five-
microneedle array assembled as an adhesive patch (B) and a 50-microneedle array assembled as an 
adhesive patch (C). Brightfield microscopy images of the skin surface of human forearms after inserting 
microneedles and applying gentian violet to stain the sites of microneedle insertion, which demonstrates 
microneedle penetration into the skin, using: a single microneedle (D), an array of five microneedles (E) and 
an array of 50 microneedles (F). Arrows in (D) and (E) point to the stained insertion sites. 
 
 
3.3.2 Microneedles vs. 26-gage hypodermic needle 
 Our next objective was to determine if microneedles cause less pain than a 26-
gage hypodermic needle. We compared the pain reported for a hypodermic needle to 
microneedles over a range of dimensions that varied length (480, 700, 960 and 1450 
μm), width (160, 245 and 465 μm), thickness (30, 45 and 100 μm), tip angle (20°, 55° 
and 90°) and the number of microneedles (5 and 50). A 5-mm deep insertion of a 26-
gage hypodermic needle was used as a positive control.  Although hypodermic needles 
are inserted clinically for example, 8 to 12 mm deep during vaccination (2006) and 
insulin delivery (Hanas, Lytzen et al. 2000; Hanas 2004), we restricted the insertion 




 Among stage I data, the raw VAS pain scores for microneedles ranged from a 
minimum of 2±2 mm (mean ± standard deviation) to a maximum of 15±17 mm, whereas 
the pain score for the hypodermic needle was 39±21 mm. In stage II, the microneedle 
pain scores ranged from a minimum of 2±2 mm to a maximum of 11±9 mm and the 
hypodermic needle pain score was 24±16 mm. Based on repeated measures ANOVA, 
each of the microneedles was found to have a pain score significantly smaller than the 
hypodermic needle positive control (Tukey’s pairwise comparison, p < 0.05). These 
results demonstrate that all the microneedles over a wide range of dimensions 
investigated in this study were less painful than the 26-gage hypodermic needle. 
 
3.3.3 Effect of microneedle length 
 To study the dependence of pain on microneedle geometry, we hypothesized 
that increasing microneedle length should increase pain, because pain receptors 
innervate both the epidermis and the dermis, and longer penetrations should therefore 
excite more receptors (Oaklander and Siegel 2005). Consistent with this hypothesis, 
mean pain scores increased with increasing microneedle length, over a range of  2±2 
mm for the shortest microneedles (480 μm) to 15±17 mm for the longest (1450 μm) 
(corrected lower bound p=0.03) (Figure 3.4 A). In addition to calculating mean pain 
scores, we also tabulated the fraction of subjects who reported each microneedle 
treatment as completely painless (i.e. VAS pain score = 0). This analysis showed that 
the frequency of painless insertions decreased with an increase in microneedle length: 
30% of subjects reported both the 480 μm and the 700 μm long microneedles as 
completely painless, whereas just 0% and 10% reported the 960 μm and 1450 μm long 
microneedles painless, respectively. 
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 Although raw pain scores generally showed variability among subjects, 
hypodermic needle pain was especially variable, ranging from 7 mm to 63 mm, with a 
mean value of 39 mm. Because of this large inter-subject variability in pain perception, 
we re-analyzed the data by normalizing all the microneedle VAS scores from each 
subject to that subjects’s own hypodermic needle control. In this way, all data are 
presented relative to a common reference pain level that is familiar to most people and 
of direct relevance to medical applications.  
 Carrying out a more detailed analysis using these normalized pain scores 
indicated that the 480 μm long microneedles produced just 5% of the pain of the 26-
gage hypodermic needle (Figure 3.4 B). Increasing microneedle length sharply 
increased pain, such that a three-fold increase in the microneedle length from 480 μm to 
1450 μm caused the pain to increase more than seven fold from 5% to 37% (corrected 
lower bound p = 0.013).  
 Comparing pairwise among the microneedles: (i) increasing microneedle length 
by at least 700 μm (i.e., 480 μm vs. 1450 and 750 μm vs. 1450 μm) significantly 
increased pain levels (Tukey’s multiple comparison, p < 0.002); increasing microneedle 
length by 480 – 490 μm sometimes increased pain significantly (i.e., 480 μm vs. 960 μm, 
p = 0.02) and sometimes did not (960 μm vs. 1450 μm, p = 0.38); and (iii) increasing 
microneedle length by up to 260 μm (i.e., 480 μm vs. 700 μm and 700 μm vs. 960) did 
not significant increase pain (Tukey’s multiple comparison, p > 0.1). This analysis 
suggests that the threshold for distinguishing differences in pain due to increment in 




Figure 3.4. The effect of microneedle length. Box plots of pain scores after insertion of 480, 700, 960 and 
1450 μm long single microneedles (160 μm wide, 45 μm thick and a tip angle of 55°): raw visual analog 
scale (VAS) pain scores (A) and the normalized pain scores (B), which were calculated as the ratio of the 
microneedle raw VAS score and the 26-gage hypodermic needle raw VAS pain score for the same subject. 
The normalized pain score of the hypodermic needle (i.e., 100%) is represented by the horizontal dotted line 
in (B). The small open circles represent individual data points. Each dotted rectangular box represents the 
interquartile range (i.e., 25 – 75%) of the pain score for a particular microneedle length, with a horizontal line 
at the median value. The vertical lines (whiskers) extend from the box boundary to the maximum and the 
minimum data points within one and a half times the interquartile range. The solid diamonds represent the 
mean pain scores for each insertion. The numbers above each box present the percentage of subjects who 




3.3.4 Effect of the number of microneedles 
 Drug and vaccine delivery applications will often require multiple microneedles. 
We hypothesized that increasing the number of microneedles should increase pain, 
because more sensory nerves would be excited using a larger number of microneedles. 
Microneedle arrays with 5 or 50 microneedles were used to test this hypothesis. 
Insertion of a 5-microneedle array caused pain at a low level, corresponding to 10% of 
the hypodermic needle (Figure 3.5). A 10-fold increase in the number of microneedles to 
a 50-microneedle array produced a relatively small increase in the pain of just 2.5 fold 
(p=0.004), which corresponded to 25% of the hypodermic needle. The arrays with 5 and 
50 microneedles were reported to be completely painless by 40% and 20% of the 
subjects, respectively. 
 
3.3.5 Effect of microneedle tip angle 
 We next hypothesized that larger tip angles would cause more tissue 
deformation during microneedle insertion and thereby cause more pain than 
microneedles with smaller tip angles. To test this hypothesis, we examined microneedles 
with tip angles of 20°, 55° and 90°, each at two different lengths of 480 μm and 960 μm. 
 At both microneedle lengths tested, no consistent or statistically significant (p > 
0.12) relationship was observed between mean pain scores and microneedle tip angle 
over the relatively large range of tip angles considered (20° to 90°)  (Figure 3.6). For the 
480 μm long microneedles, the percentage of subjects reporting completely painless 
insertions decreased with increasing tip angles, but there was no such trend for the 960 
μm long microneedles (Figure 3.6). Additional experiments using 960 µm long 
microneedles at the same tip angles, but with an increased microneedle thickness from 
 
 43 
40 μm to 100 μm similarly showed no dependence of pain on microneedle tip angle 
(data not shown). 
 
 
Figure 3.5. The effect of the number of microneedles. Box plots of normalized pain scores after insertion 
of microneedle arrays having 5 and 50 microneedles. All microneedles were 620 μm long, 160 μm wide, 45 
μm thick and had a tip angle of 55°. 
  
 
 This finding was contrary to our original hypothesis. To understand this 
observation, we examined the microneedle tips using high-magnification scanning 
electron microscopy and found them to be extremely sharp, with a radius of curvature 
less than 1 μm independent of tip angle. This suggests that pain may correlate with 
sharpness at the very tip of the microneedle, rather than the overall angle of the tip. A 
































scaled  with microneedle tip sharpness (Davis, Landis et al. 2004), which indicates that 
the force of insertion may correlate with pain. This would be consistent with previous 
studies involving hypodermic needles, which found that the intensity of pain scales with 
mechanical workload (area under the force-displacement curve) of hypodermic needle 
insertion (Egekvist, Bjerring et al. 1999a; Egekvist, Bjerring et al. 1999b). Altogether, 
these observations suggest a new hypothesis that pain depends primarily on the force of 























































Figure 3.6. The effect of microneedle tip angle. Box plots of normalized pain scores after insertion of 480 
and 960 μm long single microneedles each with a tip angle of 20°, 55° and 90°. All microneedles were 160 





3.3.6 Effect of microneedle thickness and width 
 Our last hypothesis was that increased microneedle thickness and width would 
cause more pain by engaging more pain receptors during insertion. To test this 
hypothesis, microneedles with thicknesses of 30, 45 and 100 μm and widths of 160, 245, 
and 465 μm were examined. In contrast to this hypothesis, neither increasing 
microneedle thickness by more than three fold (p = 0.6, Figure 3.7 A) nor increasing 
microneedle width by almost three fold (p = 0.30, Figure 3.7 B) had a significant effect on 
pain scores.  
 These observations are, however, consistent with previous reports that pain is 
independent of needle diameter for lancets with diameters of 800, 400 and 300 μm 
inserted to a depth of 900 μm (Fruhstorfer, Schmelzeisen-Redeker et al. 1999). They are 
also consistent with the new hypothesis that pain depends primarily on the force of 
microneedle tip insertion and not on other features of the microneedle shaft geometry 
other than length. In contrast, a study of hypodermic needles found that the likelihood of 
an insertion being painful increased with increasing needle diameter, but also noted that 
the intensity of those insertions rated as painful was insensitive to needle diameter 
(Arendt-Nielsen, Egekvist et al. 2006).   
  
3.3.7 Skin reaction to insertions 
 In addition to pain, microneedle insertions into the skin could cause skin irritation. 
Visual observation of the skin immediately after microneedle insertion revealed highly 
localized, mild erythema in the form of a light pink dot less than 1 mm across, which was 
observed at all microneedle insertion sites independent of microneedle geometry. 
Although this redness could be observed upon direct examination, essentially no 
cosmetic effect was evident when subjects were viewed from a distance. The erythema 
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decreased somewhat during the 2 h study period and was self-reported by the subjects 
to be mostly resolved when they were contacted after 24 h. There were no signs of 
edema after any microneedle insertions. 
 The appearance of a tiny droplet of blood (e.g., 1 μl) was observed at the 
insertion site after some microneedle insertions, especially those involving 1450 μm long 


































































































Figure 3.7. The effect of microneedle thickness and width. Box plots of normalized pain scores after 
insertion of 30, 45 and 100 μm thick single microneedles each 700 μm long, 160 μm wide and with a tip 
angle of 55° (A); and 160, 245 and 465 μm wide single microneedles each 700 μm long, 45 μm thick and 






3.4.1 Degree of pain reduction 
 This study shows that microneedles caused significantly less pain than a 26-
gage hypodermic needle. Using the shortest microneedles, pain scores were reduced by 
a factor of 20 compared to the hypodermic needle. Overall, pain scores from the 
diversity of microneedle geometries considered ranged from 5 to 40%, which was highly 
significant by statistical analysis. This level of pain reduction could also be significant to 
reduce needle anxiety and phobia. 
 Even though the pain reduction reported in this study is considerable, the degree 
of pain reduction from microneedle-based drug delivery is expected to be still greater. 
First of all, hypodermic needles are typically inserted 8 to 12 mm deep into the skin 
(Hanas, Lytzen et al. 2000; Hanas 2004; 2006). In this study, we limited the insertion 
depth to just 5 mm to minimize bleeding. Because pain is known to depend strongly on 
device insertion depth, as shown in this study and in the literature (Fruhstorfer, Müller et 
al. 1995) , the actual pain caused by hypodermic needles in clinical practice is expected 
to be greater than in this study and thus the relative reduction in pain by using 
microneedles should also be greater.  
 In addition, the act of injecting fluid into the skin can itself cause pain, which 
means that the positive control hypodermic needle insertion used in this study is an even 
greater underestimate of the pain caused by hypodermic injection. Because solid 
microneedles do not involve fluid injection for drug delivery, the pain associated with fluid 
injection would also be eliminated. For these reasons, the relative decrease in pain 
enabled by the use of microneedles reported in this study is based on a conservative 
study design. Even greater pain reduction should be expected from drug delivery using 
solid microneedles as compared to actual hypodermic injections. 
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 It should be noted that this analysis does not take into account pain that could be 
caused by local irritation by the drug formulation. Solid microneedles deliver a solid drug 
formulation into the skin, whereas hypodermic injection delivers a liquid drug formulation 
typically into deeper tissues. These differences may further influence pain in some cases.  
 
3.4.2 Microneedle device optimization 
 Optimization of a microneedle device requires selecting microneedle dimensions 
and overall design that meets a number of constraints, including minimizing pain, 
providing sufficient mechanical strength for insertion into the skin, and delivering the 
required dose in a manner suitable for the target population. To guide optimization that 
minimizes pain, this study supported the hypothesis that decreasing microneedle length 
and the number of microneedles reduces pain. It also showed that microneedle tip angle, 
thickness and width did not have a significant effect on pain score. Altogether, these 
observations suggested an additional hypothesis that pain depends primarily on the 
force of microneedle tip insertion and the depth to which the microneedle tip penetrates 
into the skin, but not on other features of the microneedle shaft geometry besides length. 
Validation of this new hypothesis requires additional study. 
 These findings suggest that an optimal microneedle design should involve a 
small number of short microneedles. Due to the much steeper dependence of pain on 
microneedle length compared to the number of microneedles, minimizing length should 
be especially important. For ease of insertion (Davis, Landis et al. 2004) and possible 
reduction in pain, microneedle tips should also be sharp. Although microneedle 
thickness, width and tip angle do not appear to affect pain, they do affect microneedle 
mechanical strength (Davis, Landis et al. 2004; Park, Allen et al. 2005) and therefore 




3.4.3 Reduction of anxiety and needle phobia  
 The microscopic dimensions of microneedles may further decrease the 
perception of pain due to their patient-friendly appearance. It is well known that pain 
from the use of hypodermic needles can produce poor patient compliance and that 
needle phobia produces stress, anxiety and vasovagal reaction, which can interfere with 
treatments that use needles (Hamilton 1995; Nir, Paz et al. 2003; Hanas 2004). Recent 
research using stress-reducing medical devices involving decorative and aesthetically 
pleasing syringes has shown significant reduction in needle phobia (Kettwich, Sibbitt et 
al. 2007). Microneedles should offer similar advantages, due to their small size, 
inconspicuous profile and ability to be incorporated into Band Aid-like patches that can 
be aesthetically pleasing and easy to use. Although this blinded study did not assess this 
aspect of microneedles, we expect microneedle patches to be patient friendly and 
thereby further reduce anxiety and the perception of pain. 
   
3.5 CONCLUSION 
 This study investigated the influence of microneedle design and geometry on 
pain and compared it to the pain from a hypodermic needle. Based on statistical analysis 
of the raw VAS scores, we found that all 18 of the microneedle configurations studied, 
including lengths up to 1450 μm, widths up to 465 μm, thicknesses up to 100 μm, tip 
angles up to 90˚, and as many as 50 microneedles in an array, were significantly less 
painful than a 5-mm deep insertion of a 26-gage hypodermic needle (outer diameter: 
460 μm). The shortest (480 μm) microneedles produced pain scores that were 20-fold 
lower than the hypodermic needle.  Further, many microneedle insertions were entirely 
painless (as much as 50% of the subjects reported VAS scores of zero for the 480 μm 
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long and 20° tipped microneedle), as compared to the hypodermic needle, for which 
none of the subjects reported the insertions to be painless.  
 Analysis of the normalized VAS pain scores of the different microneedle designs 
showed that microneedle length was the most influential factor affecting pain. A three-
fold increase in microneedle length produced more than a seven-fold increase in pain. 
The number of microneedles was also significant in affecting pain, although less steeply. 
A ten-fold increase in the number of microneedles increased the pain score only by 
about 2.5 times, such that the pain score from a 50-microneedle array was still just 25% 
of the pain caused by a single hypodermic needle. No statistically significant effect was 
observed due to changes in microneedle tip angle, width or thickness over the range 
investigated. Altogether, these observations suggested a new hypothesis that pain 
depends primarily on the force of microneedle tip insertion and the depth to which the 
microneedle tip penetrates into the skin, but not on other features of the microneedle 
shaft geometry besides length.  
 In conclusion, this study demonstrates that microneedles over a wide range of 
dimensions are significantly less painful than a 26-gage hypodermic needle and that 
decreasing microneedle length and number of microneedles reduces pain. These 
findings give insight into the thresholds and parameters that control pain due to micron-
scale trauma to the skin and provide a rational basis to optimize microneedle geometry 
for drug delivery applications that minimize pain. 
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CHAPTER 4: COATED MICRONEEDLES FOR TRANSDERMAL DELIVERY2 
 
ABSTRACT 
 Coated microneedles have been shown to deliver proteins and DNA into the skin 
in a minimally invasive manner. However, detailed studies examining coating methods 
and their breadth of applicability are lacking. This study’s goal was to develop a simple, 
versatile and controlled microneedle coating process to make uniform coatings on 
microneedles and establish the breadth of molecules and particles that can be coated 
onto microneedles. First, microneedles were fabricated from stainless steel sheets as 
single microneedles or arrays of microneedles. Next, a novel micron-scale dip-coating 
process and a GRAS coating formulation were designed to reliably produce uniform 
coatings on both individual and arrays of microneedles. This process was used to coat 
compounds including calcein, vitamin B2, bovine serum albumin and plasmid DNA. 
Modified vaccinia virus and microparticles of 1 to 20 μm diameter were also coated. 
Coatings could be localized just to the needle shafts and formulated to dissolve within 20 
s in porcine cadaver skin. Histological examination validated that microneedle coatings 
were delivered into the skin and did not wipe off during insertion. In conclusion, this 
study presents a simple, versatile, and controllable method to coat microneedles with 






                                                 
2 This work has been published as: Gill, H. S. and M. R. Prausnitz (2007). "Coated microneedles for 




 Biopharmaceuticals, such as peptides, proteins and future uses of DNA and RNA, 
represent a rapidly growing segment of pharmaceutical therapies (Walsh 2005). These 
biotechnology drugs are currently delivered almost exclusively by the parenteral route. 
The oral route is generally not available, due to poor absorption, drug degradation and 
low bioavailability. This is problematic, because parenteral administration with 
hypodermic needles requires expertise for delivery, can lead to transmission of blood 
borne pathogens due to accidental needle sticks or intentional needle reuse, and causes 
pain, which results in reduced patient compliance due to needle phobia (Simonsen, 
Kane et al. 1999; Nir, Paz et al. 2003).  
 Given these problems, a breadth of research activity has focused on replacing 
hypodermic needles with alternate drug delivery methods (Orive, Hernandez et al. 2003). 
Transdermal drug delivery is an especially attractive alternative, because it is usually 
easy to use, safe, and painless (Barry 2004; Prausnitz, Mitragotri et al. 2004). However, 
the tough barrier posed by the skin’s outer layer of stratum corneum has limited the 
applicability of this method to drugs that are hydrophobic, low molecular weight, and 
potent. 
 Micron-scale needles assembled on a transdermal patch have been proposed as 
a hybrid between hypodermic needles and transdermal patches to overcome the 
individual limitations of both injections and patches (Prausnitz 2004; Prausnitz, Mikszta 
et al. 2005). Microneedles have been shown to be painless in human subjects relative to 
hypodermic needles (Kaushik, Hord et al. 2001; Mikszta, Alarcon et al. 2002). Unlike 
transdermal patches, microneedles have been successfully used to deliver a variety of 
large and hydrophilic compounds into the skin, including proteins and DNA. In vitro skin 
permeability enhancement of two to four orders of magnitude was observed for small 
molecules like calcein and large compounds like proteins and nanoparticles (Henry, 
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McAllister et al. 1998; McAllister, Wang et al. 2003). In vivo delivery has been shown for 
peptides, such as insulin and desmopressin (Cormier, Johnson et al. 2004; Martanto, 
Davis et al. 2004); genetic material, including plasmid DNA and oligonucleotides (Lin, 
Cormier et al. 2001; Chabri, Bouris et al. 2004); and vaccines directed against hepatitis 
B, anthrax and Japanese encephalitis (Mikszta, Alarcon et al. 2002; Dean, Alarcon et al. 
2005; Mikszta, Sullivan et al. 2005). Microneedles can be fabricated for these 
applications by adapting the tools of the microelectronics industry for inexpensive, mass 
production (Reed and Lyev 2004). 
 Currently, four different modes of microneedle-based drug delivery have been 
investigated (Prausnitz 2004; Prausnitz, Mikszta et al. 2005). These modes are: (1) 
piercing an array of solid microneedles into the skin followed by application of a drug 
patch at the treated site (Henry, McAllister et al. 1998; Martanto, Davis et al. 2004); (2) 
coating drug onto microneedles and inserting them into the skin for subsequent 
dissolution of the coated drug within the skin (Cormier, Johnson et al. 2004); (3) 
encapsulating drug within biodegradable, polymeric microneedles followed by insertion 
into skin for controlled drug release (Park, Allen et al. 2006); and (4) injecting drug 
through hollow microneedles (Zahn, Talbot et al. 2000).  
 Among these approaches, coated microneedles are attractive for rapid bolus 
delivery of high molecular weight molecules into the skin, and can be implemented as a 
simple ‘Band-Aid’-like system for self-administration. Further, storing drugs in a solid 
phase as a coating on microneedles may enhance their long-term stability, even at room 
temperature. Consistent with this expectation, desmopressin coated onto microneedles 
maintained 98% integrity after 6 months storage under nitrogen at room temperature 
(Cormier, Johnson et al. 2004).  Coated microneedles are also especially attractive for 
vaccine delivery to the skin, because antigens can be released in the skin to target 
epidermal Langerhans cells and dermal dendritic cells for a more potent immune 
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response (Babiuk, Baca-Estrada et al. 2000). As a demonstration of this, a strong 
immune response in guinea pigs was shown against ovalbumin, a model antigen 
delivered from coated microneedles (Matriano, Cormier et al. 2002). 
 Despite the attractiveness of coated microneedles, a detailed investigation of the 
coating process has not been published. In this study, we therefore wanted to develop a 
microneedle coating process that elucidated issues involved in coating microneedles 
and to identify the breadth of applicability of coated microneedles by determining the 
different kinds of molecules and particles that can be coated and delivered into the skin.  
This study was guided by identifying essential characteristics needed for the 
microneedle coating process to achieve precise dose control, safety, and the ability to 
coat sensitive biological molecules. The coating process should: (1) make a uniform 
coating as opposed to a patchy coating to provide reproducibility and dosage control, (2) 
limit deposition only onto microneedles and not on the base substrate for tight dosage 
control and minimizing drug loss during coating, (3) avoid high temperatures to maintain 
drug integrity, (4) use aqueous coating solution to prevent denaturing of proteins and 
other biological molecules, (5) achieve high drug loading per microneedle to maximize 
drug dosage, (6) provide good adhesion of the coating to the microneedle to prevent 
wiping off on the skin during insertion and (7) have rapid, or otherwise controlled, 
dissolution kinetics in the skin for bolus, or sustained, release.  
 Among the various coating processes, such as dip coating, roll coating and spray 
coating (Bierwagen 1992), dip coating is particularly appealing for coating microneedles 
because of its simplicity and its ability to coat complex shapes.  A dip-coating process 
typically involves dipping and withdrawing an object from a coating solution, after which 
a continuous liquid film adheres and dries on the object’s surface, leaving behind a 
uniform coating. However, dip coating has been developed to coat macroscopic objects 
mostly by submerging them completely within the coating solution. Because surface 
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tension becomes dominant on the micron scale (Beebe, Mensing et al. 2002), 
conventional dip-coating methods have difficulty controlling coating of specified sections 
of micron-dimensioned structures, especially when those structures are closely spaced. 
This study sought to addresses these limitations by developing a micron-scale, dip-
coating process to coat microneedles with uniform and spatially controlled coatings 
using methods applicable to a breadth of drugs and biopharmaceuticals. 
 
4.2 MATERIALS AND METHODS 
 
4.2.1 Microneedle fabrication 
4.2.1.1 Laser cutting 
 Using methods described previously (Martanto, Davis et al. 2004), microneedles 
were cut from stainless steel sheets (Trinity Brand Industries, SS 304, 75 μm thick; 
McMaster-Carr, Atlanta, GA, USA) using an infrared laser (Resonetics Maestro, Nashua, 
NH, USA). The desired microneedle shape and dimensions were first drafted in 
AutoCAD software (Autodesk, Cupertino, CA, USA). Using this design, the infrared laser 
was operated at 1000 Hz, 20 J/cm2 energy density and 40% attenuation of laser energy 
to cut microneedles. A total of three passes were required to completely cut through the 
stainless steel sheet. A cutting speed of 2 mm/s and air purge at a constant pressure of 
140 kPa was used. Microneedles were either prepared as individual rows of needles (‘in-
plane’ needles) or as two-dimensional arrays of needles cut into the plane of the 







4.2.1.2 Cleaning and bending microneedles 
 Laser-cut stainless steel microneedle arrays were manually cleaned with 
detergent (Alconox, White Plains, NY, USA) to de-grease the surface and remove slag 
and oxides deposited during laser cutting, which was followed by thorough rinsing in 
running water. To prepare ‘out-of-plane’ microneedles, microneedles cut into stainless 
steel sheets were first manually pushed out of the sheet using either forceps or a 
hypodermic needle (26 gage, ½ inch long, Becton Dickinson, Franklin Lakes, NJ, USA) 
while viewing under a stereo microscope (SZX12, Olympus America, Melville, NY, USA), 
and then bent at 90° angle with the aid of a #9 single-edged razor blade. 
 
4.2.1.3 Electropolishing 
 To deburr and clean microneedle edges and to make the tips sharp, 
microneedles were electropolished in a solution containing glycerin, ortho-phosphoric 
acid (85%) and water in a ratio of 6:3:1 by volume (Fisher Scientific, Fair Lawn, NJ, 
USA). Electropolishing was performed in a 300 ml glass beaker at 70°C and a stirring 
rate of 150 rpm. A copper plate was used as the cathode, while microneedles acted as 
the anode. The anode was vibrated at a frequency of 10 Hz throughout the 
electropolishing process using a custom built vibrating device to help remove gas 
bubbles generated at the anodic surface during electropolishing. A current density of 1.8 
mA/mm2 was applied for 15 min to electropolish the microneedles. After electropolishing, 
microneedles were cleaned by dipping alternately three times in de-ionized water and 
25% nitric acid (Fisher Scientific) for 30 s each. This was followed by another washing 
step in hot running water and a final wash in running de-ionized water. Due to the 
electropolishing process, the thickness of the microneedles was reduced to 50 μm. 




4.2.2 Micro-dip coating 
 Microneedles were coated with different molecules using a novel micron-scale, 
dip-coating process and a specially formulated coating solution. 
 
4.2.2.1 Coating solution 
 The coating solution was composed of 1% (w/v) carboxymethylcellulose sodium 
salt (low viscosity, USP grade, CarboMer, San Diego, CA, USA), 0.5% (w/v) Lutrol F-68 
NF (BASF, Mt. Olive, NJ, USA) and a model drug/biopharmaceutical. The model drugs 
tested included 0.01% suforhodamine (Molecular Probes, Eugene, OR, USA), 0.01% 
calcein (Sigma, St. Louis, MO, USA), 3% vitamin B2 (riboflavin-5’-phosphate sodium salt 
dihydrate, Fisher Chemicals), 1% bovine serum albumin conjugated to Texas Red 
(Molecular Probes), 0.05% gWiz™ luciferase plasmid DNA (6732 base pairs, Aldevron, 
Fargo, ND, USA), 2 x 109 plaque forming units per ml of modified vaccinia virus – Ankara 
(Emory University Vaccine Center, Atlanta, GA, USA), 10% barium sulfate particles (1 
μm diameter, Fisher Scientific), 1.2 % 10-μm diameter latex beads (PN 6602796, 
Beckman Coulter, Miami, FL, USA) and 8.2% 20-μm diameter latex beads (PN 6602798, 
Beckman Coulter ), all w/v. DNA and virus were made fluorescent by incubating with 
YOYO-1 (Molecular Probes) at a dye:base pair/virus ratio of 1:5 for 1 h at room 
temperature in the dark. 
 
4.2.2.2 Coating single microneedles 
 Single microneedles were dip-coated by horizontally dipping the microneedle into 
20-30 μl of coating solution held as a droplet on the tip of a 200 μl large-orifice pipette tip 
(catalogue number 21-197-2A, Fisher Scientific). The large-orifice pipette tip was 
mounted horizontally in a clamp and the microneedle was mounted opposite to it on a 
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manual linear micropositioner (A1506K1-S1.5 Unislide, Velmex, Bloomfield, NY, USA). 
Immersion and withdrawal of the microneedle into the liquid droplet was performed 
manually by moving the microneedle while viewing under a stereomicroscope (SZX12, 
Olympus America). 
 
4.2.2.3 Coating rows of microneedles 
 In-plane rows of microneedles were dip coated using an in-house designed 
coating device. The coating device consisted of two parts: (1) the coating solution 
reservoir and (2) the micropositioning dip coater. 
 
4.2.2.3.1 Coating solution reservoir 
 The coating solution reservoir was designed to restrict access of the coating 
liquid only to the microneedle shaft to prevent contamination of the base. The coating-
solution reservoir consisted of two laminated parts: the ‘bottom plate’ and the ‘cover 
plate’, both of which were made of polymethylmethacrylate (McMaster-Carr) (Figure 4.1 
A). The bottom plate had a central feeding channel (1 mm deep x 0.5 mm wide) 
machined into one of its faces, with a through hole drilled across to the other face. This 
hole acted as the inlet port to fill the channel with the coating solution. The cover plate 
had five holes (400 µm diameter) drilled into it at the same interval as the microneedles 
in the in-plane row to be coated. These ‘dip-holes’ acted as individual dipping reservoirs 
to coat each of the microneedles in the row. The two plates (bottom and cover plates) 
were aligned and adhered to each other using solvent bonding with methylene chloride 






4.2.2.3.2 Micropositioning dip coater 
 To enable three-dimensional alignment and dipping of microneedle rows into the 
dip-holes, three linear-micropositioners were assembled on a 6.35 mm-thick, flat, acrylic 
plate (McMaster-Carr) (Figure 4.1 B). The first micropositioner (x-micropositioner: 
A1503K1-S1.5 Unislide, Velmex) was used to control the position of the in-plane 
microneedle row. The other two micropositioners were assembled one on top of the 
other on the acrylic plate to create a composite y-z motion micropositioner (two 
A1503K1-S1.5 Unislides, Velmex) that was used to control the position of the coating 
solution reservoir.  The three micropositioners together allowed the alignment of the in-
plane microneedle row to the dip-holes. The x-micropositioner was used to horizontally 
dip the microneedles into and out of the dip-holes. The coating was performed manually 
while viewing under a stereo microscope (SZX12, Olympus America). Control over the 
length of the microneedle shaft to be coated was exercised manually using the x-
micropositioner. Tolerance for misalignment was included by designing the dip-hole 
diameter to be twice the width of the microneedles. 
 
 
Figure 4.1.  Schematic diagrams of in-plane microneedle row-coating device. (A) Cross sectional view 
of the coating solution reservoir showing the microneedles aligned with the dip holes. (B) Isometric 
projection of the entire device showing the x,y and z-micropositioners used to align the microneedles with 
dip holes of the coating-solution reservoir. The cylindrical tube represents the stereo-microscope objective, 
which is used to view the microneedle alignment and coating process facilitating manual control. 
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4.2.2.4 Coating arrays 
 Microneedle arrays were dip-coated using a method and dipping device similar to 
that used to coat in-plane rows of microneedles. The coating-solution reservoir and the 
microneedle-array holder were pre-aligned opposite to each other on a vertical rod. The 
cover plate of the coating-solution reservoir contained 50 dip-holes at the same spacing 
as the microneedles in the array. The coating-solution reservoir was stationary, while the 
microneedle-array holder could slide up and down the rod. Pins were provided on the 
microneedle-array holder to position a microneedle array on the holder in alignment with 
the dip-holes.  To coat the microneedles, the microneedle-array holder was manually slid 
down the rod to dip the microneedles of the array into the 50 dip-holes below. 
 
4.2.3 Microneedle patch assembly 
 Coated microneedle arrays were assembled into transdermal patches containing 
pressure-sensitive adhesive to adhere to the skin. These patches were fabricated using 
either multiple in-plane rows of microneedles or individual arrays of out-of-plane 
microneedles.  
  
4.2.3.1 Microneedle patches from multiple in-plane rows of microneedles 
 A set of ten in-plane rows of microneedles with each row containing five 
microneedles were assembled into a patch of 50 microneedles. First, ten slits, each 75 
μm wide and 7.7 mm long (i.e. equal to the length of an in-plane row) were laser cut into 
a 1.6 mm-thick, single-sided polyethylene medical foam tape (TM9716, MACtac, Stow, 
OH, USA) using a CO2 laser (LS500XL, New Hermes, Duluth, GA, USA). The ten 
microneedle rows were then manually inserted into each slit from the non-adhesive side 
of the foam tape and glued to the foam tape using a medical grade adhesive (Loctite 
4541, Rocky Hill, CT, USA). The adhesive was allowed to cure for 24 h.  A polyethylene 
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medical foam tape (0.8 mm thick; TM9942, MACtac) was then cut into a disc of 16 mm 
diameter and affixed onto the dried glue area to provide a cushioned backing to facilitate 
pressing the patch during insertion. 
 
4.2.3.2 Microneedle patches from complete out-of-plane microneedle arrays 
 To assemble a microneedle patch using a complete out-of-plane microneedle 
array, a circular disc of 20 mm diameter was first cut from a 0.8 mm-thick, single-sided 
medical foam tape (TM9942, MACtac) using the CO2 laser. In the middle of this disc, a 
rectangular piece of the adhesive release liner equal in dimensions to the periphery of 
the array (i.e. 12 mm x 12 mm) was cut out using the CO2 laser and peeled off. The 
stainless steel microneedle array was then attached to this exposed adhesive. The patch 
at this stage has a release liner-covered adhesive layer around the attached array. To 
further provide a layer of pressure-sensitive adhesive on the stainless steel surface of 
the attached array, a double-sided, poly-ethylene-terephthalate carrier tape (63.5 μm 
thick; T04314A, MACtac) was attached as follows. The poly-ethylene-terephthalate film 
was first perforated with holes of 400 μm diameter at the same spacing as the 
microneedles using a CO2 laser. The tape was then slipped over the microneedles using 
a custom-built alignment device and pressed to stick against the stainless steel 
substrate without contaminating the microneedles. 
 
4.2.4 Imaging and histology 
 Fluorescence micrographs of coated microneedles and histological skin sections 
were collected using an Olympus IX70 fluorescent microscope with a CCD camera (RT 
Slider, Diagnostic Instruments, Sterling Heights, MI, USA). Brightfield micrographs were 
collected using an Olympus SZX12 stereo microscope with a CCD camera (Leica DC 
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300, Leica Microsystems, Bannockburn, IL, USA). Digital x-ray imaging to detect barium 
sulfate was done using the Faxitron MX20 cabinet X-ray (Faxitron X-Ray, Wheeling, IL, 
USA).  
 Histological examination of cadaver skin was conducted on frozen sections. 
Porcine cadaver skin was pierced with microneedles for 1 min, frozen in OCT compound 
(Tissue-Tek, 4583, Sakura Finetek, Torrance, CA, USA), and cut into 10 µm-thick 
sections using a cryostat (Cryo-Star HM 560MV, Microm, Waldorf, Germany). 
 
4.2.5 In vitro dissolution time and delivery efficiency 
 Single microneedles (n=3) coated with vitamin B2, calcein or sulforhodamine 
were inserted into porcine cadaver skin for 10 s or 20 s. Upon removal, these 
microneedles were imaged by fluorescence microscopy to check for presence of 
residual coating. To determine the delivery efficiency of coated microneedles, rows of 
five microneedles coated with vitamin B2 were inserted into pig cadaver skin for 5 min 
(n=3). The mass of vitamin B2 on the inserted and non-inserted microneedle rows was 
determined by dissolving the coatings in deionized water through vigorous mixing, 
quantifying the vitamin B2 concentration in the resulting solution via fluorescence 
spectroscopy (SpectraMax Gemini, Molecular devices, Sunnyvale, CA, USA), and 
multiplying the measured concentration by the volume of deionized water used for 
dissolution to yield the amount of vitamin B2 that was adherent to the microneedles. 
Similarly, the mass of vitamin B2 left behind on the skin surface during microneedle 
insertion was estimated by applying tape (Scotch super 33, McMaster-Carr) to the skin 
surface, removing the tape, dissolving the material removed by the tape in deionized 
water, and determining the vitamin B2 content by fluorescence spectroscopy. Using a 
mass balance, the amount of vitamin B2 delivered into the skin was determined by 
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subtracting the amount remaining on the microneedles and on the skin surface after 
insertion from the amount originally on non-inserted microneedles. 
 
4.2.6 Delivery of molecules and particles 
4.2.6.1 Delivery from individual microneedles in vitro 
 Single microneedles (n=3) coated with calcein were inserted into porcine cadaver 
skin for 20 s and removed. For particle delivery, barium sulfate particles (1 μm diameter, 
as determined by scanning electron microscopy, data not shown), or latex beads (10 or 
20 μm diameter) were inserted into porcine cadaver skin for 1 min (n=3 single 
microneedles for each insertion). After removing the microneedles, the skin surface was 
examined by brightfield microscopy for coating residue. Porcine cadaver skin was then 
examined histologically to assess the extent of delivery of microneedle coatings into the 
skin. The use of porcine cadaver skin was approved by the Georgia Institute of 
Technology Institutional Animal Care and Use Committee (IACUC).  
 
4.2.6.2 Delivery for assembled microneedle patches in vitro and in vivo 
 For in vitro testing, out-of-plane microneedle arrays (n=3) were coated, 
assembled into patches and manually inserted into human cadaver skin for 1 min. After 
1 min, the patch was removed and visually examined by brightfield microscopy to 
qualitatively assess the amount of residual coating left on the microneedles. The human 
cadaver skin was also imaged by brightfield microscopy to assess release and delivery 
of coatings into the skin. For in vivo analysis, non-coated patches of out-of-plane arrays 
were sterilized using ethylene oxide and manually applied onto the forearms of human 
subjects (n=3) for 30 s. Gentian violet (a violet topical antifungal agent, 2% solution, 
Humco, Texarkana, TX, USA) was then applied on the treated site for 1 min and wiped 
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away using isopropanol swabs. Gentian violet selectively stained the sites of skin 
perforation, which identified the sites of microneedle insertion. The use of human 





4.3.1 Fabrication of stainless steel microneedles  
 Our first objective was to fabricate microneedles with appropriate mechanical 
properties for reliable insertion into skin and appropriate surface properties for dip-
coating with drugs. We selected stainless steel as the microneedle material because it 
has a well-established FDA safety record, provides good mechanical strength, and can 
be easily cut using a laser. However, laser-cutting stainless steel produced microneedles 
with rough edges covered with slag deposits (Figure 4.2 A).  
 To produce clean, smooth, and sharp microneedle surfaces, we developed an 
electropolishing technique to remove this slag from the microneedles. Mechanical 
methods like abrasive cleaning and buffing were difficult to implement without bending or 
otherwise damaging the microneedles. In contrast, electropolishing utilized a simple, 
reliable procedure that was effective to remove all of the slag and debris. This approach 
yielded microneedles with smooth surfaces and very sharp tips (tip radius 0.5 to 1 μm) 
(Figure 4.2 B). We believe that electropolishing was especially effective, because current 
density (i.e., etching rate) is largest at sites of high curvature, which inherently targets 






Figure 4.2.  Effect of electropolishing on microneedle surface. Scanning electron micrographs of: (A) a 
microneedle tip with slag and debris residue remaining after cleaning with detergent powder and (B) a 
microneedle tip after electropolishing, resulting in removal of slag and debris, clean edges, and sharp tip. 
 
 
 Laser cutting coupled with electropolishing provides a potentially versatile 
method to prepare microneedles having a variety of geometries according to the pattern 
in which the laser is programmed to cut. To assess this versatility in the context of 
microneedle fabrication, we attempted to laser-cut and electropolish microneedles with 
increasing geometrical complexity. Using a simpler microneedle design, this process 
was used to create microneedles of different lengths and widths (Figure 4.3 A). As a 
more complex design, microneedles were fabricated with small through-holes (which we 
call ‘pockets’) of different shapes and sizes in the shafts of these microneedles (Figure 
4.3 B). Microscopic examination showed that the inside surfaces of these pockets were 
smooth and clean. We believe that this is the first report of pocketed microneedles, 
which can provide protective cavities to transport particles into the skin, as discussed 
further below. As a still more complex design, we tested the ability of the process to 
make contoured surfaces in the form of barbs and serrated edges. Although such 
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surfaces are more difficult to clean, debris was successfully removed with uniform 
cleanliness and smoothness (Figure 4.3 C). While these needle designs may be useful 
for improved microneedle retention, cutting or other effects in the skin, they are intended 
in this study only to demonstrate the capabilities of this fabrication process and have not 
been optimized for in vivo applications. 
 
 
Figure 4.3.  Fabrication of different microneedle geometries. Scanning electron micrographs of: (A) 
microneedles having different lengths and widths at a constant tip angle of 55°, (B) microneedles with 
‘pockets’ of different shapes and sizes etched through the microneedle shaft, and (C) microneedles with 
complex geometries, such as contoured surfaces in the form of barbs and serrated edges. 
 
 
 In addition to fabricating individual microneedles with different shapes, the laser 
fabrication process was also used to fabricate two different kinds of microneedle arrays 
in which all needles have the same geometry: (1) in-plane microneedle rows containing 
microneedles oriented with their axis parallel to the sheet (Figure 4.4 A, a representative 
in-plane row with five microneedles) and (2) out-of-plane arrays with multiple rows of 
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microneedles sticking out of the substrate with their axis perpendicular to the substrate 
(Figure 4.4 C, a representative out-of-plane array with 50 microneedles).  
 
4.3.2 Microneedle array patches 
 To facilitate their insertion and retention into the skin, arrays of microneedles 
were integrated into adhesive patches. These patches were designed to have a uniform 
pressure-sensitive adhesive layer on one complete side of the patch intended to contact 
the skin. The adhesive layer was periodically disrupted via small holes or slits to allow 
the microneedles to stick out for penetration. The adhesive served to hold the 
microneedles firmly against the skin by compensating for the mechanical mismatch 
between the flexible skin tissue and the rigid microneedle substrate, especially in the 
case of out-of-plane microneedle arrays. Microneedle arrays prepared on the basis of 
this design are shown for patches of in-plane microneedles (Figure 4.4 B) and out-of-




Figure 4.4.  Different types of microneedle arrays and patches. Brightfield micrographs of: (A) an in-
plane row with five microneedles, (B) a 50-microneedle patch after assembly of ten in-plane rows into slits of 
a foam-tape backing, (C) an out-of-plane microneedle array with 50 microneedles, and (D) a 50-microneedle 
patch assembled by mounting an out-of-plane array onto a foam-tape backing and then affixing a perforated, 
double-sided adhesive film onto the base substrate between microneedles. 
 
 
4.3.3 Micro-dip coating of microneedles 
 Our next objective was to deposit uniform coatings on microneedle shafts. 
Although the conventional dip-coating process is fairly simple, it is most suitable for 
macroscopic coatings. Our attempts to achieve micron-scale control over coating by 
simply dipping and withdrawing microneedles from an aqueous solution resulted in non-
uniform coatings with frequent spreading of the solution onto the base substrate. 
Representative brightfield images of such non-uniform coatings obtained by dipping 
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microneedles in a 3% (w/v) aqueous solution of vitamin B2 are shown in Figure 4.5 A 
(single microneedle) and Figure 4.5 B (out-of-plane array). 
 Based on optimized coating methods developed in other contexts (Schunk, Hurd 
et al. 1997), reduced surface tension and increased viscosity of the coating solution 
should improve the coating outcome by increasing the wettability of the microneedle 
surface and increasing the coating thickness, respectively. In addition to lowering 
surface tension and increasing viscosity, the ideal excipients had to meet a number of 
additional specifications. They needed to be water-soluble (for aqueous dipping 
formulations), FDA-approved as injectable excipients (for safety), solid at room 
temperature (to convert into a solid coating upon drying) and possess high surfactant or 
viscosity enhancement activity per unit mass (to minimize the excipient content and 
thereby maximize drug content in the dry coatings). Sodium salt of 
carboxymethylcellulose (low viscosity) and Lutrol F-68 NF were found to fulfill these 
criteria as a viscosity enhancer and surfactant, respectively. After optimization to 
minimize their concentration in the coating solution, these excipients were found to give 
uniform coatings at concentrations of 1% (w/v) carboxymethylcellulose and 0.5% (w/v) 
Lutrol F-68 NF using vitamin B2 as the model compound (Figure 4.5 C). 
 Further efforts, however, were required to address the problem of microneedle 
array substrate contamination with coating solution. To address this, we designed a 
special micro-dip-coating device that covered the dipping solution reservoir with a thin 
sheet containing micron-sized holes corresponding to the size and position of the 
microneedles in the array (Figure 4.1). This physical masking eliminated solution contact 
with the substrate of microneedles. When properly aligned using micropositioners, only 
microneedles could dip through the micron-sized holes and into the coating solution, 
which resulted in a controlled micro-dip-coating process.  
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 Using this design philosophy, three different coating devices were built to coat 
single microneedles, in-plane rows of microneedles, and out-of-plane arrays of 
microneedles, as described in the Materials and Methods section. These micro-dip-
coating devices were able to localize coatings only to microneedle shafts for single 
microneedles (Figure 4.5 C), out-of-plane arrays (Figure 4.5 D) and in-plane rows 
(Figure 4.5 E) of microneedles. To further test the ability of this approach to control the 
length of microneedles getting coated, in-plane rows of microneedles were coated to 
predetermined lengths of 25%, 50%, 75% and 100% length coverage (Figure 4.5 E). 
Thus, through the combination of a suitable coating solution and coating device, highly 
controlled and uniform coatings can be achieved on microneedles. The approach is 
probably applicable to coating other microstructures as well.  
 Finally, it is also worth noting that the dead volume of these coating devices was 
10 μl for the row-coating device, and 100 μl for the array-coating device. Therefore, only 
very small coating solution volumes are sufficient to coat microneedles, which is 





Figure 4.5.  Examples of poor and good microneedle coatings via brightfield micrographs of vitamin 
B2 coated microneedles. Poor, non-uniform coatings with base-substrate contamination on: (A) a single 
microneedle and (B) a 50-microneedle out-of-plane array. Improved coating uniformity and elimination of 
base-substrate contamination after addition of coating solution excipients and use of a micro-dip-coating 
device for (C) a single microneedle, (D) a 50-microneedle out-of-plane array, and (E) an in-plane 
microneedle row. Controlled length segment coverage at (E1) uncoated, (E2) 25% coated, (E3) 50% coated, 
(E4) 75% coated and (E5) 100% coated, demonstrating spatial control of the microneedle coating process. 
 
 
4.3.4 Coating a large range of compounds 
 Our next objective was to determine how broadly this approach could be applied 
to coat different molecules and particles onto microneedles. To study this question, the 
same coating solution and coating methods were used to reproducibly coat seven 
different compounds onto microneedles:  calcein and vitamin B2 (low molecular weight 
molecules representative of synthetic drugs), bovine serum albumin and plasmid DNA 
(high molecular weight biomolecules representative of protein and gene therapeutics), 
modified vaccinia virus (a virus particle representative of some vaccines), and latex and 
barium sulfate microparticles (organic and inorganic particles representative of controlled 
release and other particulate systems). These compounds spanned in size from small 
molecules (e.g., vitamin B2) to micron-scale particles (e.g., 20-μm latex beads). We 
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believe this is the first time that coating of microneedles with virus and microparticles has 
been studied. In all cases, coatings were reproducibly applied onto the microneedles 
(n=3 single microneedles for each compound). Moreover, the coatings were uniform 
across the entire microneedle length (representative images shown in Figure 4.6). 
 
 
Figure 4.6.  Breadth of molecules and microparticles coated onto microneedles. Fluorescent or 
brightfield micrographs of single microneedles coated with: (A) calcein, (B) vitamin B2, (C) bovine serum 
albumin (BSA) conjugated with Texas Red, (D) plasmid DNA conjugated with YOYO-1, (E) modified vaccinia 




4.3.5 Dissolution times and delivery of coated molecules 
 To determine the dissolution time of coated molecules from microneedles, 
microneedles coated with vitamin B2 (Figure 4.7 A-before) were inserted into porcine 
cadaver skin. Removal from skin 10-s after insertion showed that most of the coating 
was removed (data not shown) and 20 s after insertion the microneedle coating was 
completely removed (Figure 4.7 A-after). 
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 To determine if microneedle coatings were being delivered into the skin, as 
opposed to, for example, flaking off onto the skin surface, calcein-coated microneedles 
were inserted into porcine cadaver skin. After removing the microneedles and examining 
the skin surface, no calcein coating residue was observed (data not shown). 
Examination of histological sections of the skin revealed deposition of calcein along the 
shaft of the insertion path within the skin (Figure 4.7 B). Together these observations 
suggest that calcein coated onto microneedles was delivered into the skin without wiping 
off on the skin surface. Similar results were also observed for sulforhodamine-coated 
microneedles (data not shown), suggesting that the results are more generally 
applicable to different molecules. 
 To further quantify the delivery efficiency of coated microneedles, rows of 
microneedles coated with vitamin B2 were inserted into pig cadaver skin. A total mass of 
7.86 ± 0.3 μg of vitamin B2 was originally coated on these microneedles. After a 5-min 
insertion of these microneedles into skin, 7.18 ± 0.4  μg (91.4 ± 6 %) of the vitamin B2 
was delivered into the skin, whereas 0.17 ± 0.1 μg (2.1 ± 1 %) was found on the skin 
surface and 0.51 ± 0.2  μg (6.5 ± 2 %) remained adhered to the microneedle surface 
after removal from the skin. We conclude that these coatings were able to remain 
adherent during insertion into the skin and then efficiently dissolve off the microneedles 
within the skin for delivery of greater than 90% of the coated vitamin B2. 
 
4.3.6 Delivery of microparticles 
 It was also of interest to deliver microparticles into the skin, which has not been 
addressed in previous studies. Delivery of microparticles is challenging, because larger 
microparticles are more likely to wipe off onto the skin surface during insertion into the 
skin. To prevent microparticle coatings from wiping off, we hypothesized that faster 
 
 75 
insertion (momentum) and seclusion of microparticles within protective cavities in the 
form of holes or ‘pockets’ in the microneedles would facilitate carrying microparticles into 
the skin. To test this hypothesis, we coated microneedles with particles having three 
different diameters:  1-μm diameter barium sulfate particles, and 10- and 20-μm 
diameter latex beads. After insertion into porcine cadaver skin at slow speed (0.5 to 1 
mm/s), only barium sulfate particles were successfully delivered into porcine skin without 
wiping off onto the skin surface (Figure 4.7 C).  
 At higher insertion speed (1 to 2 cm/s), the momentum of the microneedles was 
able to carry the coating of 10-μm diameter particles into the skin (Figure 4.7 D); 
however, 20-μm diameter beads were still found predominantly as residue on the skin 
surface (data not shown). The 20-μm diameter latex particles were successfully 
delivered into the skin after loading them into the protective cavity of a pocket within the 
microneedle shaft and delivering at 1 to 2 cm/s (Figure 4.7 E). Therefore, by using 
appropriate microneedle design and insertion methods, even relatively large 





Figure 4.7.  In vitro dissolution and delivery from coated microneedles. (A) Single microneedle coated 
with vitamin B2 before and after a 20 s insertion into porcine cadaver skin imaged by fluorescence 
microscopy. The absence of fluorescence in the image after insertion indicates complete dissolution of the 
coating in the skin. (B) Histological section of porcine cadaver skin after inserting a calcein-coated 
microneedle (inset on left) and (C) X-ray micrograph of intact porcine cadaver skin after inserting a barium 
sulfate-coated microneedle (inset on left). The arrows in (B) and (C) point to the microneedle insertion sites 
and the bright regions represent calcein and barium sulfate delivery into the skin. The absence of 
fluorescence on top of the skin suggests that the coating did not wipe off during insertion. (D) Histological 
section of porcine cadaver skin after inserting a microneedle coated with 10-μm diameter beads (inset on 
left) and (E) histological section of porcine cadaver skin after inserting a ‘pocketed’ microneedle containing 
20-μm diameter beads (inset at bottom). In (D) and (E), the double lined arrows point to the microneedle 
insertion sites, while the solid black arrows point to some of the beads delivered into the skin, which appear 
as tiny circles. The absence of beads on the skin surface indicates that beads did not wipe off during 
insertion. Sc = Stratum Corneum, Ep = Epidermis, De = Dermis. 
 
 
4.3.7 Delivery from a microneedle array patch  
 To evaluate the performance of microneedle arrays assembled in a patch, coated 
microneedle patches (Figure 4.4 D) were inserted into human cadaver skin and non-
coated microneedles were inserted into the skin of human subjects. After inserting and 
removing microneedles coated with Trypan Blue from cadaver skin, surface examination 
of the treated skin showed an array of blue dots corresponding to sites of microneedle 
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penetration and coating deposition from the array (Figure 4.8 A). No residue was 
observed on the skin surface indicating delivery of coatings into the skin. 
 Although we did not prepare coated microneedles suitable for human use, we did 
want to evaluate the performance of microneedle patches in human subjects. Out-of-
plane arrays containing 50 uncoated microneedles were inserted and removed from the 
forearms of humans subjects. To determine if microneedles inserted, a solution of 
gentian violet was applied to the skin to stain sites of microneedle insertion. Complete 
microneedle insertion was obtained (n=3 subjects, Figure 4.8 B). The subjects reported 
that insertion of the arrays did not cause discomfort. 
 
 
Figure 4.8.  In vitro and in vivo performance of microneedle patches in human skin. (A) Surface view 
of human cadaver skin imaged by brightfield microscopy after inserting a 50-microneedle patch dip-coated 
with trypan blue dye. The 50 dark spots correspond to sites of trypan blue coating delivered and dissolved in 
the skin from the 50 microneedles in the patch. (B) Skin from the forearm of a human subjected imaged by 
brightfield microscopy after inserting a microneedle patch containing 50 microneedles and subsequently 
applying gentian violet to stain the sites of microneedle insertion, which demonstrates microneedle 








 This study showed that micro-dip coating provides a versatile technique to coat 
microneedles with a wide variety of molecules including small synthetic compounds, 
proteins and DNA. We have also reported for the first time that viruses and a variety of 
microparticles can be coated onto microneedles. This coating method uses aqueous 
formulations with FDA-approved excipients at room temperature. Histological 
examination of skin after insertion of coated microneedles showed successful delivery 
into the skin within seconds. This detailed study of the microneedle coating process and 
its breadth of applicability serves to compliment previous studies demonstrating delivery 
of peptides and proteins to the skin using coated microneedles (Matriano, Cormier et al. 
2002; Cormier, Johnson et al. 2004; Widera, Johnson et al. 2006). 
 
4.4.1 Microneedle fabrication methods 
 This study presented fabrication methods to produce microneedles suitable for 
coating. Although the laser-cutting method could be used with a variety of different 
metals and other materials, this study employed stainless steel, which is used in many 
FDA-approved medical devices and is inexpensive. Microneedles were fabricated to 
have a variety of different geometries. For the first time, we have reported the fabrication 
of ‘pocketed’ microneedles (Figure 4.3 B). Pockets provide a protective cavity within the 
microneedle shaft and were used to deliver particles up to 20-μm in diameter into the 
skin without wiping off during insertion.  
 Microneedles with other complex geometries, such as contoured surfaces in the 
form of barbs and serrated edges, were fabricated and polished to have clean edges 
and sharp tips (Figure 4.3 C). Some of these shapes can be used to help anchor 
microneedles within the skin for improved insertion and retention (Matriano, Cormier et 
al. 2002; Cormier, Johnson et al. 2004); however, they may cause skin damage or pain 
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upon withdrawal. Microneedles of different lengths and widths (Figure 4.3 A) can be 
fabricated using this method.  
 Using a bench-scale apparatus, finished microneedle arrays were cut and 
polished at a rate of two 50-needle arrays per hour. For large-scale manufacturing, this 
rate can easily be increased by orders of magnitude by using higher power lasers that 
can cut more quickly and can be beam-split to cut multiple arrays in parallel using fully 
automated processes. Use of multiple lasers can increase throughput still further through 
parallel processing. Likewise, larger and multiple electropolishing baths can increase 
polishing rates. Finally, the manual process using in this study to bend microneedles for 
out-of-plane arrays can also be easily automated for mass production. 
 
4.4.2 Microneedle coating methods 
 The success of coated microneedles for drug delivery depends on the ability to 
reliably coat a controlled drug layer onto microneedles. Our initial attempts to coat 
microneedles by dipping into an aqueous drug solution resulted in patchy to no surface 
coverage (Figure 4.5 A). To overcome this difficulty, we formulated a coating solution 
with increased viscosity and reduced surface tension containing 1% 
carboxymethylcellulose and 0.5% Lutrol F-68 NF as viscosity enhancer and surfactant, 
respectively. This enabled complete and uniform coverage of the dipped microneedle 
surface (Figure 4.5). This coating formulation was shown to be very versatile. Small 
molecules, macromolecules and microparticles were all applied as uniform coatings 
(Figure 4.6). The two excipients used to modify the dipping solution have already been 
approved by the FDA as excipients in injectable formulations, so this coating formulation 
should also be safe for use in humans.  
Another important component of the micro-dip-coating process is the dip-coating device. 
Simply dipping microneedles into a small beaker containing dipping solution often 
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resulted in contamination of the microneedle substrate (Figure 4.5 B). Capillary forces 
are mainly responsible for the rise of the free meniscus along the microneedle shaft to 
eventually touch the base substrate. This effect is amplified in an array due to the close 
spacing of the microneedles, which enhances the capillary effect and can lead to 
bridging of coating solution between adjacent microneedles.  
 To address these issues, we have developed a dip-coating design that uses dip 
holes with dimensions similar to that of individual microneedles instead of a large, open 
coating surface to prevent the meniscus rise and to physically mask the base substrate 
between microneedles. This design philosophy was incorporated into three different 
micro-dip-coating devices to coat single microneedles, in-plane rows, and out-of-plane 
microneedle arrays. Micropositioners were also incorporated into the dipping devices to 
align microneedles with dip holes. Using these micro-dip-coating devices, coating 
deposition can be highly controlled to localize only on microneedles and, when desirable, 
to coat only portions along the shaft of microneedles in a reproducible manner (Figure 
4.5 E). In the context of this and other on-going studies, this coating method has been 
used by us to reliably and reproducibly prepare many hundreds of microneedle devices 
for in vitro and in vivo drug and vaccine delivery studies. 
 Concerning the practical use of micro-dip-coating, the devices developed for this 
study (Figure 4.1) require very small volumes of coating solution, ranging from 10 μl for 
single microneedles to 100 μl for 50-needle, out-of-plane arrays. The ability to use small 
reservoirs of coating solution is important, because many experimental and established 
biotherapeutics are expensive and available only in limited quantity. Another practical 
issue is that air bubbles were sometimes formed in the dip-coating device, which 
interfered with the coating process. To prevent this, vent holes were incorporated into 
the design to release air (Figure 4.1). While coating large numbers of microneedle 
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devices, evaporation of coating solution from the dipping reservoir sometimes left behind 
solid deposits that could block the dip-coating holes. To prevent this, the syringe used to 
fill the dipping reservoir was manually pulsated to mix the coating solution.  
 
4.4.3 Delivery from coated microneedles 
 Delivery from coated microneedles was found to be efficient, where the vast 
majority of coated drug was deposited in the skin and essentially no residue was found 
on the skin surface, which suggests high bioavailability. Although efficient, the total 
amount of drug that can be delivered is constrained by the relatively small surface area 
of microneedles. Using vitamin B2 as a model drug, we were able to coat up to 2.6 μg of 
drug per microneedle (750 μm long and 200 μm wide, data not shown). Based on a 
maximum array size of a few hundred microneedles, we can conclude that hundreds of 
micrograms up to perhaps 1 mg of drug can be coated onto an array. Therefore, coated 
microneedles are most suitable for potent drugs, such as therapeutic proteins, DNA and 
vaccines. Vaccine delivery using coated microneedles is especially attractive, because 
microneedle-based delivery to the skin can target dendritic cells residing in the epidermis 
for a more potent immune response. Further, storage and delivery of vaccine in solid-




 Motivated by previous results demonstrating coated microneedles to deliver 
drugs and vaccines to the skin, here we sought to carry out a detailed study examining 
coating methods and their breadth of applicability. Using laser cutting followed by 
electropolishing, stainless steel microneedles of different geometries and configurations 
 
 82 
were fabricated with sharp tips and clean edges suitable for coating. To facilitate 
insertion and adhesion to the skin, microneedle patches were developed with pressure-
sensitive adhesive surrounding the base of the microneedles.  
 A novel micro-dip-coating apparatus was designed to control surface tension-
driven wicking of coating solution up microneedle shafts and onto the base substrate. A 
coating formulation was also developed to achieve uniform coating solution deposition 
on microneedles by using low concentrations of carboxymethylcellulose and Lutrol F-68 
NF as excipients to increase viscosity and decrease surface tension, respectively. Using 
this approach, single microneedles, in-plane rows of microneedles, and out-of-plane 
arrays of microneedles were coated without contaminating the base and with micron-
scale control over the length of the microneedle shaft to be coated. For the first time, 
organic and inorganic microparticles as well as viruses were coated onto microneedles, 
in addition to vitamin B2, calcein, bovine serum albumin, and plasmid DNA.  
 Microneedle coatings dissolved within seconds after insertion into cadaver skin.  
Successful delivery into skin was achieved from microneedles surface coated with 
molecules as well as microparticles up to 10 μm in diameter. Using novel ‘pocketed’ 
microneedles to mechanically protect coatings during insertion, 20-μm diameter particles 
were delivered into skin without wiping off onto the skin surface. Integrated patches 
containing 50-microneedle arrays were also shown to insert into the skin of human 
subjects and to deliver their coated payload into human cadaver skin. Altogether, this 
study provides versatile microneedle fabrication and controlled micro-dip-coating 
methods that enable coating of microneedles using a mild process with FDA-approved 
excipients with a wide variety of molecules and microparticles for delivery to the skin. 
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CHAPTER 5: COATING FORMULATIONS FOR MICRONEEDLES3 
 
ABSTRACT 
 The purpose of this study was to develop a rational basis for designing coating 
solution formulations for uniform and thick coatings on microneedles and to identify 
coating strategies to form composite coatings, deliver liquid formulations, and control the 
mass deposited on microneedles. To achieve this goal, microneedles were fabricated 
using laser-cutting and then dip-coated using different aqueous, organic solvent-based 
or molten formulations. The mass of riboflavin (vitamin B2) coated onto microneedles 
was determined as a function of coating and microneedle parameters. Coated 
microneedles were also inserted into porcine cadaver skin to assess delivery efficacy. It 
was found that sharp-tipped microneedles, including pocketed microneedles, were 
fabricated. Excipients that reduced coating solution surface tension improved coating 
uniformity, while excipients that increased solution viscosity improved coating thickness. 
Evaluation of more than 20 different coating formulations using FDA approved excipients 
showed that hydrophilic and hydrophobic molecules could be uniformly coated onto 
microneedles. Model proteins were also uniformly coated on microneedles using the 
formulations identified in the study. Pocketed microneedles were selectively filled with 
solid or liquid formulations to deliver difficult-to-coat substances, and composite drug 
layers were formed for different release profiles. The mass of riboflavin coated onto 
microneedles increased with its concentration in the coating solution, the number of 
coating dips and microneedles in the array. Coatings rapidly dissolved in the skin without 
wiping off on the skin surface. Thus, microneedles and coating formulations can be 
designed to have a range of different properties to address different drug delivery needs. 
                                                 
3 This work has been published as: Gill, H. S. and M. R. Prausnitz (2007). "Coating formulations for 




 Conventional transdermal delivery of drugs is limited to small, lipophilic and 
potent molecules (Prausnitz, Mitragotri et al. 2004). As an alternative approach, 
microneedles provide a minimally invasive method to create micron-scale pathways into 
the skin for delivery of small and large molecular weight compounds including proteins, 
in a manner expected to be safe, painless and cost-effective (Prausnitz 2004; Prausnitz, 
Mikszta et al. 2005). Microneedles are individual needles or arrays of needles having 
micron dimensions. They can be fabricated using micromachining tools adapted from the 
microelectronics industry (Reed and Lyev 2004). Both solid and hollow microneedles 
have been used in different modes to increase skin permeability by orders of magnitude 
to deliver large molecular weight molecules and nanoparticles into the skin (Henry, 
McAllister et al. 1998; McAllister, Wang et al. 2003; Chabri, Bouris et al. 2004). In vivo 
delivery has been shown for small molecules (Gardeniers, Luttge et al. 2003; Sivamani, 
Stoeber et al. 2005); peptides, such as insulin (Gardeniers, Luttge et al. 2003; McAllister, 
Wang et al. 2003; Martanto, Davis et al. 2004) and desmopressin (Cormier, Johnson et 
al. 2004); genetic material, including plasmid DNA (Mikszta, Alarcon et al. 2002) and 
oligonucleotides (Lin, Cormier et al. 2001); and vaccines directed against hepatitis B 
(Mikszta, Alarcon et al. 2002)  and anthrax (Mikszta, Sullivan et al. 2005). 
 An attractive method of transdermal delivery using microneedles involves the use 
of coated microneedles (Gill and Prausnitz 2007a). This process involves coating a drug 
formulation onto solid microneedles and inserting them into the skin for subsequent 
dissolution of the drug within the skin. Coated microneedles have previously been shown 
to deliver peptides (Cormier, Johnson et al. 2004) and proteins (Matriano, Cormier et al. 
2002) into the skin in vivo. Robust immune responses have also been generated in 
guinea pigs against an ovalbumin model antigen using this approach (Widera, Johnson 
et al. 2006).  
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 Although, coated microneedles have been used to deliver proteins and drugs into 
the skin, detailed studies of the coating process itself have not been published. 
Excipients are known to affect drug stability and activity (Yoshioka and Stella 2002), and 
therefore a single coating formulation may not be universally applicable to coat all 
therapeutic compounds and proteins. Therefore, it is desirable to identify a rational basis 
for designing coating formulations and different coating strategies, which can enable 
uniform coating of therapeutics with diverse physicochemical properties. To address this, 
we sought to study the effects of coating methods and formulations, and thereby provide 
a rational basis for designing microneedles and coating formulations for different 
applications. The micron length scales of microneedles impose special coating 
challenges to obtain uniform coatings and to obtain spatial control over the region of the 
microneedle to be coated. This is largely because the effects of surface tension, 
capillarity and viscous forces become more prominent at these small length scales. 
Therefore, in a companion study, we developed a novel micro-dip-coating process that 
applied uniform coatings with micron-scale control over the length of the microneedle 
shaft to be coated (Gill and Prausnitz 2007a). Using this device we investigated the 
range of compounds and molecules that can be coated onto microneedles and found 
that small molecules, proteins, DNA, viruses and microparticles as large as 10 μm in 
diameter could be applied onto microneedles as uniform and stable coatings (Gill and 
Prausnitz 2007a). Coatings were applied not only to the surface of microneedles, but 
could also be filled into ‘pocket’ cavities cut into the microneedles.  
 This study seeks to address the physical chemistry of coating formulations in 
greater detail to: (i) determine factors that affect coating uniformity and thickness, (ii) 
develop composite drug coatings to expand the utility of coated microneedles, (iii) deliver 
liquid formulations using solid microneedles, and (iv) examine the effect of microneedle 
and coating parameters on the mass of drug coated onto microneedles. To attain these 
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objectives, we varied the physical properties of the coating solution formulations to 
control the fluid mechanics of the dip-coating process and the thermodynamics of 
microneedle surface wetting. 
 The process of wetting a solid with a liquid under static conditions is described by 
the Young equation. According to this equation, the contact angle should be zero for the 
liquid to spread on the solid surface to form a uniform liquid film (Stokes, Evans et al. 
1997), which, upon drying, would provide a uniform solid coating on the solid substrate. 
In a coating process, however, the system is not at rest but in a dynamic state as the 
microneedle gets dipped into and out of the dipping solution and the gravity and local 
surface tension gradients cause micro-flows in the liquid film adhering to the 
microneedle surface. Therefore, the static contact angle is no longer an adequate 
measure of spreading, and the dynamic equilibrium depends upon: (i) the 
hydrodynamics of the system, (ii) the physical properties of the coating solution and the 
solid substrate, and (iii) the rate of evaporation of the solvent (Stokes, Evans et al. 1997). 
Unfortunately, the complex physics of dynamic wetting is not fully understood, which 
makes theoretical predictions of coating uniformity and thicknesses difficult (Blake and 
Ruschak 1997; Stokes, Evans et al. 1997). Therefore, while an understanding of the 
physics of coating can serve as a guide, the control and optimization of microneedle 
coatings requires experimental study. 
 Based on the physics of dip-coating, it is recognized that the dip-coating process 
consists of two distinct steps generally occurring in sequence: (a) the dipping and 
withdrawal step, resulting in the formation of a liquid film on the solid substrate, and (b) 
the drying step, resulting in the conversion of the adherent liquid film into a solid coating 
(Scriven 1988). In the first step, the formation of the liquid film after dipping and 
withdrawal is fluid mechanically controlled, such that the thickness of the liquid film 
formed on the solid substrate depends on the withdrawal speed of the solid substrate 
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and the physical properties of the coating solution, notably the surface tension and 
viscosity (Scriven 1988). A faster withdrawal speed of the solid substrate, a higher 
viscosity of the coating solution, and a lower surface tension of the coating solution tend 
to produce thicker liquid films. There correspondingly exists a critical speed of 
withdrawal for each coating solution-substrate combination, below which a liquid film 
does not form on the substrate because the hydrodynamic force of withdrawal is unable 
to overcome the forces of gravity and solution surface tension. If the substrate is 
withdrawn above the critical speed, an adherent liquid film is formed even from 
thermodynamically de-wetting liquids due to the hydrodynamic drag, which overcomes 
the opposing forces of surface tension and gravity. However, air entrainment in the liquid 
film at very high withdrawal speed prevents usage of systems with excessively high 
critical speed requirements (Scriven 1988; Stokes, Evans et al. 1997). 
 In the second step involving drying of the adherent liquid film on the substrate, 
the fate of the entrained liquid film is determined by a complex interaction of the 
hydrodynamics of the entrained liquid film, the rate of solvent evaporation, and the 
tendency of the liquid film to attain its thermodynamic equilibrium on the solid surface 
(Scriven 1988; Kheshgi 1997). Thermodynamically, the deposited liquid film may 
completely wet the surface, which favors formation of a uniform coating, or, alternatively, 
may have a tendency to de-wet the surface via a surface tension-driven contraction. In 
this case, increasing the coating solution viscosity can significantly slow down the de-
wetting process and provide the coating solution sufficient residence time on the solid 
surface to allow for solvent evaporation to form the solid film before de-wetting can occur 
(Scriven 1988). This kinetic effect, therefore, provides a means to coat devices with 
liquid formulations that thermodynamically favor de-wetting of the solid surface. 
 Guided by these physical principles, this study investigated the effect of coating 
solution surface tension and viscosity, and microneedle surface modification on (i) 
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microneedle coating uniformity, (ii) the mass of drug coated on microneedles, and (iii) 
the ability to fill pockets in microneedles with coating solution. The coating solution 
surface tension was modulated by the addition of surfactants and by using non-aqueous 
solvents. The coating solution viscosity was also modified to increase the coating 
thickness in order to coat larger amounts of a model drug onto microneedles. 
  
5.2 MATERIALS AND METHODS 
 
5.2.1 Fabrication of microneedles 
 Using methods described in detail previously (Gill and Prausnitz 2007a), 
microneedle geometries were first drafted in AutoCAD software (Autodesk, Cupertino, 
CA, USA) and then cut into 75 μm thick stainless steel sheets (Trinity Brand Industries, 
SS 304; McMaster-Carr, Atlanta, GA, USA) using an infrared laser (Resonetics Maestro, 
Nashua, NH, USA). To form pockets in microneedles, the desired shapes, dimensions 
and locations of the pockets on the microneedle shaft were also drafted and then cut 
together with the microneedles. ‘In-plane’ microneedles were fabricated as one-
dimensional rows of microneedles oriented parallel to their base substrate. ‘Out-of-plane’ 
microneedles were fabricated as two-dimensional arrays with microneedles bent 
perpendicularly out of the plane of their base substrate.  
 To deburr and clean microneedle edges and pockets, and to make the tips sharp, 
microneedles were electropolished in a solution containing glycerin, ortho-phosphoric 
acid (85%) and water in a ratio of 6:3:1 by volume (Fisher Chemicals, Fair Lawn, NJ, 
USA) by applying 1.8 mA/mm2 of current for 15 min. Microneedles were then washed 





5.2.2 Micron-scale dip-coating 
 Single microneedles, and arrays of multiple microneedles, were coated with 
molecules using a micron-scale dip-coating process developed previously (Gill and 
Prausnitz 2007a). Briefly, a coating solution containing a model drug and, in most cases, 
a surfactant and a viscosity enhancer was prepared in an aqueous or organic solvent. 
Microneedles were then dipped into the coating solution held in a dip-coating device. 
Coatings were formed by dipping just once into the coating solution, unless otherwise 
specified. The withdrawal speed of microneedles from the coating solution was manually 
maintained at approximately 2 mm/s to produce solid films and at approximately 0.35 
mm/s to fill the pockets with a liquid. The microneedles coated with solid films were 
allowed to air-dry for at least 24 h before use, whereas the pocketed microneedles filled 
with liquid were used immediately to minimize liquid evaporation. 
 
5.2.3 Coating solution formulations 
 Aqueous coating solution formulations (w/v % unless otherwise specified) were 
prepared using DI water according to the following recipes: Formulation A1: 0.1% 
sulforhodamine (Molecular Probes, Eugene, OR, USA). Formulation A2: 1% 
carboxymethylcellulose sodium salt (CMC, low viscosity, USP grade, CarboMer, San 
Diego, CA, USA), 0.5% Lutrol F-68 NF (BASF, Mt. Olive, NJ, USA), 0.1% 
sulforhodamine. Formulation A3: 52% (w/w) sucrose (Fisher Chemicals), 0.2%(w/w) 
Tween 20 (Sigma, St. Louis, MO, USA), 0.1% sulforhodamine. Formulation A4: 0.5% 
hyaluronic acid (Sigma), 0.5% Lutrol F-68 NF, 0.1% sulforhodamine. Formulation A5: 
0.5% xanthan gum (Sigma), 0.5% Lutrol F-68 NF, 0.1% sulforhodamine. Formulation A6: 
1% sodium alginate (Sigma), 0.5% Lutrol F-68 NF, 0.1% sulforhodamine. Formulation 
A7: 5% polyvinylpyrrolidone (BASF), 0.5% Lutrol F-68 NF, 0.1% sulforhodamine. 
Formulation A8: 52% (w/w) sucrose, 0.5% Lutrol F-68 NF, 0.1% sulforhodamine. 
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Formulation A9: 25% sucrose, 0.1% sulforhodamine. Formulation A10: 80% (v/v) 
glycerol, 20% (v/v) aqueous solution of 0.1% sulforhodamine. Formulation A11: 1% 
CMC, 0.5% Lutrol F-68 NF, 0.2% sodium fluorescein (Sigma). Formulation A12: 80% 
(v/v) glycerol, 20% (v/v) green food dye (Kroger, Atlanta, GA, USA). Formulation A13: 
80% (v/v) glycerol, 20% (v/v) yellow food dye (Kroger). Formulation A14: 80% (v/v) 
glycerol, 20% (v/v) red food dye (Kroger). 
 Organic solvent coating solution formulations (w/v % unless otherwise specified) 
were prepared according to the following recipes: Formulation O1: 5% poly(lactic-co-
glycolic acid) (PLGA, Absorbable Polymer International, Pelham, AL, USA) in acetonitrile 
(Fisher Chemicals). Formulation O2: 5% polyvinylpyrrolidone, 0.1% curcumin (Fisher 
Chemicals) in ethanol (Fisher Chemicals). Formulation O3: 5% PLGA, 0.03% 
sulforhodamine in acetonitrile. 
 
5.2.4 Coating solution viscosity and contact angle measurement 
 Viscosity of the aqueous coating solution containing CMC and sucrose was 
measured using an Ubbelohde type viscometer (viscometer no. 200-c21, Cannon 
Instrument Company, State College, PA, USA). Static advancing contact angles of the 
coating formulations containing various excipients were measured on electropolished 
stainless steel using a VCA 2500 XE contact angle system (AST Products, Billerica, MA, 
USA). Both the viscosity and the contact angles were measured at room temperature 
with a sample size of at least n=5 for each solution. 
 
5.2.5 Effect of coating solution surface tension and viscosity 
 To study the significance of surfactants and viscosity enhancers in producing 
uniform coatings on microneedles, single microneedles (n=3) were dipped in 
formulations A1, A2 and A3. Aqueous solutions of individual constituents of formulations 
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A2 and A3 with 0.1% sulforhodamine were also used to evaluate their relative and 
synergistic effects. Further, to assess the ability of different viscosity enhancers to 
produce uniform coatings using Lutrol F-68 NF as the surfactant, single microneedles 
(n=3) were dipped in formulations A4, A5, A6, A7 and A8. Dipped microneedles were air-
dried for 24 h and examined by fluorescence microscopy using an Olympus IX70 
fluorescence microscope (Olympus America, Center Valley, PA, USA) with a CCD 
camera (RT Slider, Diagnostic Instruments, Sterling Heights, MI, USA) to assess coating 
uniformity. 
 
5.2.6 Microneedle surface modification 
 To enable coating of microneedles without the use of excipients in the coating 
solution, we modified the stainless steel surface properties by depositing silicon dioxide 
or PLGA. Silicon dioxide was deposited using a vapor deposition method (PlasmaTherm 
PECVD, Plasma-Therm, St. Petersburg, FL, USA), while PLGA was deposited by 
dipping the microneedles in formulation O1. Surface-modified microneedles were then 
dipped into formulation A1, dried, and examined by fluorescence microscopy to assess 
coating uniformity. 
 
5.2.7 Coatings involving hydrophobic molecules, molten coating solutions and 
pocketed microneedles  
 To coat hydrophobic molecules, single microneedles (n=3) were dip-coated using 
formulations O2 or O3. Microneedles dipped in formulation O2 were immersed in water 
for 15 s and checked for loss of coating from the microneedle surface by fluorescence 
microscopy. To apply coatings of essentially 100% drug, single microneedles with or 
without rectangular pockets (400 μm long x 50 μm wide) were dipped in molten liquid 
solutions of lidocaine (Sigma) at 100°C or polyethylene glycol (MW 1500, Fisher 
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Chemicals) at 45°C, each containing up to 0.01% (w/v %) sulforhodamine. A hot plate 
was used as the heat source. 
 To apply coatings into microneedle pockets, single microneedles (n=3) with a 
rectangular pocket 400 μm long and 50 μm wide were dipped in formulation A2, A9 or 
A10. To coat both the microneedle surface and the pockets using formulation A2, a total 
of 6 dips each separated by 15 s were used. Multiple dips separated by drying intervals 
enabled filling the pockets with more material as compared to just a single dip. However, 
for formulations A9 and A10, single dips were used to fill just the pockets. For 
formulation A9, single dips prevented patchy coatings on the surface that can result from 
repeated dips and microneedle surface irregularities. For formulation A10, a single dip 
was sufficient to fill just the pockets, because the coating remained as a liquid phase. 
After each of these coating procedures, microneedles were air dried for at least 24 h and 
examined by fluorescence microscopy to assess coating uniformity. However, the liquid-
filled pocketed microneedles were used immediately for imaging or insertion into porcine 
cadaver skin to minimize liquid evaporation. 
 
5.2.8 Composite coatings 
 Single microneedles with or without pockets were sequentially dipped in different 
formulations to produce composite coatings of multiple molecules. Four different 
schemes were evaluated. (1) Pocketed microneedles with three circular pockets (90 μm 
diameter each) were sequentially dipped into different formulations to fill each pocket 
with a separate solution. This was achieved by first dipping all three microneedle 
pockets into formulation A12 and then sequentially dipping them into DI water, 
formulation A13, DI water and formulation A14. At each DI water wash step, the length 
of microneedle immersed into the wash water and all subsequent dip solutions was 
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sequentially decreased by one pocket length to retain the formulation filled in the pocket 
from the previous dip, but cleaning the other pocket(s). (2) Non-pocketed microneedles 
were dipped into formulation O3 (6 dips) and then into formulation A11 (6 dips). (3) Non-
pocketed microneedles were sequentially dipped into formulation A2, O1 and A11. (4) 
Microneedles with a rectangular pocket (400 μm x 50 μm) were dipped sequentially into 
formulations A9, O1 and A11. Between sequential dips and after completion of 
composite coatings, microneedles were air dried and imaged by fluorescence 
microscopy. 
 
5.2.9 Protein coatings 
 To assess the ability of optimized formulations to coat proteins, fluorescein 
isothiocyanate-labeled, (i) insulin derived from bovine pancreas (MW= 6 kDa, Sigma) 
and (ii) bovine serum albumin (BSA) (MW= 66 kDa, Sigma) were coated onto 
microneedles (n=3). Insulin (0.075% w/v) and BSA (0.15% w/v) were each coated onto 
single microneedles using excipients of formulations A2, A4 and A6. Microneedles were 
then air dried and imaged by fluorescence microscopy.  
 
5.2.10 Determination of mass in coatings 
 To modulate the mass of material coated onto microneedles, coating parameters 
and microneedle parameters were investigated. The coating parameters that were 
studied included, (i) the concentration of a model drug in the coating solution and (ii) the 
number of dips during coating, and the microneedle parameters that were investigated 
included, (i) the number of microneedles in the array and (ii) the ability to selectively fill 
the microneedle pockets. Riboflavin (vitamin B2, riboflavin-5’-phosphate sodium salt 
dihydrate, Fisher Chemicals) was used as the model drug in the coating formulations. In-
plane rows of microneedles were dipped into a solution containing 1% sodium salt of 
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CMC, 0.5% Lutrol F-68 NF and a range of riboflavin concentrations. For the study of 
coating parameter (i), riboflavin was used at 0.01%, 0.1%, 1%, 2%, 3% and 4% 
concentrations (n=5 rows for each condition) with 6 dips at 15 s intervals between dips. 
For coating parameter (ii), a 3% riboflavin concentration was used with 1, 3, 6, 12 or 24 
dips at 15 s intervals between dips (n=5 rows for each condition). To study microneedle 
parameter (i), a 3% riboflavin solution was used with out-of-plane arrays having 5 or 50 
needles (n=3 arrays for each condition) with 6 dips at 15 s intervals between dips. To 
investigate microneedle parameter (ii), i.e. the ability of pocketed microneedles to carry 
the model drug exclusively within the pockets and without coating the surfaces, in-plane 
rows with five microneedles each having a rectangular pocket (400 μm x 50 μm) were 
dipped into an aqueous formulation containing 1% or 3% riboflavin and 25% sucrose 
with 6 dips at 15 s intervals between dips. All coated microneedles were allowed to dry 
for at least 24 h and imaged by brightfield microscopy using an Olympus SZX12 stereo 
microscope (Olympus America) with a CCD camera (Leica DC 300, Leica Microsystems, 
Bannockburn, IL, USA). The mass of riboflavin in the coatings was determined by 
dissolving the coatings off the microneedles by immersing in DI water and vortexing for 1 
min, and then measuring riboflavin concentration by calibration fluorescence 
spectroscopy (SpectraMax Gemini, Molecular Devices, Sunnyvale, CA, USA; excitation 
= 450 nm, emission = 534 nm). The mass of riboflavin in the coatings was then 
calculated by multiplying the riboflavin concentration by the volume of DI water used to 
dissolve the coatings (typically 1 ml). 
 
5.2.11 Microneedle delivery into skin in vitro 
 Single, non-pocketed microneedles coated with formulation A2 (n=3) and single, 
pocketed (rectangular pocket - 400 μm x 50 μm) microneedles coated with formulation 
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A10 (n=3) were each manually inserted into abdominal porcine cadaver skin for 20 s and 
then removed. Microneedle insertion speed was manually maintained at 0.5 to 1 mm/s 
or 1 to 2 cm/s for microneedles coated with formulation A2 and A10, respectively. After 
removing the microneedles, the skin surface was examined by brightfield microscopy for 
coating residue. The skin was then examined histologically to assess the extent of 
delivery of microneedle coatings into the skin. The use of porcine cadaver skin has been 
approved by the Georgia Institute of Technology Institutional Animal Care and Use 
Committee (IACUC).  
 
5.2.12 Microneedle penetration into skin of human subjects 
 For in vivo analysis, out-of-plane arrays of non-coated microneedles were 
assembled into adhesive patches (Gill and Prausnitz 2007a), ethylene oxide sterilized, 
and manually applied to the volar forearms of human subjects (n=3). After removing the 
microneedle patch, gentian violet (2% solution, Humco, Texarkana, TX, USA) was 
applied to the treated site for 1 min and then wiped away using isopropanol swabs. 
Gentian violet selectively stained the sites of skin perforation, which identified the sites of 
microneedle penetration. The use of human subjects has been approved by the Georgia 
Institute of Technology Institutional Review Board (IRB). 
 
5.3 RESULTS AND DISCUSSION 
5.3.1 Microneedles for coating and insertion 
 Stainless steel microneedles with appropriate mechanical properties, sharp tips 
and clean edges were prepared in different configurations for dip-coating. Microneedles 
were fabricated as single microneedles without pockets (Figure 5.1 A), single 
microneedles with three circular pockets each 90 μm in diameter (Figure 5.1 B), single 
microneedles with a single rectangular pocket measuring 400 μm by 50 μm (Figure 5.1 
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C), in-plane microneedle rows each containing five microneedles (Figure 5.1 D) and out-
of-plane microneedle arrays each with 50 microneedles (Figure 5.1 E). All needles were 
700 μm in length, 160 μm in width and 50 μm in thickness. In-plane rows each with five, 





Figure 5.1. The different microneedle designs used for coating experiments. Brightfield microscopy 
image of (A) a single microneedle and (B) a circular-pocketed microneedle. (C) Scanning electron 
microscopy image of a rectangular-pocketed microneedle. (D) Brightfield microscopy image of an ‘in-plane’ 
row of five microneedles attached to a macroscopic base substrate for ease of handling. (E) Scanning 





5.3.2 Uniform coatings with spatial control 
 For dose reliability, it is critical to consistently apply uniform coatings just to the 
microneedle shafts without contaminating the substrate. Using custom-designed dip-
coating devices, microneedles of different configurations including single microneedles, 
in-plane rows of microneedles and out-of-plane microneedles, were uniformly coated 
with spatial control over the microneedle length being coated. A representative example 
of a riboflavin-coated, out-of-plane microneedle array containing 50 microneedles is 
shown in Figure 5.2 A and a representative magnified view of a single microneedle from 
the coated array is shown in Figure 5.2 B. The properties of coating solution excipients 
required to obtain uniform coatings are quantitatively assessed below. 
 
 
Figure 5.2. Out-of-plane microneedle array uniformly coated with riboflavin. Imaging by brightfield 
microscopy shows (A) uniform coating of microneedle shafts without contamination of the base substrate of 







5.3.3 Effect of coating solution surface tension and viscosity 
 Dose reproducibility and a high drug loading into microneedle coatings are critical 
for pharmaceutical drug and vaccine delivery applications of coated microneedles. This 
requires precision deposition of uniform and thick coatings onto microneedle shafts. 
Control over physical properties and kinetic parameters that affect the thermodynamics 
and hydrodynamics of dip-coating are expected to result in uniform and thick coatings. 
The two important physical properties of the dipping formulation that are known to 
influence the thermodynamics and hydrodynamics of dip-coating are surface tension and 
viscosity. However, the complex physics of dip-coating is not fully understood to develop 
theoretical models that can accurately predict the effect of surface tension and viscosity 
on coating uniformity and thickness, especially at the micron length scales of 
microneedles. Therefore, we dip-coated microneedles using different formulations to 
experimentally study their effect on coating uniformity and coating thickness. 
 First, microneedles were dipped in an aqueous solution containing 
sulforhodamine as a model drug. This formulation did not produce any coating on the 
microneedle (Figure 5.3 A). Thermodynamics of wetting dictates that only solutions that 
can completely wet the substrate i.e. have contact angles that approach zero can 
produce uniform films on the substrate, but the static contact angle of DI water on 
electropolished stainless steel was measured to be 47.5 ± 3 degrees. This large contact 
angle is the result of the aqueous coating solution having a surface tension (72 mN/m at 
25 °C) (Lide 2006) much larger than the stainless steel substrate (39.6 mJ/m2) (Zhao, 
Wang et al. 2007). We therefore added Lutrol F-68 NF, a surfactant, which lowered the 
coating solution surface tension and thereby decreased the contact angle to 25.9 ± 5 
degrees. This produced a uniform, but thin, coating on the microneedles (Figure 5.3 B). 
 Thicker coatings should increase the drug loading on microneedles. Based on 
the hydrodynamics of dip-coating, thicker coatings can be obtained by increasing the 
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coating solution viscosity, because elevated viscosity increases the hydrodynamic drag 
on the liquid during substrate withdrawal and leads to an increase in the volume of the 
liquid film that is formed on the microneedle upon withdrawal. Thus, to test the ability of 
a higher viscosity of the aqueous formulation to produce thicker coatings, CMC, a 
viscosity enhancer, was added to the aqueous coating solution. The surfactant, Lutrol F-
68 NF was not included in the formulation to independently study the effect of the 
viscosity enhancer. Using a 1% (w/v) aqueous CMC solution (viscosity: 47 ± 0.5 mPa.s) 
as the coating solution, a thicker coating was produced on the microneedle. However, 
the coating was localized towards the center, away from the microneedle periphery 
(Figure 5.3 C). This phenomenon of de-wetting suggested that the high surface tension 
of the CMC-containing aqueous solution induced contraction of the liquid film on the 
microneedle during the drying phase.  
 Finally, we simultaneously modified the surface tension and the viscosity of the 
coating solution by adding both the surfactant and the viscosity enhancer, which resulted 
in thick and uniform coatings (Figure 5.3 D). Thus, application of the macro-scale 
principles of thermodynamics and hydrodynamics of wetting and dip-coating to the 
micron length scale of microneedles enabled the formation of (i) uniform coatings on 
microneedles by matching the surface energies of the coating solution and the substrate 
to promote wetting and (ii) thicker coatings by increasing the viscosity of the coating 
solution, which increased the volume of the liquid film adhering to the microneedle upon 
withdrawal from the coating solution. These two criteria form a general basis for 
designing coating solution formulations to produce uniform coatings on microneedles. 
 In order to test the generality of these findings, we coated microneedles using 
another aqueous surfactant-viscosity enhancer system. Based on a previous study 
(Widera, Johnson et al. 2006), we selected Tween 20 as the surfactant and sucrose as 
the viscosity enhancer. A similar trend in coating uniformity and thickness was observed 
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for these aqueous coating solutions. A coating solution containing only Tween 20 
(contact angle: 25.3 ± 4 degrees) and sulforhodamine as the model drug resulted in a 
very thin, but uniform layer on the microneedle surface (Figure 5.3 E), while coating with 
only sucrose (52% w/w, viscosity: 18.7 ± 0.1 mPa.s) produced a thicker coating which 
was localized along the center of the microneedle shaft (Figure 5.3 F). Next, combining 
Tween 20  with sucrose increased the spread of the coatings on the microneedle surface, 
although the tip still remained uncoated (Figure 5.3 G). Thus, this surfactant-viscosity 
enhancer combination gave results similar to the Lutrol F-68 NF and CMC combination. 
Uncoated microneedle tips can slightly decrease the amount of drug coated onto 
microneedles. However, if this decrease is not significant, the excipients may be 
acceptable. 
 
5.3.4 Choice of excipients for coatings 
 The previous set of experiments identified two formulations useful for 
microneedle coatings, both of which utilized excipients categorized by the FDA as safe 
for parenteral delivery (Kibbe 2000). Optimization among these and other possible 
coating formulations will depend on drug physicochemical properties and needs of 
specific applications. For example, the use of CMC as a viscosity enhancer may be 
preferred over sucrose, because just 1% CMC (w/v) increased viscosity more than twice 
as much as 52 % (w/w) sucrose. Minimizing excipient concentrations maximizes drug 
content in the coatings. Comparing the surfactants, Lutrol F-68 may be preferred over 
Tween 20, because Lutrol F-68, which is solid at room temperature, produced hard 
coatings, whereas, Tween 20, which is a liquid at room temperature, produced coatings 
with a waxy texture. 
 For specific applications, it may be desirable to use other excipients, for example, 
to avoid unfavorable drug-excipient interactions. Therefore, based on the coating 
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formulation design criteria established above, we examined the ability of five additional 
viscosity enhancers in combination with Lutrol F-68 surfactant to produce good coatings. 
In all five cases, using hyaluronic acid (Figure 5.3 H), xanthan gum (Figure 5.3 I), 
sodium alginate (Figure 5.3 J), polyvinylpyrollidone (Figure 5.3 K) and sucrose (Figure 
5.3 L) as the viscosity enhancers, thick uniform coatings were formed, although the 
sucrose formulations did not coat the tips, which may be due to the crystallinity and 
relatively high surface tension of sucrose. Altogether, this suggests that decreasing 
surface tension and increasing viscosity of the coating solution is a broadly applicable 
approach to rationally design optimized coating solution formulations. 
 
 
Figure 5.3. Effect of surface tension and viscosity on coating uniformity on microneedles with 
sulforhodamine as the model drug. Fluorescence microscopy images with supplemental brightfield 
illumination to also view the microneedle outline after dip-coating single non-pocketed microneedles from 
different formulations. (A) Aqueous coating without excipients (Formulation A1). Based on Formulation A2, 
(B) coating only with Lutrol F-68 (F68), (C) coating only with carboxymethylcellulose (CMC), and (D) coating 
with the full formulation. Based on Formulation A3, (E) coating only with Tween 20, (F) coating only with 
sucrose, and (G) coating with the full formulation. Coating with F68 and (H) hyaluronic acid (HA) 
(Formulation A4), (I) xanthan gum (XG) (Formulation A5), (J) sodium alginate (SA) (Formulation A6), (K) 
polyvinylpyrrolidone (PVP) (Formulation A7), and (L) sucrose (Formulation A8). Aqueous coating without 
excipients (Formulation A1) on microneedle surfaces modified by pre-coating with (M) silicon dioxide (SiO2) 





5.3.5 Surface modification for coating 
 The addition of excipients may be undesirable for some drugs due to 
incompatibility between the drug and the excipients, which may lead to loss of drug 
activity (Yoshioka and Stella 2002). Rather than matching the surface energies of the 
coating solution and the microneedle surface by lowering the surface tension of the 
coating solution using a surfactant, we instead raised the surface energy of the stainless 
steel microneedles by making it more hydrophilic by pre-coating the microneedles with a 
thin layer of silicon dioxide. Subsequent coating with an excipient-free, aqueous solution 
of sulforhodamine resulted in a uniform but thin coating (Figure 5.3 M), consistent with 
coating using appropriately matched surface energies, but inadequate viscosity. 
 As an additional approach, the stainless steel microneedle surface was pre-
coated with PLGA, which also resulted in a uniform, but thin coating using an excipient-
free solution (Figure 5.3 N). Although, PLGA provides a hydrophobic surface that does 
not improve the thermodynamics of the microneedle-coating solution surface energy 
mismatch, we believe it instead increased surface roughness, which increased the 
hydrodynamic drag to allow entrainment of a liquid film and reduced the surface tension-
induced fluid contraction on the microneedle surface, and thereby increased the 
residence time for drying of a thin film on the PLGA surface. Although these excipient-
free methods produced only thin coatings, surface modification may nonetheless be well 
suited for coating sensitive protein solutions, since protein solutions are often inherently 
viscous and can act as self-viscosity enhancers to increase the coating thickness. 
 
5.3.6 Coating proteins 
 To directly assess the ability of optimized formulations to coat proteins, we 
coated insulin and bovine serum albumin onto microneedles using Lutrol F68 as the 
surfactant and either CMC, hyaluronic acid or sodium alginate as the viscosity enhancer. 
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Uniform coatings were obtained on the microneedle shafts for both proteins and all 
formulations tested (Figure 5.4). These observations are consistent with our previous 
work (Gill and Prausnitz 2007a), which demonstrated coating of peptides, proteins, DNA, 
viruses and microparticles. Together, these results suggest that the coating formulations 




Figure 5.4. Microneedles with protein coatings. Fluorescence microscopy images with supplemental 
brightfield illumination of single non-pocketed microneedles dip coated with fluorescein isothiocyanate-
labeled insulin and bovine serum albumin (BSA) using Lutrol F-68 (F68) and carboxymethyl cellulose (CMC) 
(Formulation A2), Lutrol F-68 and hyaluronic acid (HA) (Formulation A4) and Lutrol F-68 and the sodium salt 





5.3.7 Coating hydrophobic molecules 
 Having studied a variety of approaches to coat microneedles from aqueous 
formulations, we next wanted to investigate coating of hydrophobic molecules. This 
provided an interesting formulation challenge, because excipients for this application 
need to be soluble in an organic coating solution solvent as well as soluble in the 
aqueous environment of the skin for rapid dissolution off the microneedle after insertion. 
We therefore selected an amphiphilic viscosity enhancer, polyvinylpyrrolidone (PVP), 
which has good solubility in water and in ethanol, the organic solvent selected for the 
coating solution. Use of an organic solvent also removed the need to add surfactant, 
since ethanol already has a low surface tension (21.8 mN/m at 25 °C) (Lide 2006). For 
this study, curcumin was used as the model hydrophobic drug. Curcumin is also 
fluorescent, making it easy to visualize the coatings. 
 Microneedles prepared using this formulation resulted in uniform coatings of the 
microneedle surfaces (Figure 5.5 A). Consistent with the design, dipping the coated 
microneedles into DI water for just 15 s completely removed the coatings. Even though 
curcumin has negligible solubility in water, dissolution of PVP excipient caused the 
microneedle coating to fall off the microneedle surface (Figure 5.5 B). Using an alternate 
approach, microneedles were coated using PLGA as the viscosity enhancer from an 
acetonitrile-based coating solution containing sulforhodamine. This formulation approach 
also resulted in uniform coatings (Figure 5.5 C). Because PLGA coatings degrade slowly 
in water, this formulation is envisioned to provide controlled release from coated 
microneedles left in the skin for an extended period of time. 
 
5.3.8 Molten coating solutions 
 To simplify the coating formulation further, we next wanted to investigate 
coatings prepared without solvent or excipient. Because many solid drugs can remain 
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stable above their melting point, microneedles could be coated by dipping them into pure 
drug as a molten liquid. This method would enable coatings made of 100% drug and 
therefore result in higher mass loaded per microneedle. To test this idea, both pocketed 
and non-pocketed microneedles were dip-coated into molten lidocaine. Because the 
molten lidocaine was very viscous, the resulting coatings were thick and covered the 
entire surface in both non-pocketed (Figure 5.5 D) and pocketed (Figure 5.5 E) 
microneedles. As an additional model compound, molten polyethylene glycol (PEG) was 
coated onto microneedles, which was unable to coat non-pocketed microneedles well 
(data not shown). This probably occurred because molten PEG has high surface tension 
(45 mN/m at 70 °C) (Cheboyina, O'Haver et al. 2006). However, molten PEG was able 
to fill the interior of pocketed microneedles (Figure 5.5 F). These observations show that 
by using the molten liquid coating approach, drugs can be coated in their pure state on 
the surface of microneedles and inside microneedle pockets. As another variation, 
coating microneedles via the molten formulations may provide a way to coat and deliver 
hydrophobic molecules using molten polymers as a non-volatile solvent, because molten 
substances like PEG and PVP are known to improve solubility of hydrophobic drugs 
(Leuner and Dressman 2000). 
 
5.3.9 Pocketed microneedles 
 We next wanted to explore other ways to fill drug formulations into microneedle 
pockets. Pockets in microneedles can provide a protective cavity that can be exploited to 
deliver drug formulations that would otherwise be difficult to coat onto microneedles or 
would wipe off on the skin surface during insertion. The previously successful 
formulation comprising Lutrol F-68 and CMC was used to coat pocketed microneedles, 
and was found to coat both the microneedle surfaces as well as fill the pockets (Figure 
5.5 G). Thus, the use of formulations with surfactant and viscosity enhancer may provide 
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a general method to coat and fill pocketed microneedles. However, in some 
circumstances it may be desirable to only fill the protective pockets without coating the 
microneedle surfaces. We were able to selectively fill the pockets by (i) removing the 
surfactant to inhibit surface wetting and increase the critical speed of liquid film formation, 
(ii) keeping the viscosity enhancer to help retain coating solution within pockets, and (iii) 
increasing the solids content by using 25% sucrose to help produce a conformal solid 
layer in the pockets (Figure 5.5 H). 
 In some cases it may be desirable to store and deliver a drug in liquid solution. 
Pocketed microneedles offer the further possibility to deliver drug formulations as liquids. 
In this way, the liquid can be protected from wiping off the microneedle during insertion 
into skin (see below). Dipping microneedles in a viscous glycerol solution containing 
sulforhodamine selectively filled the pockets without coating the microneedle surfaces 
(Figure 5.5 I). Glycerol has a high surface tension (62.5 mN/m at 25 °C) (Lide 2006) and 
such a high critical speed of liquid film formation that it does not produce liquid films on 
the microneedle surface. Yet, it is viscous enough to fill the pockets by counteracting the 
surface tension that tends to collapse the liquid drop formed inside the pocket. To further 
prevent micron-scale surface roughness from accumulating any liquid drops, 
microneedle withdrawal from the glycerol solution was done at a slow speed (about 0.35 
mm/s). A limitation of this approach, however, is that the liquid in the pockets can 
evaporate: the glycerol in this example completely evaporated after approximately 24 h 
at ambient conditions. A similar coating using sulforhodamine dissolved in propylene 
glycol also selectively filled the pockets, but evaporated more rapidly (data not shown). 
For extended storage, these liquid filled pockets can be made more stable, for example, 





5.3.10 Composite coatings 
 Some therapeutic delivery scenarios may require the application of different 
drugs from the same microneedle and may require different drug release profiles. To 
address this scenario, our next objective was to study composite drug coatings as a way 
to coat multiple drugs on the same microneedle. As a first example, microneedles were 
prepared to each have three circular pockets. Using the liquid glycerol method to 
selectively fill pockets, a sequence of dipping and washing steps (see Materials and 
Methods) was used to fill the upper pocket with a red dye, the middle pocket with a 
yellow dye and the lower pocket with a green dye (Figure 5.5 J). This “traffic signal” 
design enabled microneedles with three different model drugs each sequestered in 
different pockets to avoid drug-drug interactions. 
 We also explored ways to prepare layered coatings, such that each layer could 
contain different drugs and could be formulated to have different release kinetics. To 
have a burst release of a first drug followed by slow release of a second drug, a PLGA 
layer containing sulforhodamine was overcoated with water-soluble excipients containing 
sodium fluorescein (Figure 5.5 K). To achieve sequential burst releases separated by a 
delay, a coating made of water soluble excipients containing sulforhodamine was 
overcoated with PLGA followed by applying another layer containing water-soluble 
excipients and sodium fluorescein (Figure 5.5 L). As another double-burst approach, 
microneedle pockets were selectively filled with water-soluble excipients containing 
sulforhodamine and covered with PLGA, which was then followed by another layer 
containing water-soluble excipients and sodium fluorescein (Figure 5.5 M). Dipping 
these layered composite microneedles into DI water for 1 min caused the exposed 
water-soluble layers to dissolve, while the PLGA layers and the water-soluble layers 
beneath them remained intact (data not shown). Variations on these composite coatings 
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could be tailored to meet drug delivery requirements for complex delivery profiles for 
single or multiple drugs. 
 
 
Figure 5.5. Microneedles with hydrophobic coatings, molten formulation-based coatings, coatings of 
pocket designs, and composite coatings. Fluorescence microscopy images with supplemental brightfield 
illumination to also view the microneedle outline after dip coating single microneedles (non-pocketed unless 
specified) from different formulations. Coating resulting from Formulation O2, containing polyvinylpyrrolidone 
and fluorescent curcumin in ethanol solvent (A) before and (B) after dipping in water for dissolution test. (C) 
Coating resulting from Formulation O3, containing poly(lactic co-glycolic acid) (PLGA) in acetonitrile solvent 
with fluorescent sulforhodamine. Coating resulting from liquid molten lidocaine containing fluorescent 
sulforhodamine on (D) non-pocketed microneedles and (E) pocketed microneedles. (F) Coating resulting 
from liquid molten polyethylene glycol containing fluorescent sulforhodamine. Coatings of pocketed 
microneedle designs from aqueous solutions of fluorescent sulforhodamine, (G) using Formulation A2 
containing carboxymethylcellulose and Lutrol F-68, (H) using Formulation A9 containing sucrose, and (I) 
using Formulation A10 containing glycerol. (J) Three circular pockets filled with glycerol solution containing a 
green dye (bottom pocket), a yellow dye (middle pocket) and a red dye (apical pocket) using Formulation 
A12, A13 and A14, respectively. (K) Two distinct coating layers from sequential dips, first in poly(lactic co-
glycolic acid) (PLGA) in acetonitrile solvent with fluorescent sulforhodamine (Formulation O3) and then in an 
aqueous solution of carboxymethylcellulose, Lutrol F-68 and sodium fluorescein (Formulation A11). (L) 
Three distinct coating layers from sequential dips, first in an aqueous solution of carboxymethylcellulose, 
Lutrol F-68 and sulforhodamine (Formulation A2), then in poly(lactic-co-glycolic acid) in acetonitrile 
(Formulation O1) and lastly in an aqueous solution of carboxymethylcellulose, Lutrol F-68 and sodium 
fluorescein (Formulation A11). (M) Three distinct coating layers from sequential dips, first in an aqueous 
solution of sucrose containing fluorescent sulforhodamine (Formulation A9), then in poly(lactic-co-glycolic 
acid) in acetonitrile solvent (Formulation O1), and lastly in an aqueous solution of carboxymethylcellulose, 







5.3.11 Factors affecting mass in coatings 
 Because microneedles are small, they are inherently limited to deliver small 
doses of drug. To determine how much drug could be delivered using microneedles and 
how to coat microneedles with controlled amounts of drug, we studied the effect of four 
parameters on the mass of drug coated onto microneedles using riboflavin (vitamin B2) 
as the model drug. First, two coating parameters were examined, which showed that the 
concentration of drug in the coating solution and the number of coating dips increased 
both the mass of drug coated onto microneedles and the thickness of the coating 
(Figures 5.6 A and B). At the maximum concentration of riboflavin used (i.e. 4%), a mass 
of 2.6 ± 0.3 μg of riboflavin was coated per microneedle. At the maximum number of dips 
used (i.e. 24 dips), a mass of 6.4 ± 0.8 μg riboflavin was coated per microneedle. 
Although we determined that coatings containing up to 1.8 μg riboflavin (i.e. 6 dips) 
successfully inserted into porcine cadaver skin, thicker coatings may wipe off onto the 
skin surface during insertion, which would limit their utility. Despite this limitation, these 
results suggest that a patch about 10 to 20 cm2 in size containing a few hundred 
microneedles is capable of delivering up to 1 mg of drug. 
 Changing microneedle design also affected drug coating. For example, 
increasing the number of microneedles from 5 to 50 did not change the drug mass on 
each microneedle and therefore proportionally increased the mass on the array 
approximately ten fold (Figure 5.6 C). This demonstrates the consistency and uniformity 
of the coatings among the needles of the arrays. Filling drug selectively into pockets 
reduced the amount of drug per microneedle. For example, filling the pockets with 
riboflavin using an aqueous formulation containing 3% riboflavin and 25% sucrose 




Figure 5.6. Mass of riboflavin coated on microneedles as a function of formulation and microneedle 
parameters. Effect of (A) riboflavin concentration in coating solution, (B) number of coating solution dips, 
(C) number of microneedles in the array, and (D) riboflavin concentration during selective coating of 
microneedle pockets. The coatings were done using (A), (B) and (C) Formulation A2, and (D) Formulation 
A9, with riboflavin as the model drug. Inset images show brightfield microscopy views of microneedles 
representative of the ones used to generate the data in the graphs. 
  
 
these relationships, a single coating or microneedle parameter or a combination can be 
used to coat a pre-determined mass of drug onto microneedles. 
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 As an additional assessment, we studied the reproducibility of controlling the 
amount of drug coated on to microneedles for drug delivery. While standard deviation 
bars are shown for the specific experiments in the graphs in Figure 5.6, the average 
relative standard deviation (RSD) of all the standard deviation bars in Figures 5.6 A, B 
and C equals 19%. As a comparison, the ‘readily acceptable’ pass criteria established by 
the FDA for the manufacture of tablets and capsules is set at RSD ≤ 5% . We expect 
that since the current microneedle coating process is performed manually, improved 
control of temperature and humidity in the coating environment, precision in making 
coating formulations, and automation of the coating process should reduce the RSD to 
within acceptable limits. 
 
5.3.12 In vitro and in vivo insertion into skin 
 It is important to prepare microneedle coatings that not only adhere to 
microneedles, but adhere to them during insertion into the skin and then dissolve off 
within the skin. To assess this, microneedles coated using many of the formulations 
discussed above were inserted into porcine cadaver skin. Coated microneedles were 
found to insert into the skin, their coatings did not wipe off onto the skin surface, and the 
coatings dissolved off the microneedles within less than 1 min and remained in the skin 
after microneedle removal.  
 Figure 5.7 A shows a representative result for a non-pocketed microneedle 
coated with an aqueous formulation of sulforhodamine. The histological section of pig 
skin after insertion and removal of the microneedle displays the track left in the skin at 
the site of microneedle insertion and the fluorescence of coated sulforhodamine 
deposited in the skin. Note the lack of fluorescence on the skin surface consistent with 
deposition within the skin, and not on the surface. After removal, the microneedle was 
clean, indicating complete delivery of the coated formulation. No noticeable difference 
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was perceived in the manual effort required to insert a coated versus an uncoated 
microneedle into porcine cadaver skin. 
 Through a companion study, quantitative assessment of the percentage of model 
drug delivered into the skin was made (Gill and Prausnitz 2007a). It was found that after 
a 5-min insertion of riboflavin coated microneedle rows with 5 needle shafts, 91 ± 6 % of 
the riboflavin was delivered into the skin, whereas 2 ± 1 % was found on the skin surface 
and 7 ± 2 % remained adhered to the microneedle surface after removal from the skin. 
 Figure 5.7 B shows a representative result for a pocketed microneedle filled with 
a liquid, glycerol-based formulation of sulforhodamine. As proposed, the pocket 
protected and carried the liquid formulation into the skin for subsequent and rapid 
release within the skin. Microneedle insertion speed affected the tendency of the liquid in 
the coatings to wipe off on the skin surface. Low insertion speeds (0.5 to 1 mm/s), 
typically used for inserting microneedles coated with a solid film, led to wiping off of 
some liquid on the skin surface (data not shown). To prevent this liquid wipe off during 
insertion, higher insertion speed of about 1-2 cm/s was used, which reduced the contact 
time between the liquid contained in the pockets and the skin surface, thus preventing 
liquid wipe off on the skin surface. 
 As a final assessment, we wanted to determine if these microneedles can insert 
into the skin of human subjects in vivo. Because we did not have IRB approval to use 
coatings on human subjects, we inserted a non-coated 50-microneedle array into the 
skin of human subjects. After removing the microneedles, a dye was applied to the skin 
to stain the sites of microneedle penetration into the skin. Brightfield imaging of the skin 
surface displayed stained dots that correspond to the insertion sites of all 50 of the 
microneedles in the array (Figure 5.7 C). Insertion of 50-microneedle arrays into the skin 




Figure 5.7. Insertion of microneedles into skin in vitro and in vivo. Histological sections of porcine 
cadaver skin after insertion and removal of (A) a non-pocketed microneedle coated with a solid-phase 
(Formulation A2) and (B) a pocketed microneedle filled with a liquid-phase (Formulation A10). The images 
exhibit perforations in the skin at the sites of microneedle penetration, which are surrounded by fluorescence 
of sulforhodamine released from the coatings indicated by the arrows. Images offset to the left show the 
coated microneedles used at the same magnification. Imaging was done using combined brightfield and 
fluorescence microscopy. (C) Brightfield microscopy surface image of skin on the forearm of a human 
subject stained with gentian violet after insertion and removal of an out-of-plane, 50 microneedle patch. The 




 Motivated by previous demonstrations of peptide and protein delivery using 
coated microneedles, this study provides the first detailed examination of the design and 
control of microneedle coating formulations. First, stainless steel microneedles with or 
without pockets were fabricated by laser micromachining. Then, microneedle coating 
solution formulations were designed by recognizing the need to lower solution surface 
tension (i) to promote good wetting of the microneedle surface and (ii) to decrease the 
critical speed of film formation, which facilitates retention of a liquid film on the 
microneedle after dipping. Good surface wetting was achieved through the addition of 
FDA approved surfactant excipients, the use of organic solvents, and modification of 
microneedle surface properties. Coating solutions were also designed to increase 
solution viscosity by using FDA approved viscosity enhancing excipients. Increased 
viscosity led to increased volume of liquid film adhering to the microneedles and an 
increased residence time of the adherent liquid film, producing thicker and more uniform 
 
 114 
coatings. When selectively filling pockets, increased solution viscosity was helpful, but 
surface tension was kept high in order to prevent coating of the microneedle surface. 
 Depending on drug properties, different aqueous, organic and molten coating 
formulations were used to coat microneedle surfaces and also to incorporate drugs into 
pockets in solid and liquid phases. Model proteins, insulin and bovine serum albumin, 
were coated onto microneedles using three different coating formulations, which 
demonstrates the versatility of this coating approach. Using an amphiphilic excipient, a 
hydrophobic molecule was also coated from an ethanol-based formulation and released 
from the microneedle in aqueous medium within 1 min. Composite drug coatings were 
applied as distinct layers, and to distinct regions on the microneedle, to either segregate 
different drugs from each other or to facilitate combination of burst and controlled 
release from the same microneedle.  
 The mass of a model drug, riboflavin, coated on microneedles was found to 
increase with its concentration in the coating solution, the number of coating solution 
dips, and the number of microneedles in the array. These data indicated that up to 1 mg 
of drug can be expected to be coated on a few hundred microneedles on a patch size of 
about 10 to 20 cm2. The average relative standard deviation of the current microneedle 
coating process was found to be 19%, although reduced deviation is expected with 
automated manufacturing. Microneedle insertion into skin was demonstrated and shown 
to rapidly release coatings within the skin and not wipe off on the skin surface. 
Altogether, this study shows that microneedle coating formulations can be designed to 








 Although naked DNA-based vaccines have shown promising results in rodents, 
their effectiveness in humans by a similar intramuscular route is severely limited due to 
their poor immunogenicity. In contrast, the intradermal route has shown hundreds of fold 
higher potency, but there is lack of a convenient and inexpensive method of intradermal 
delivery of DNA vaccines. Recently, microneedles have been developed for painless 
delivery to the skin, and have been used to show humoral response to conventional viral 
and protein based vaccines. The hypothesis of this study was that DNA-coated 
microneedles can be used to elicit an efficient cellular immune response. To test this 
hypothesis, groups of mice were immunized intradermally, either using microneedles 
coated with a plasmid encoding the hepatits C virus (HCV) non-structural (NS) 3/4A 
protein or via the gene gun. The intramuscular route of immunization was also compared. 
After immunization, in vivo functional NS3/4A-specific cytotoxic T lymphocytes (CTLs) 
were effectively primed using similar, or lower, DNA doses on microneedles as when 
using the gene gun or intra muscular injection. A 30-fold lower dose delivered to the skin 
using coated microneedles produced an in vivo CTL response similar to a 100 μg dose 
delivered by the intramuscular route. In conclusion, this study showed that microneedle 
based intradermal delivery of an HCV DNA vaccine has a high potency similar to the 
gene gun based delivery, while in contrast, the intramuscular route was less potent. 
 
 
                                                 
4 This work was done in collaboration with Dr. Matti Sãllberg and Dr. Jonas Sõderholm at the Division of 




 DNA vaccines are attractive alternatives to conventional virus- or protein-based 
vaccines. Their advantages include: easy manipulation and versatility to express 
different antigens, rapid and inexpensive mass-production capability, stability at room 
temperature and the ability to generate both humoral and cellular immune responses 
(Garmory, Perkins et al. 2005). Plasmid DNA vaccines are therefore considered as good 
vaccine candidates for a wide variety of pathogenic infections, especially those requiring 
cellular responses, like HIV, hepatitis C virus (HCV) and malaria (Greenland and Letvin 
2007).  
 However, low potency of DNA vaccines in humans has prevented their use as 
vaccines in a clinical setting. Few milligram of DNA is typically required to generate a 
robust immune response in humans (Donnelly, Berry et al. 2003; Graham, Koup et al. 
2006). To reduce the dose of DNA required for vaccination, various methods like 
adjuvants and different routes of delivery are being investigated (Greenland and Letvin 
2007). Intradermal immunization has shown about three orders of magnitude potency 
improvement in humans and non-human primates using gene guns and electroporation  
(Roy, Wu et al. 2000; Luckay, Sidhu et al. 2007). However, gene guns and 
electroporation are not attractive for mass vaccinations because they require elaborate 
vaccination protocols and equipment, and the gene gun typically requires multiple shots 
to deliver even a few microgram of DNA (Babiuk, Baca-Estrada et al. 2000; Peachman, 
Rao et al. 2003). Therefore, there is need for a convenient and robust intradermal DNA 
vaccine delivery method. 
 Recently, microneedles, which are sharp micron-sized structures that can 
painlessly penetrate the skin have been used to deliver micro-and macro-molecules 
(Prausnitz 2004; Prausnitz, Mikszta et al. 2005); genetic material, including plasmid DNA 
and oligonucleotides (Lin, Cormier et al. 2001; Chabri, Bouris et al. 2004); and vaccines 
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directed against hepatitis B, anthrax and Japanese encephalitis (Mikszta, Alarcon et al. 
2002; Dean, Alarcon et al. 2005; Mikszta, Sullivan et al. 2005) into the skin. Coated 
microneedles are especially attractive because they are readily coated with uniform 
coatings of proteins, plasmids and viruses, and can be assembled as ‘Band-Aid’ like 
coated microneedle patches for easy self-administration (Gill and Prausnitz 2007a), 
which is expected to facilitate mass vaccination. 
 Coated microneedles have been previously used to study the humoral response 
against a model antigen, i.e., ovalbumin, using ovalbumin-coated microneedles for 
immunization (Widera, Johnson et al. 2006). However, the ability of coated microneedles 
to deliver DNA vaccines has not been studied before. Furthermore, only humoral 
immune responses have been measured from other microneedle-based vaccinations 
(Matriano, Cormier et al. 2002; Mikszta, Alarcon et al. 2002; Mikszta, Sullivan et al. 
2005; Alarcon, Hartley et al. 2007). The ability to prime cellular responses using 
microneedle-based immunization has not been shown. Therefore, in this study we 
sought to measure the cellular immune response in vivo after the delivery of a DNA 
vaccine coated onto microneedles. 
 Induction of cellular immune responses is an important aspect of developing a 
therapeutic vaccine against HCV. Cytotoxic T lymphocytes  (CTL) are generally thought 
to play an important role in clearance of the HCV infection by killing HCV infected 
hepatocyte cells and by secreting antiviral cytokines (Chisari 1997). Recently, DNA 
immunizations in mice using a low dose of hepatitis C, codon optimized plasmid DNA 
vaccine, coNS3/4A, administered through a gene gun, produced robust CTL responses 
(Frelin, Alheim et al. 2003). We hypothesized that an intradermal delivery of this DNA 
vaccine through DNA-coated microneedles should similarly be able to induce a strong 
CTL response.  
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 Therefore, in this study, hepatitis C, codon optimized plasmid DNA vaccine, 
coNS3/4A, was coated onto microneedles and delivered into the skin of mice. CTL 
response after immunization was measured using chromium release assay and an in 
vivo tumor challenge assay. Microneedle effectiveness was also compared to gene gun 
and intramuscular (i.m.) delivery of the DNA vaccine. 
 
6.2 MATERIALS AND METHODS 
 
6.2.1 Microneedle fabrication and coating 
 Stainless steel microneedles were fabricated as described previously (Gill and 
Prausnitz 2007a). Briefly, microneedles were cut from stainless steel sheets using an 
infrared laser and electropolished to yield sharp, clean microneedles. Microneedles were 
then uniformly coated with the antigen, i.e., plasmid coNS3/4A, using an in-house 
developed dip-coating device. The aqueous coating solution consisted of, 1% (w/v) CMC, 
0.5% (w/v) F-68 and  4 mg/ml coNS3/4A plasmid. The coating solution excipients, CMC 
and F-68 were added  to modulate the coating solution surface tension and viscosity to 
obtain uniform coatings; and the high concentration of DNA solution was used to allow 
coating of a high mass of DNA on the microneedles (Gill and Prausnitz 2007b). The 
mass of plasmid DNA coated on to microneedles was then determined using UV 
spectrophotometery, and each row of five microneedles was found to be coated with 1.6 
μg of DNA.  
 Because plasmid coatings were difficult to visualize, the uniformity of coatings 
was assessed by coating microneedles with a model colored compound, vitamin B2 
(Fisher Scientific, Fair Lawn, NJ, USA). The coating solutions for vitamin B2 and the 




6.2.2 Cell lines 
 The SP2/0-Ag14 myeloma cell line (H-2d) was maintained in DMEM medium 
supplemented with 10% FCS (Sigma Chemicals, St Louis, MO, USA), 2 mM L-glutamin, 
10 mM HEPES, 100 U/ml penicillin, 100 μg/ml streptomycin, 1 mM nonessential amino 
acids, 50 μM β-mercaptoethanol, and 1 mM sodium pyruvate (GIBCO-BRL, 
Gaithersburgh, MD, USA). SP2/0-Ag14 cells with stable expression of NS3/4A were 
maintained in 800 μg geneticin (G418)/ml complete DMEM medium (Frelin, Alheim et al. 
2003). 
 RMA-S cells were maintained in RPMI 1640 medium supplemented with 5% FCS, 
2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin. All cells were grown 
in a humidified 37°C, 5% CO2 incubator.  
 
6.2.3 Immunization protocol 
 The experimental protocol was approved by the ethical committee for animal 
research at Karolinska Institute. HCV coNS3/4A plasmid DNA was used as the 
immunization antigen. 
 To assess the ability to induce CTL activity via microneedle based immunizations,  
groups of 4-8 week old female C57BL/6 (H-2b) mice (n=4 per group, Charles River, 
Uppsala, Sweden) were either immunized via gene gun (Bio-Rad Laboratories, Hercules, 
CA, USA) at a dose of 4 μg/mouse or via microneedles at a dose of 8 μg/mouse (5 
microneedles per mouse x 1.6 μg plasmid DNA per microneedle). A third non-immunized 
group (n=2 mice) of naïve mice served as the negative control. 
 For in vivo tumor challenge studies, groups of 4–8 week old female BALB/c (H-
2d) mice (n=5 per group) were either immunized with DNA coated microneedles (3.2 μg 
dose per mouse, 2 microneedles x 1.6 μg plasmid DNA per microneedle) or an 
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intramuscular (i.m.) injection of 100 μg of coNS3/4A in the tibialis anterior muscle. A third 
non-immunized group (5 mice) served as the negative control. 
 For coated microneedle-based immunizations, microneedles coated with plasmid 
DNA were manually inserted into trimmed abdominal or back skin and held for 1 min to 
allow dissolution of coated antigen into the skin. For gene gun-based immunizations, 
plasmid DNA was linked to 1-μm diameter gold particles for subsequent immunizations 
according to protocols supplied by the manufacturer. 
 
6.2.4 Detection of NS3/4A-specific CTL activity  
 Two weeks after immunization, spleen cells from DNA-immunized C57BL/6 mice 
or naïve mice were resuspended in complete RPMI 1640 medium supplemented with 
10% FCS, 2 mM L-glutamin, 10 mM HEPES, 100 U/ml penicillin and 100 μg/ml 
streptomycin, 1 mM nonessential amino acids, 50 μM β-mercaptoethanol, and 1 mM 
sodium pyruvate. In vitro stimulation was carried out for 5 days in 25-ml flasks at a total 
volume of 12 ml, containing 25x106 spleen cells and 25x106 irradiated (2000 rad) 
syngeneic spleenocytes. The re-stimulation was performed in the presence of 0.05 μM 
NS3/4A H-2Db binding peptide, a nine-mer sequence – GAVQNEVTL, corresponding to 
a NS3 CTL epitope in H-2b mice, synthesized by automated peptide synthesis as 
described previously (Frelin, Alheim et al. 2003). After 5 days of in vitro stimulation, a 
standard 51Cr-release assay was performed. Effector cells were harvested and a 4-h 51Cr 
assay was performed in 96-well U-bottom plates in a total volume of 200 μl. A total of 
1x106 target cells (peptide-pulsed RMA-S cells) were labeled for 1 h at 37°C with 20 μl of 
51Cr (5 mCi/ml) and then washed three times in PBS. Different numbers of effectors and 
51Cr-labeled target cells (5x103 cells/ well) were added to wells at effector:target (E:T) 
ratios of 60:1, 20:1, and 7:1. The level of cytolytic activity was determined after 
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incubation of effectors and targets for 4 h at 37°C. A volume of 100 μl supernatant was 
harvested and the radioactivity was measured with a γ-counter.  
 Results were expressed according to the following formula:  
percent specific lysis =(experimental release -spontaneous release)/(maximum release-
spontaneous release). Experimental release is the mean counts/minute released by the 
target cells in the presence of effector cells. Maximum release is the radioactivity 
released after lysis of target cells with 10% Triton X-100. Spontaneous release is the 
leakage of radioactivity into the medium of target cells . 
 
6.2.5 In vivo functionality of primed NS3-specific CTLs 
 In vivo challenge of immunized mice with SP2/0 myeloma cell line expressing 
coNS3/4A was performed according to the method described by Encke et al. (Encke, zu 
Putlitz et al. 1998). In brief, groups of BALB/c mice immunized once with microneedles 
or i.m. were injected with 1x106 coNS3/4A-expressing SP2/0 cells subcutaneously into 
the right flank. The kinetics of the tumor growth was determined by measuring the tumor 
size through the skin upto day 14 after tumor injection. The mean tumor sizes were 
compared using the analysis of variance (ANOVA) test. 
 
6.3 RESULTS AND DISCUSSION 
 
6.3.1 Uniform plasmid coatings  
 In-plane stainless steel microneedles measuring 700 μm in length and 160 μm in 
width were fabricated as a row of five microneedles. To ensure dose reproducibility, it is 
important to achieve a uniform plasmid coating on the microneedles. Because the 
plasmid coatings were difficult to visualize, the uniformity of coating was first determined 
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by using vitamin B2 as a model drug. After coating with vitamin B2, all the five 
microneedles of the row were found to be uniformly coated (Figure 6.1 A). Next, as an 
indirect method to assess plasmid coating uniformity, the plasmid-coated microneedles 
were physically scraped to damage the coating and visualize the parts of the 
microneedle surface coated with the plasmid. This analysis demonstrated that the 
plasmid was uniformly coated on all the five individual microneedles in the row. A 
representative single microneedle of the row after scraping is shown in Figure 6.1 B.  
 
 
Figure 6.1. Coated microneedles. (A) Microneedle row with five microneedles uniformly coated with 
vitamin B2 as a model drug. (B) Plasmid coating uniformly formed on the microneedle surface and 




6.3.2 Priming of NS3-specific CTLs by microneedle delivery 
 Because CTL responses are important to eliminate hepatitis C and other virus 
infected cells, we investigated the ability of microneedles to induce a CTL response. 
From the 51Cr release assay it was found that both the microneedle and gene gun 
immunized mice showed antigen specific cell lysis, while the naïve mice did not show 
any significant response (Figure 6.2). Even at low effector to target ratios (E/T ratio), 
significant target cell lysis was observed, indicating a robust immune response from 
DNA-coated microneedles, comparable to that from the gene gun based immunization.  
 Previous studies have shown that intradermal delivery of low (≤ 10 μg) doses of 
the codon optimized NS3/4A DNA plasmid effectively primes NS3-specific CTLs in 
Balb/c and C57BL/6 mice (Frelin, Ahlen et al. 2004). A single immunization with 4 μg of 
coNS3/4A using a gene gun primed in vitro-detectable CTLs (Figure 6.2 A). Importantly, 
a single 8 μg dose of coNS3/4A DNA delivered using microneedles primed a response 
fully comparable to the gene gun (Figure 6.2 B). The naïve mice did not show a 
detectable CTL activity (Figure 6.2 C). It has been previously shown that a single i.m. 
injection of the same low dose also fails to generate a robust CTL response (Frelin 
2004). These results collectively indicate that similar to a gene gun, microneedle based 
Intradermal immunization in mice produces a robust CTL response at low doses, without 
the use of an adjuvant. 
 
6.3.3 In vivo functionality of primed NS3-specific CTLs 
 An in vitro detection of robust NS3-specific CTLs does not imply that these cells 
also have a strong CTL activity in vivo. Therefore, we next wanted to conduct a 
functional in vivo test to measure the ability of the CTLs to kill HCV infected cells in vivo. 
Because HCV is a noncytolytic virus, a relevant model to characterize this in vivo CTL  
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Figure 6.2. Microneedle based immunization induces antigen specific CTLs, in vitro. C57Bl/6 mice 
were immunized once with codon optimized NS3/4A using either (A) microneedles (8 μg dose), (B) gene 
gun (4 μg dose) or (C) no immunization and sacrificed on week 2. The spleen harvested cells (effector cells, 
25x106 cells) were restimulated with a specific NS3 H-2Db peptide and 25X106 irradiated naive C57Bl/6 
spleenocytes cells. On day 5, 5x103 RMA-S cells were loaded with the H-2Db specific peptide and used as 
target cells. The specific cell lysis of target cells was then measured at different effector to target cell ratios. 
 
 
response is to determine the inhibition of tumor growth in vivo, using syngeneic 
lymphoma cells expressing the viral antigen. This assay is based on the principle that 
the injected syngeneic tumor cells will continue to grow in mice without in vivo functional 
CTLs against NS3/4A, but will diminish in size in mice with in vivo NS3/4A specific CTLs. 
Therefore, BALB/c mice immunized with microneedles or the i.m route were challenged 
with SP2/0 myeloma cells stably expressing NS3/4A. At day 14, the tumor size reduction 
was significant (p < 0.05) in the microneedle and the i.m. immunized mice (tumor size 
about 5 mm) as compared to the naïve mice (tumor size about 15 mm) Figure 6.3. It is 
important to note that a 3.2 μg dose delivered from coated microneedles and a 100 μg 
dose given i.m. produced similar reduction in tumor size.  
 These results highlight two significant findings. First, that just 3.2 μg of DNA 
delivered via coated microneedles could generate CTLs comparable to those generated 
by an i.m. delivery of 100 μg DNA, and second that the CTLs could produce lytic activity 
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in vivo, especially of cells endogenously expressing NS3/4A, much like an HCV infected 
hepatocyte. These results collectively suggest that the CTLs generated should be 
effective in lysing HCV infected hepatocytes, which also express NS3/4A in vivo. 
 
   
 
Figure 6.3. Microneedle immunization reduces tumor size in vivo. SP2/0 cells (1 x 106) stably 
transfected with NS3/4A were injected subcutaneously into the flank of naïve and immunized Balb/C mice. 
After 8 days of injecting the tumor, the size of the tumor was big enough to be measured and it was 
monitored till 14 days after tumor injection. 
 
 
6.3.4 Implications for microneedle-based plasmid DNA vaccination 
 Recently microneedles have been coated with DNA for rapid delivery into the 
skin (Gill and Prausnitz 2007a). The advantages of microneedles are that they cause 
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minimal discomfort and pain, are expected to be inexpensive and can be easily 
administered. Therefore, we tested a newly developed DNA based vaccine targeting the 
hepatitis C virus, a common infection in developing countries and for which no vaccine is 
yet available. We showed that microneedles were successfully coated with hepatitis C 
NS3/4A DNA vaccine in a controllable dose of 1.6 μg per row of five microneedles. 
Although we used multiple insertions of these rows for delivery of 8 or 3.2 μg dose, 
arrays of microneedles with tens and hundreds of microneedles can be easily fabricated 
instead, to deliver tens or hundreds of microgram of DNA into the skin in a single 
microneedle insertion. 
 Intradermal immunization using the coNS3/4A DNA-coated microneedles 
resulted in the priming of antigen specific CTLs at low vaccine doses (3 to 8 μg) and 
without the use of any additional adjuvants. The magnitude and efficiency of the lytic 
activity of the CTLs primed through microneedle and gene gun was similar. This 
suggests that these two approaches of intradermal delivery can yield comparable results. 
This is of significance because gene gun mediated delivery has consistently shown up to 
1000 fold higher potency than the i.m. route in larger animal models and phase-I human 
clinical trials (Fuller, Loudon et al. 2006). 
 Further, NS3/4A-expressing tumor-cell growth was inhibited in the vaccinated 
mice unlike in the naïve mice, demonstrating that the CTLs were effective in vivo as well. 
Importantly, the same level of protection through an i.m. administration required more 
than 30-fold higher dose of the coNS3/4A plasmid. This is in concurrence with previous 
observations when high doses (about 100 μg) of NS3/4A administered by a standard i.m. 
injection were required for a similar effect (Frelin, Ahlen et al. 2004). Also, based on 
previous work it is known that a low i.m. dose of the DNA in mice does not produce an 
effective immune response. Thus, microneedles coated with the coNS3/4A plasmid DNA 
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effectively prime lytic CTLs that are functional in vivo, and demonstrated about a 30-fold 
higher potency. 
 Microneedles used for coating DNA were about 700 μm in length. From previous 
skin histology studies we know that coatings from the microneedle surface dissolve in 
the skin and are delivered into the epidermis and the dermis. Therefore, we expect that 
different cell populations may have helped in generating a potent immune response. 
Antigen presenting cells, i.e., the Langerhans cells found in the epidermis and the 
dermal dendritic cells; and the keratinocytes of the epidermis may all have a role in the 
immune response (Bos 2005). 
 In conclusion, the present data suggests that a NS3/4A-expressing DNA plasmid 
can be effectively delivered through the skin using coated microneedles to elicit a robust 
CTL response specific for the hepatitis C virus. Similarities between the immune 
response from coated microneedle- and gene gun-based immunizations suggest that 




 Microneedles were successfully coated with hepatitis C NS3/4A DNA vaccine in 
a controllable dose of 1.6 μg per row of five microneedles. Mouse immunization using 
NS3/4A coated microneedles resulted in antigen specific cytotoxic T-lymphocyte 
production at low vaccine dose (3 to 8 μg) and without the use of adjuvants. Chromium 
release CTL assay demonstrated that the CTL response was robust, while the in vivo 
tumor challenge assay demonstrated that the cytotoxic T-lymphocytes had the ability to 
recognize and kill cells expressing the antigen, NS3/4A, in vivo. Together, these results 
show that coated microneedle-based immunization has the potential to be used for 
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intradermal immunization against hepatitis C. More broadly, this experiment suggests 
that coated microneedles have the potential to be used for administering DNA vaccines 
to the skin in a safe and painless manner, and may offer a convenient method for mass 
immunization in humans. 
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CHAPTER 7: SELECTIVE REMOVAL OF STRATUM CORNEUM BY 




This study sought to determine if microdermabrasion can selectively remove full-
thickness stratum corneum as a novel method of transdermal drug delivery. Although 
microdermabrasion has been used for cosmetic treatment of skin for decades, no study 
has assessed the detailed effects of microdermabrasion conditions on the degree of 
skin-tissue removal. Therefore, we histologically characterized the skin of rhesus 
macaques and human subjects after exposure to a range of different microdermabrasion 
conditions. Using a mobile tip, an increase in the number of treatment passes led to 
greater tissue removal ranging from minimal effects to complete removal of epidermis, 
although intra- and inter-subject variability was significant. Of note, these data showed 
for the first time that selective removal of full-thickness stratum corneum with little 
damage to deeper tissue could be achieved using microdermabrasion. In the stationary 
mode of microdermabrasion, selective stratum corneum removal was not observed, but 
micro-blisters could be seen. Similar tissue removal was observed in human subjects. 
As proof of concept for drug delivery applications, a model fluorescent drug (fluorescein) 
was delivered through microdermabraded skin and antibodies were generated after 
topical application of vaccinia virus in monkeys. In conclusion, microdermabrasion can 
selectively remove full-thickness stratum corneum with little damage to deeper tissues 
and thereby enhance transdermal flux and enable epidermal vaccination. 
                                                 
5 This work was done in collaboration with Dr. Andrew Fedanov, Dr. Senthilkumar Sakthivel, Dr. Ifor 
Williams, Dr. Seth Yellin, Dr. David Garber, Dr. Frances Priddy, Dr. Silvija Staprans and Dr. Mark 




 This study tested the hypothesis that microdermabrasion can selectively remove 
full-thickness stratum corneum with little damage to deeper tissues and thereby enhance 
transdermal flux and enable epidermal vaccination. Although applications to drug 
delivery are new, microdermabrasion was first introduced in 1985 and has become a 
popular cosmetic procedure, widely used to treat scars, acne and other cosmetic-
dermatologic conditions (Spencer 2005). Mechanistically, microdermabrasion involves 
impingement of sharp microparticles on the skin surface, which are then removed under 
vacuum into a waste container along with the abraded skin tissue. Partial-thickness 
removal of the skin’s top-most layer, the stratum corneum, has been demonstrated in 
microdermabraded skin in human subjects (Spencer 2005). Because stratum corneum 
provides the primary transport barrier to entry of drugs into the skin, microdermabrasion 
has been proposed as a method to remove the stratum corneum and thereby enhance 
transdermal drug delivery (Lee, Shen et al. 2003; Fujimoto, Shirakami et al. 2005). 
 Transdermal drug delivery is of interest as an alternative to the oral route, which 
is not suitable for many drugs, especially biopharmaceuticals, due to their poor 
absorption and degradation in the gastrointestinal tract (Degim and Celebi 2007). 
Biopharmaceuticals therefore usually require painful injections for their administration. 
Because the skin has a dense vasculature just 100 μm below the skin surface, the 
transdermal route offers an attractive alternative for systemic delivery of 
biopharmaceuticals and other drugs. Furthermore, the Langerhans cells in the viable 
epidermis are considered an attractive target for vaccine delivery to generate a robust 
immune response (Partidos, Beignon et al. 2003).  
 Despite the attractiveness of the skin, the stratum corneum barrier has limited the 
transdermal route to just 16 FDA-approved drugs, all of which are small and lipophilic 
molecules that require a low dose (Prausnitz, Mitragotri et al. 2004). To overcome the 
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transport barrier provided by the stratum corneum two different approaches can be 
followed: (i) to disrupt or bypass the stratum corneum or (ii) to physically remove the 
stratum corneum.  
 In accordance with the first approach, many chemical and physical methods have 
been investigated, including solvents and surfactants, iontophoresis, electroporation, 
sonoporation, high velocity jets and particle bombardment methods, and microneedles 
(Prausnitz, Mitragotri et al. 2004). Based on the second approach, lasers and thermal 
ablation have been investigated to remove stratum corneum using focused thermal 
energy (Sintov, Krymberk et al. 2003; Fang, Lee et al. 2004a). This second approach of 
stratum corneum removal should be highly effective for drug delivery, since it completely 
removes the transport barrier, but its application has been constrained by the need to 
develop methods that selectively remove stratum corneum without damaging deeper 
tissues. In addition, removal of stratum corneum can also expose the keratinocytes of 
the viable epidermis for direct efficient targeting by drugs, for example by viral vectors for 
gene therapy of skin diseases (Titeux and Hovnanian 2006).  
 Various researchers have shown increased permeability of freshly excised 
animal skin to very low molecular weight compounds (<300 Da) after microdermabrasion, 
recording a 12-fold increase in delivery of estradiol (Fujimoto, Shirakami et al. 2005), a 
25-fold increase for vitamin C (Lee, Shen et al. 2003), and a 15-fold increase for 5-
aminolaevulinic acid (Fang, Lee et al. 2004b). These studies have reported thinning of 
the stratum corneum, but have not demonstrated full-thickness removal of stratum 
corneum. In contrast to microdermabrasion, which uses vacuum to produce flow of 
microparticles, a related approach called microscission uses a positive pressure to 
accelerate and impinge microparticles on the skin. Using this approach, lidocaine 
delivery and blood glucose measurement was demonstrated in vivo in human subjects 
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(Herndon, Gonzalez et al. 2004). Of note, neither microdermabrasion nor microscission 
has been successfully used before to deliver macromolecules or vaccines. 
 In this study, we propose that selective full-thickness removal of stratum corneum 
is the key to enabling microdermabrasion to increase skin permeability to 
macromolecules and vaccines. To identify such conditions and test our hypothesis, we 
carried out a detailed study of skin histology after microdermabrasion at different 
conditions. Specifically, microdermabrasion was performed in vivo on the skin of rhesus 
macaques and human subjects. Multiple skin biopsies were then obtained from the 
microdermabraded sites and histologically analyzed to assess the effects of 
microdermabrasion on the different skin layers. In addition, the suitability of 
microdermabraded sites for drug delivery was assessed in rhesus macaques using 
sodium fluorescein and modified vaccinia Ankara (MVA) virus as model compounds for a 
hydrophilic drug and a vaccine, respectively. 
  
7.2 MATERIALS AND METHODS 
 
7.2.1 Microdermabrasion apparatus  
 Microdermabrasion was performed using an FDA-approved device (MegaPeel® 
Gold Series, DermaMed International, Lenni, PA, USA) with disposable 
microdermabrasion tips having a skin-contacting hole with a 7 mm inner diameter 
(Figure 7.1 A). The size and morphology of the aluminum oxide particles (DermaMed 
International) used for microdermabrasion were determined through scanning electron 
microscopy (LEO-1530, LEO electron microscopy, Cambridge, England). The particles 
were found to have highly irregular shapes with sharp edges (Figure 7.1 B).  The largest 
dimension of the majority of the particles was between 100 to 200 μm, although a small 




Figure 7.1. Microdermabrasion tip and particles. A microdermabrasion tip pressed on a black paper in a 
stationary mode with aluminum oxide microparticles flowing inside the tip (A), and scanning electron 
microscopy image of aluminum oxide microparticles with a small population of very small particles (pointed 
to by white arrows) (B). 
 
 
 To facilitate reliability in the manual microdermabrasion procedure, rectangular 
stencils (55 x 30 mm) made of polyethylene medical foam tape (TM9716, MACtac, Stow, 
OH, USA) with slits (40 x 10 mm) precisely cut using a CO2 laser (LS500XL. New 
Hermes, Duluth, GA, USA) were attached to the skin of rhesus macaques and human 
subjects. For the mobile tip mode, the tips were moved manually back and forth within 
the slit of the stencil. The slit width of 10 mm closely accommodated the outer diameter 
of the microdermabrasion tip and thereby facilitated repeated motion over the same path 
on the skin. For the stationary tip mode, the microdermabrasion tip was placed directly 







7.2.2 In vivo rhesus macaque microdermabrasion 
 Microdermabrasion was performed on the backs of rhesus macaque monkeys 
(Yerkes National Primate Research Center, Emory University, Atlanta, GA) after 
trimming the hair and cleaning the skin with ethanol swabs.  
 For the mobile mode of microdermabrasion, two pressure settings of 25 kPa at 
100, 200 and 300 passes and 50 kPa at 10, 30, 50, 80 and 100 passes were each 
tested in triplicate. Three monkeys were assigned for each pressure level group, and 
each monkey of the group received all the passes at different skin sites to enable every 
monkey to act as its own control. One pass is defined as the movement of the 
microdermabrasion tip from one end to the other on the treated skin site exposed 
through the stencil slit. The hand-piece was manually moved at a speed of 
approximately 40 mm/s and the flow rate of microparticles was kept at 70% of the 
maximum flow rate of the instrument. A vacuum pressure of 50 kPa was selected 
because it is considered a medium dermabrasion setting by the manufacturer, and this 
pressure resulted in complete stratum corneum removal in preliminary experiments on 
porcine cadaver skin (data not shown). A lower vacuum pressure of 25 kPa was also 
selected to determine the effect of pressure. A non-microdermabraded, but trimmed and 
ethanol-cleaned section of skin from the back of the monkeys was used as a negative 
control. 
 The stationary mode of microdermabrasion was performed by keeping the hand-
piece stationary on the skin and exposing the skin to a vacuum pressure of 30 kPa or 50 
kPa for 3 s or 6 s each. The treatments were done in triplicate with  (n=3 monkeys, each 
monkey received all the treatments). To facilitate direct comparison between 
microdermabrasion in the mobile mode and the stationary mode, the equivalent 
microdermabrasion exposure time in the mobile mode was calculated by dividing the tip 
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diameter (7 mm) and by the speed of tip movement (40 mm/s) and then multiplying by 
the number of passes.  
 A 6 mm skin biopsy was obtained from the center of each microdermabraded 
and control skin site (mobile mode = center of stencil; stationary mode = center of 
treated skin), mounted in OCT (Tissue-Tek®, Fisher Scientific, Pittsburg, PA, USA), and 
frozen in liquid nitrogen for histological analysis. This protocol was approved by the 
Emory University IACUC.  
 
7.2.3 Microdermabrasion of human subjects 
 Sixteen healthy human volunteers, consisting of 6 males and 10 females aged 19 
to 40 years old, were recruited for the study from the general population of Atlanta, GA, 
USA. 
 A group of six subjects was exposed to the mobile mode of microdermabrasion 
at 40 kPa vacuum pressure with seven passes of the hand-piece at a speed of 
approximately 13 mm/s (i.e., three times slower than that used in monkeys). Two groups 
of five subjects each were exposed to the stationary mode of microdermabrasion at a 
vacuum pressure 30 kPa and 45 kPa, respectively, for 3 s each. The flow rate of 
microparticles was always kept at 70% of the maximum flow rate of the instrument. 
 For each subject, microdermabrasion was performed on the volar forearm. One 
forearm was randomly selected for microdermabrasion and the other forearm acted as 
the negative control. The mobile and the stationary modes of microdermabrasion and 
the subsequent biopsy collection were performed in a manner similar to that of the 
monkeys, with the exception that the size of the skin biopsy was 1 mm. This protocol 





7.2.4 Histology and microscopy 
 Skin biopsies embedded in OCT were cut into 10-μm thick sections using a 
cryostat (Cryo-Star HM 560 MV, Microm, Waldorf, Germany) and mounted onto glass 
slides (Fisher Scientific). All the skin sections except those from sites exposed to sodium 
fluorescein were stained with hematoxylin and eosin (H&E). Skin sections were then 
examined either for removal of skin layers or for delivery of sodium fluorescein using 
brightfield or fluorescence microscopy, respectively (Nikon Eclipse 600, Nikon, Tokyo, 
Japan), with a CCD camera (Retiga 1300, QImaging, Surrey, BC, Canada). 
 
7.2.5 Histological assessment of skin layers 
 Quantitative analysis was carried out on biopsies taken from monkeys exposed 
to mobile-mode microdermabrasion. In this case, 30 consecutive H&E-stained skin 
sections from the biopsy were scored visually for full-thickness removal of stratum 
corneum and of viable epidermis. Two investigators independently scored the biopsies 
by determining the percentage of each tissue layer with full-thickness removal on each 
slide.  Stratum corneum and viable epidermis were each categorized into the intervals 0-
25% removal, 26-50% removal, 51-75% removal or 76-100% removal, and scored as 0, 
1, 2 or 3, respectively. For example, a skin section with full-thickness removal of stratum 
corneum on slightly less than half of the slide and with almost all of the viable epidermis 
intact was scored ‘1’ for stratum corneum and ‘0’ for epidermal removal. 
 The resulting data were presented in two ways. First, the average score was 
calculated for each condition to provide a single number that characterized the degree of 
tissue removal from each layer. To provide additional information about variability, the 
distribution of scores for each condition was also reported as a histogram. 
 Qualitative analysis was carried out for the remaining biopsies taken from 
monkeys exposed to stationary-mode microdermabrasion and all biopsies taken from 
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humans. In this case, 3 to 5 consecutive sections each were visually assessed for 
damage and characterized qualitatively.  
  
7.2.6 Topical delivery to microdermabraded skin 
 To assess the ability to deliver drugs through microdermabraded skin, 200 μl of 
an aqueous solution containing 10 % (w/v) sodium fluorescein (parenteral injection-
grade, Akron, Buffalo Grove, IL, USA), was applied topically for 2 h on skin 
microdermabraded at 25 kPa for 100, 200 and 300 passes, and at 50 kPa for 50 passes 
(n=3 monkeys). Topical application of the fluorescein solution to a non-
microdermabraded skin site was used as a negative control. An 8-mm diameter skin 
biopsy was collected from each skin site to assess delivery into the skin by fluorescence 
microscopy of histological sections.  
 The fluorescein solution also contained 5 μg/ml human MIP-3α protein (360-
MP/CF, R&D Systems, Minneapolis, MN, USA) and 1 x 109 plaque forming units (PFUs) 
of MVA virus, which were added to assess delivery of larger compounds. However, our 
immunohistochemical staining protocol failed to stain positive controls and, therefore, we 
have no results concerning delivery of these compounds. 
 In a separate study, we assessed the delivery of MVA by measuring the immune 
response from topical application of this model vaccine (Tatsis, Lin et al. 2007) onto 
microdermabraded skin. The skin of monkeys (n=3) was exposed to  of phosphate-
buffered saline containing 6 x 108 PFUs of MVA virus after microdermabrasion at 25 kPa 
and 10-15 passes as a primary immunization. A booster dose was applied 11 weeks 
later after microdermabrasion at 50 kPa and 50 passes at a different site on the back of 
the monkeys. Blood samples were collected 1 day before the primary immunization, 6 
weeks after primary immunization and 1 week after the booster dose. The blood 
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samples were analyzed in triplicate using ELISA to determine the end point titers of the 




7.3.1 Mobile microdermabrasion in monkeys 
7.3.1.1 Qualitative measure 
 To test the hypothesis that microdermabrasion can selectively remove full-
thickness stratum corneum with little damage to deeper tissues, we histologically 
characterized the skin of rhesus macaques after exposure to microdermabrasion at 50 
kPa vacuum pressure as a function of the number of passes across the skin. 
 Histological analysis showed a broad range of removal effects on the stratum 
corneum and the viable epidermal layers of the skin, as compared to the untreated skin 
(Figure 7.2 A). In general, more skin was removed with increasing number of passes. At 
10 passes, the stratum corneum and viable epidermis resembled the negative control, 
exhibiting full-thickness stratum corneum removal only at occasional focal regions 
(Figure 7.2 B). At 30 and 50 passes, larger areas of the skin were seen to have full-
thickness removal of stratum corneum accompanied by little damage to the viable 
epidermis (Figure 7.2 C and D). At 80 and 100 passes there was almost complete 
removal of the stratum corneum accompanied by extensive damage to the viable 
epidermis and some damage to the dermis (Figure 7.2 E and F). In support of our 
hypothesis selective removal of full-thickness of stratum corneum with little damage to 
deeper tissues was observed at 30 to 50 passes. 
 Aluminum oxide particles with diameters less than 5 μm were sometimes 
observed sticking to the skin after microdermabrasion (indicated by arrows in Figure 7.2 
E). Note that most microdermabrasion particles are on the order of 100 μm in size and 
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that these small adherent particles are from the particulate debris (Figure 7.1 B). 
Adherent particles were almost always seen after 80 and 100 passes (> 90% of skin 
sections), but only occasionally present after 10, 30 and 50 passes (< 5% of skin 
sections). This result may be explained by the observation that body fluid including blood 
was often observed on the skin surface after 80 and 100 passes, whereas fluid was 
generally not seen after 10, 30 and 50 passes, although mild to strong erythema was 
common. We hypothesize that the small particles adhered to the wet skin created after 
80 and 100 passes due to surface tension forces. 
 
 
Figure 7.2. Effect of number of passes on removal of skin layers in monkeys after mobile 
microdermabrasion. Brightfield images of H&E stained skin sections from biopsies obtained from an 
untreated control site (A), and sites exposed to mobile mode of microdermabrasion with 50 kPa vacuum 
pressure and with 10 passes (B), 30 passes (C), 50 passes (D), 80 passes (E) and 100 passes (F). Solid 
line indicates intact stratum corneum and is drawn at the junction of the stratum corneum and the epidermis 
layers, dotted rectangles indicate areas of complete stratum corneum removal, and solid arrows point to 





7.3.1.2 Quantitative measure (effect of number of passes) 
 To quantify the effects of microdermabrasion on skin tissue removal, the extent 
of full-thickness removal of stratum corneum and of viable epidermis was visually scored 
on a scale of 0 to 3 (see Materials and Methods section). Based on these scores, the 
mean tissue removal scores were computed as a function of the number of 
microdermabrasion passes (Figure 7.3 A). The mean tissue removal scores represent 
the average fraction of a given skin section from which the full thickness of the stratum 
corneum or viable epidermis was removed. Further, as a measure of the variability of 
tissue removal, the distribution of scores for each condition was also reported as a 
histogram (Figure 7.3 B). 
 This analysis showed that the extent of full-thickness stratum corneum removal 
and the extent of full-thickness viable epidermis removal both increased with increasing 
number of passes, as measured by the mean tissue removal score (ANOVA, p < 0.05, 
Figure 7.3 A) and the frequency of non-zero tissue removal scores (Figure 7.3 B).  
 Stratum corneum was mostly intact until 30 microdermabrasion passes, at which 
point 34% of the skin sections, including skin from all three monkeys, had substantial 
removal of stratum corneum (with a mean tissue removal score of 0.6 ± 0.9), which was 
accompanied by just 5% of the skin sections exhibiting substantial removal of viable 
epidermis (with a mean tissue removal score of 0.1 ± 0.4). At 50 passes, 99% of the skin 
sections had substantial stratum corneum removal (with a mean tissue removal score of 
1.7 ± 0.7), which was accompanied by 23% of the skin sections exhibiting substantial 
removal of viable epidermis (with a mean tissue removal score of 0.3 ± 0.6). At 80 and 
100 passes, 99 – 100% of skin sections had substantial stratum corneum removal (with 
mean tissue removal scores of 2.6 ± 0.6 and 3.0 ± 0.2, respectively), which was 
accompanied by 92 – 99% of skin sections exhibiting substantial removal of viable 
epidermis (with means tissue removal scores of 1.9 ± 0.8 and 1.8 ± 0.9, respectively).  
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 These results are consistent with the qualitative analysis above and show that 
significant stratum corneum removal can be achieved with almost no damage to viable 
epidermis after 30 passes and that widespread stratum corneum removal can be 
achieved with low levels of damage to viable epidermis after 50 passes. Although further 
optimization is needed, these findings suggest that microdermabrasion might be used for 
transdermal drug delivery at conditions that selectively breach the stratum corneum 
barrier without causing significant damage to living tissue below.  
 
7.3.1.3 Quantitative measure (effect of vacuum pressure) 
 To determine the effect of microdermabrasion vacuum pressure on skin tissue 
removal, microdermabrasion was also performed at 25 kPa. Because vacuum pressure 
is the driving force for the flow of microparticles, a decrease in the vacuum pressure 
from 50 to 25 kPa is expected to decrease the microparticle kinetic energy and flow rate. 
In an attempt to compensate for this, more passes were used at this lower pressure, 
which yielded full-thickness stratum corneum tissue removal scores of 2.9 ± 0.4, 3.0 ± 
0.1 and 2.3 ± 1.1 and viable epidermis tissue removal scores of 2.9 ± 0.4, 3.0 ± 0.1 and 
2.3 ± 1.1 at 100, 200 and 300 passes, respectively (histology images not shown). Blood 
was generally observed following microdermabrasion, and residual particles were also 
seen on the histology sections. These results suggest that we overcompensated for the 
expected reduction in efficacy at the lower pressure, because all three conditions led to 
almost complete removal of both the stratum corneum and the viable epidermis. Indeed, 
the tissue removal scores at 25 kPa and 100 passes were similar to those at 50 kPa and 
100 passes, which suggests that this two-fold change of pressure had less effect than, 






Figure 7.3. Tissue removal scores of skin layers. Quantitative representation of removal scores of 
stratum corneum and epidermis for a control site and sites exposed to different pass numbers at a mobile 
mode of microdermabrasion of 50 kPa vacuum pressure, as frequency distribution for a total of 180 scores 
for each site (A), and their means (B). Numbers above the bars represent percent frequency (A) and means 
(B). Error bars correspond to the standard deviations. SC=stratum corneum, Ep=Epidermis. 
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7.3.2 Stationary microdermabrasion in monkeys 
 The stationary mode of microdermabrasion is simpler to perform than the mobile 
mode because the microdermabrasion tip just needs to be held against the skin for a 
fixed period of time. We therefore characterized the histological effects on skin tissue 
removal from stationary microdermabrasion to assess its ability to selectively remove 
full-thickness stratum corneum. Similar to the untreated skin (Figure 7.4 A), the stratum 
corneum and the viable epidermis were both generally intact following exposure at 30 
kPa for 3 s (Figure 7.4 B) and 6 s (Figure 7.4 C). However, using a higher vacuum 
pressure of 50 kPa with an exposure time of 3 s led to microscopic blisters (separation of 
viable epidermis from the dermis, indicated by the double-line arrow in Figure 7.4 D) 
accompanied by partial removal of stratum corneum (Figure 7.4 D), while a 6 s exposure 
time led to extensive removal of both stratum corneum and viable epidermis (Figure 7.4 
E). 
 For most drug delivery scenarios, blister formation is an unnecessary injury that 
should be avoided. However, for vaccine delivery applications, blisters may enhance the 
immune response by recruiting inflammatory cells to the delivery site (Bos 2005). 
 Residual particles were observed on some histology sections (indicated by 
single-line arrows in Figures 7.4 C, D and E). Overall, selective full-thickness removal of 
the stratum corneum was not observed, but was instead mostly accompanied by 
extensive damage to the viable epidermis.  
 The mobile and the stationary modes at 50 kPa can be compared by calculating 
an equivalent exposure time for the mobile-mode procedures (see Materials and 
Methods). Stationary-mode dermabrasion for 6 s can be compared to mobile-mode 
dermabrasion at 30 passes and 50 passes, which have equivalent exposure times of 5.3 
s and 8.8 s, respectively. While both of these mobile-mode conditions yielded selective 
stratum corneum removal with little damage to deeper tissues, the stationary-mode 
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procedure caused extensive epidermal tissue damage. These different responses may 
be explained by the possibly stronger effects of continuous exposure for 6 s compared to 
intermittent exposure for a similar amount of time, but broken up into 30 or 50 segments.  
 
 
Figure 7.4. Effect of exposure time and vacuum pressure on removal of skin layers in monkeys. 
Brightfield images of H&E stained skin sections from biopsies obtained from an untreated control site (A), 
and sites exposed to stationary mode of microdermabrasion with 30 kPa vacuum pressure and exposure 
time of 3 s (B) or 6s (C), and 50 kPa vacuum pressure and exposure time of 3 s (D) or 6s (E). Solid line 
indicates intact stratum corneum and is drawn at the junction of the stratum corneum and the epidermis 




7.3.3 Mobile and stationary microdermabrasion in humans 
 To determine the applicability of these results in rhesus macaques to humans, 
we carried out an additional study of the mobile and stationary modes of 
microdermabrasion on the skin of human subjects. As compared to control skin (Figure 
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7.5 A), selective removal of stratum corneum was observed using a mobile tip at 40 kPa 
(Figure 7.5 B and C) and blisters were also sometimes seen (Figure 7.5 C). Because the 
IRB-approved protocol limited the maximum number of tip passes to seven and the 
vacuum pressure to 40 kPa, we used a slower speed of tip movement to increase the 
exposure time of microdermabrasion, which may explain the occurrence of microscopic 
blisters. However, this result validated the ability to selectively remove the stratum 
corneum in humans similar to that observed in monkeys. Inter-subject variability in full-
thickness stratum corneum removal was high and full-thickness removal of stratum 
corneum was observed in two of the six subjects. 
 Stationary microdermabrasion performed for 3 s at 30 kPa  produced 
microscopic blisters generally beneath intact stratum corneum (indicated by double-lined 
arrows in Figure 7.5 D) and at 45 kPa caused extensive removal of both stratum 
corneum and viable epidermis (Figure 7.5 E). Similar to the observation in monkeys, the 
stationary mode was unable to produce selective removal of the stratum corneum. 
Residual particles were also seen on the skin surface (indicated by single-lined arrows in 
Figures 7.5 D and E). 
 Despite the occurrence of microscopic blisters, the procedure was well tolerated 
by the subjects and no visible signs of damage were observed at the treated sites by 
study personnel. Mild erythema was often present, but no visible damage to the skin or 
bleeding was seen. 
 
7.3.4 Drug and vaccine delivery to monkeys 
 To test our hypothesis that full-thickness stratum corneum removal can enhance 
transdermal flux and enable epidermal vaccination, we measured the extent of topical 
delivery through dermabraded skin. Topical application of sodium fluorescein, a model 
fluorescent hydrophilic compound, on non-microdermabraded skin resulted in essentially 
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no detectable delivery across the stratum corneum (Figure 7.6 A). However, application 
to microdermabraded skin enhanced transdermal flux and delivered fluorescein deep 




Figure 7.5. Mobile and stationary mode of microdermabrasion in humans. Brightfield images of H&E 
stained human skin sections from biopsies obtained from an untreated control site (A), sites exposed to 
mobile mode of microdermabrasion with 40 kPa vacuum pressure and 7 passes (B and C), and sites 
exposed to stationary mode of microdermabrasion with an exposure time of 3 s and a vacuum pressure of 
30 kPa (D) and 45 kPa (E). Solid line indicates intact stratum corneum and is drawn at the junction of the 
stratum corneum and the epidermis layers, dotted rectangles indicate areas of complete stratum corneum 




 Topical application of MVA, which is a live attenuated virus that serves as a 
model vaccine, generated virus-specific antibodies measured in the blood after primary 
immunization (antibody titer: 530 ± 230, p>0.05) and a still greater response after the 
booster dose (antibody titer: 5300 ± 1800, p<0.05). This result demonstrates the ability 
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to deliver viral particles through microdermabraded skin that produce a significant 




Figure 7.6. In vivo delivery through dermabraded skin. Fluorescent images of skin sections obtained 
from sites topically perfused with a sodium fluorescein solution for 2 h, without microdermabrasion treatment 








7.4.1 Histological changes in skin layers 
 Despite widespread use of microdermabrasion in clinical practice, the 
microscopic changes in the skin that are caused by this procedure have not been 
studied in detail before. The few studies that have done histologic evaluation of skin after 
microdermabrasion have reported thinning of stratum corneum at the specific conditions 
tested (Shim, Barnette et al. 2001; Tan, Spencer et al. 2001). No previous study has 
documented that microdermabrasion can cause a range of skin tissue removal effects, 
including selective removal of full-thickness stratum corneum at some conditions and 
removal of the viable epidermis and formation of micro-blisters at other conditions.  
 In this study we performed a detailed histologic evaluation over a broad range of 
microdermabrasion parameters using the skin of monkeys and humans in vivo. In 
monkeys, 10 passes of microdermabrasion caused thinning of stratum corneum that 
rarely led to full-thickness stratum corneum removal. This observation is consistent with 
other reports in humans under conditions representative of conventional cosmetic 
microdermabrasion (Tan, Spencer et al. 2001; Karimipour, Kang et al. 2005), which 
typically involves just a few passes (Spencer 2005), although variations in vacuum 
pressure, microdermabrasion devices and tip designs, speed of tip movement and 
device operators complicate direct comparisons. For the first time, we have also looked 
at the effect of larger numbers of passes and have shown that selective full-thickness 
removal of stratum corneum can be achieved at both 30 and 50 passes. 
 The effects of microdermabrasion were found to be heterogeneous. Not only was 
there considerable inter-subject variability, but intra-subject variability was consistently 
seen at the micron scale. Heterogeneity was generally seen among the 30 consecutive 
sections collected within a 300 μm interval from each skin biopsy. This variability may be 
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explained by the stochastic process of particle flight and impingement with the skin 
during the microdermabrasion process. In human subjects, a greater variability in 
stratum corneum removal was observed. This variability may be due in part to the fewer 
(just 3 - 5) sections that were collected for analysis. Given the micron-scale 
heterogeneity associated with microdermabrasion, future histologic studies would benefit 
from analyzing a larger number of sections spanning a larger area of the biopsy. 
 Micro-blisters were sometimes observed after microdermabrasion, especially 
after stationary microdermabrasion. These micro-blisters may represent an early stage 
of suction blister formation, which is a well-established technique used to harvest 
epidermis for transplantation or to study inflammatory reactions and wound healing in 
skin (Gupta and Kumar 2000). Typically, about 40 kPa vacuum pressure is applied for 1 
- 3 h to create blisters measuring 10 - 30 mm in diameter to harvest the epidermis for 
grafting. 
 
7.4.2 Implications for transdermal drug delivery 
 Microdermabrasion has only recently been investigated for transdermal drug 
delivery. Previous studies have demonstrated transdermal flux enhancement only for 
very low molecular weight compounds <300 Da) under conditions that were not shown to 
remove full-thickness stratum corneum. To deliver larger molecules, biopharmaceuticals 
and vaccines, removal of full-thickness stratum corneum is probably required. Even 
small regions (e.g., microns) of full-thickness stratum corneum removal should have a 
large impact on skin permeability to macromolecules, which are of nanometer 
dimensions. Such micron-sized “leaks” in the skin barrier have been created using 
microneedles and shown to increase skin permeability by orders of magnitude 
(McAllister, Wang et al. 2003).  
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 In this study, we have shown full-thickness removal of stratum corneum from 
areas with characteristic dimensions of less than 100 μm up to approximately 1000 μm, 
which depended on microdermabrasion conditions. As a proof-of-concept that 
microdermabrasion makes skin permeable, we have dramatically increased transdermal 
delivery of a model drug, fluorescein, and demonstrated a heightened antibody response 
generated by a model live-virus vaccine. This is the first demonstration of delivery of a 
molecule larger than 300 Da in size and the first demonstration of delivery of a viral 
vaccine to generate an immune response by microdermabrasion. These results were 
enabled by using large numbers of microdermabrasion passes to remove full-thickness 
stratum corneum, which differs from previous work that has involved much fewer passes 
that only thinned the stratum corneum.  
 Overall, these results suggest that microdermabrasion under suitable conditions 
may be used as a skin pre-treatment followed by subsequent application of a 
transdermal patch to delivery drugs, biopharmaceuticals and vaccines. Because this 
process exposes the viable epidermis, gene delivery to epidermal keratinocytes may 
also be possible through direct application of cell transfection agents. 
 In a related process called microscission, microparticles were impinged on the 
skin using a high pressure carrier gas to create 50-200 μm deep microconduits in the 
skin (Herndon, Gonzalez et al. 2004). Microscissioning is similar to the stationary mode 
of microdermabrasion, but differs in the use of high-pressure gas rather than vacuum 
suction to propel the microparticles. Lidocaine delivery and glucose measurements from 
blood extracted through the microconduits were demonstrated. Because these 
microconduits were at least 50 μm deep, microscissioning may produce more deep-
tissue trauma than microdermabrasion with selective full-thickness stratum corneum 
removal. The microscissioning procedure was enhance through the additional use of 
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protective masks with micron-sized openings applied to the skin surface to control the 
diameter of the microconduits. This use of masks may also be useful as an adjunct to 
microdermabrasion in order to better control and localize the microdermabrasion effects 
to smaller skin areas for better cosmetic appearance and decreased tissue trauma. 
 
7.4.3 Implications for cosmetic use 
 Microdermabrasion is presently approved as a class I device by the FDA 
(Spencer 2005). As a result, phase III clinical trials demonstrating the safety and efficacy 
of microdermabrasion have not been done. Based on this study in monkeys and human 
subjects, it is expected that large numbers of passes in the mobile mode should be 
avoided to prevent full-thickness removal of stratum corneum and, possibly, deeper 
tissues. Small numbers of passes just removes partial-thickness stratum corneum, which 
has been documented by previous researchers as well (Karimipour, Kang et al. 2005; 
Spencer 2005).  
 The stationary mode of microdermabrasion should also be avoided, because of 
its tendency to form micro-blisters. Furthermore, topical creams and ointments for 
cosmetic or other purposes should be used with caution after microdermabrasion, 
because the stratum corneum thinning may enhance absorption of the topical 
formulations, leading to increased and possibly adverse effects. 
 
7.5 CONCLUSION 
 Motivated by the need to microscopically characterize the effects of 
microdermabrasion on skin and the goal to selectively remove full-thickness stratum 
corneum for transdermal drug delivery, we performed mobile and stationary 
microdermabrasion on the skin of rhesus macaques and human subjects in vivo. This is 
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the first detailed study to characterize the effects of microdermabrasion on skin over a 
broad range of microdermabrasion conditions. 
 In the monkeys, the degree of skin tissue removal increased with the number of 
passes in the mobile mode. At 30 and 50 passes, selective full-thickness removal of 
stratum corneum was observed with little damage to the viable epidermis. At larger 
numbers of passes, viable epidermis was removed. Using the stationary mode, selective 
stratum corneum removal was not achieved. Typically, either the stratum corneum and 
epidermis were both intact, with possible formation of micro-blisters at the dermal-
epidermal junction, or the stratum corneum and epidermis were both removed. Similar 
tissue removal trends were observed in human subjects using both the mobile and 
stationary modes of microdermabrasion. Finally, delivery of sodium fluorescein and an 
enhanced antibody response to MVA virus were demonstrated.  
 Thus, this study demonstrated for the first time that microdermabrasion can 
selectively remove full-thickness stratum corneum with little damage to deeper tissues 
and thereby enhance transdermal flux and enable epidermal vaccination. 
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CHAPTER 8: CONCLUSIONS 
 
 Majority of biopharmaceutical drugs and vaccines continue to be delivered by 
means of painful and potentially unsafe hypodermic injections. Although the transdermal 
route is attractive, the stratum corneum layer provides a formidable transport barrier and 
prohibits delivery of biopharmaceuticals via the skin. In this research we developed and 
characterized two different approaches, i.e., coated microneedles and 
microdermabrasion to facilitate painless transdermal delivery of biopharmaceuticals.   
  
Coated microneedles 
 Stainless steel was selected to fabricate microneedles because of its high 
mechanical strength and known history of use in medical devices. Based on laser cutting 
and electropolishing a versatile stainless steel microneedle fabrication process was 
developed. Using this process, microneedles with sharp tips, clean surfaces and 
complex geometries were fabricated. Novel pocketed microneedles, i.e., microneedles 
with through-holes in the shaft, were also fabricated. For convenient application of 
microneedle arrays on the skin, prototype microneedle patches with arrays of 
microneedles were developed. Pressure-sensitive adhesive was integrated on these 
patches to: (i) secure the microneedle patch on the skin and (ii) prevent the skin-pierced 
microneedles from regressing out of the skin due to skin recoil when the force used to 
apply the patch ceases to exist. 
 With the goal of optimizing microneedle geometry for minimal pain from insertion, 
we conducted a pain study in human subjects using microneedles of different 
dimensions and numbers. A 26-gage hypodermic needle inserted 5-mm deep into the 
skin was used as a positive control for comparison. Statistical comparison between all 
the different microneedle dimensions that were investigated (lengths as much as 1450 
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μm, widths as much as 465 µm, thicknesses as much as 100 μm and as many as 50 
microneedles in an array) showed that all microneedles were statistically less painful 
than the 26-gage hypodermic needle (outer diameter of 460 μm). In addition, many 
microneedle insertions were rated as entirely painless (as much as half the subjects 
scored the 480 μm long and 20° tipped microneedle as having zero pain) as compared 
to the hypodermic needles for which none of the subjects reported the insertions to be 
painless. Based on this study microneedle length was found to be the most influential 
factor affecting pain. A three fold increase in microneedle length produced more than a 
seven fold increase in pain. The numbers of microneedles was also significant in 
affecting pain, though less steeply. A ten fold increase in the number of microneedles 
from 5 to 50 increased the pain by just around two and half times. No statistically 
significant effect was observed due to change in tip angle, width or thickness over the 
range investigated. This study suggested that microneedle length and numbers are 
important parameters to optimize to obtain minimally painful microneedle devices for 
drug delivery. 
 To produce uniform coatings on microneedles without contaminating their 
substrate, a novel micro-dip-coating method was designed. The coating device primarily 
controlled the surface tension-driven rise of coating solution up the microneedle shafts to 
prevent contamination of the substrate. Based on this design, coating devices were 
fabricated to coat single microneedles, in-plane microneedles or out-of-plane 
microneedles. A coating formulation was also developed to achieve uniform films on 
microneedles. This formulation used low concentrations of carboxymethylcellulose and 
Lutrol F-68 NF as excipients to increase the viscosity and to decrease the surface 
tension of the coating solution, respectively. Using the coating devices and the coating 
formulation, vitamin B2, calcein, bovine serum albumin, and plasmid DNA were coated 
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onto microneedles. For the first time, organic and inorganic microparticles as well as 
viruses were also coated onto microneedles. This study demonstrated that a broad 
range of compounds could be coated on the microneedles. Assessment of the 
performance of coated microneedles showed that microneedle coatings dissolved within 
seconds after insertion into cadaver skin.  Successful in vitro delivery into skin was 
achieved for microneedles coated with microparticles up to 10 μm in diameter. Using 
novel ‘pocketed’ microneedles to mechanically protect coatings during insertion, 20-μm 
diameter particles were delivered into skin without wiping off onto the skin surface. 
Integrated patches containing 50-microneedle arrays were also shown to insert into the 
skin of human subjects and to deliver their coated payload into human cadaver skin. 
Collectively these results demonstrated that (i) microneedles coated with drug could be 
reliably inserted into the skin without drug wiping off on the skin surface, and (ii) the 
coatings rapidly dissolved off the microneedle surface after microneedle insertion into 
the skin. 
 A detailed study of coating formulations was performed to develop a rational 
basis for designing coating solution formulations for uniform and thick coatings on 
microneedles, and to identify coating strategies to form composite coatings, deliver liquid 
formulations, and control the mass deposited on microneedles. Recognizing that lower 
solution surface tension promotes good wetting of the microneedle surface, FDA-
approved surfactants, organic solvents, and microneedle surface modification methods 
were successfully tested to promote uniform coatings. Use of viscosity enhancers led to 
thicker microneedle coatings, promoted by increase in the volume of liquid film adhering 
onto the microneedles after dipping, and an increase in the residence time of this 
adherent liquid film on the microneedle. Control over coating solution surface tension 
and viscosity also enabled filling of pockets in microneedle with purely liquid or solid 
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films. Thus, control over the coating solution viscosity and surface tension enabled 
predictable uniform coating of microneedle surfaces and/or pockets. Furthermore, a 
hydrophobic molecule was also coated on microneedles using an ethanol-based 
formulation. Surfactants were not required in this case because ethanol already has a 
low surface tension. We further tested the ability to form multi-layered coatings, with 
each layer consisting of a different drug. Several different drug-layers were successfully 
coated on top of each other, including first filling pockets with drugs and then 
overcoating with another film. Such multilayered coatings can facilitate combination of 
burst and controlled release from the same microneedle. We also investigated 
quantitatively the mass of drug in microneedle coatings. The mass of a model drug, 
riboflavin, coated on microneedles was found to increase with its concentration in the 
coating solution, the number of coating solution dips, and the number of microneedles in 
the array. Based on this data, up to 1 mg of drug can be expected to be coated on a few 
hundred microneedles on a patch size of about 10 to 20 cm2. Altogether, microneedle 
coating formulations can be designed to have a range of different properties to address 
a variety of different drug delivery scenarios. 
 Finally, coated microneedle characterization was done in vivo by immunization of 
mice using hepatitis-C DNA coated microneedles. Antigen specific T-cell response was 
generated at low vaccine dose (3 to 8 μg) and without the use of adjuvants. Chromium 
release CTL assay demonstrated that the CTL response was robust in vitro. The in vivo 
tumor challenge assay demonstrated that the cytotoxic T-lymphocytes also had the 
ability to recognize and kill cells expressing the immunizing antigen in vivo. This study 
suggests that DNA-coated microneedles have potential to deliver DNA vaccines into the 






 Microdermabrasion has potential to selectively, yet completely remove the 
stratum corneum barrier for topical delivery of biopharmaceuticals. Motivated to 
determine the effect of different microdermabrasion conditions on skin and to identify 
conditions for full-thickness removal of stratum corneum, we performed 
microdermabrasion in vivo in human volunteers and monkeys. Using the mobile mode of 
microdermabrasion, the degree of removal of the stratum corneum and viable epidermis 
was found to increase with the number of passes. At 50 passes, selective removal of 
stratum corneum was observed with little damage to the viable epidermis. Quantitative 
measurement demonstrated that at 50 passes, at least 25% of the skin was devoid of 
stratum corneum, and much less of the skin had viable epidermis removed. Under the 
stationary mode, selective stratum corneum removal was not achieved but micro-blisters 
(separation of viable epidermis and dermis) were observed. Similar removal trends were 
observed in human subjects under both the mobile and the stationary modes of 
microdermabrasion.  Finally, delivery of sodium fluorescein and MVA virus was 
demonstrated after their topical application on microdermabraded skin. An antibody 
response was detected from the topical delivery of MVA. Thus, in this study, we 
demonstrated for the first time that microdermabrasion can be used to selectively 
remove the stratum corneum layer and also demonstrated the ability to deliver model 
hydrophilic compounds and virus through the microdermabraded skin. 
 
 Altogether, the coated microneedle and microdermabrasion studies have shown 
that both approaches can be used to target the skin for delivery of hydrophilic and large 
molecular weight compounds including proteins, DNA and viruses. More broadly, both 
coated-microneedles and microdermabrasion have the potential to enable painless 
transdermal delivery of biopharmaceuticals and vaccines in a convenient manner. 
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CHAPTER 9: RECOMMENDATIONS 
  
 Experimental results from this thesis research have demonstrated the ability of 
coated microneedles and microdermabrasion to deliver hydrophilic and large molecular 
weight materials in vivo. Microneedles coated with hepatitis C DNA were able to elicit 
strong T-cell responses in mice. In the case of microdermabrasion, a preliminary 
experiment with topical application of MVA on the skin of monkeys generated MVA 
specific antibodies. Based on these promising results and unpublished data, I believe 
that coated microneedles and microdermabrasion have potential to be developed as 
transdermal drug delivery methods for application in clinics or for self-administration. 
Specifically, both these methods have the ability to emerge as safer and largely painless 
vaccine administration methods suitable for mass immunizations. To fully develop each 
method for clinical use, I make the following recommendations. 
 
9.1 COATED MICRONEEDLES 
 
9.1.1 Advancement of microneedle fabrication and coating process 
9.1.1.1 Improvement in microneedle fabrication 
 In this study, microneedles were fabricated from stainless steel using laser 
cutting. Although laser cutting is very versatile, mass fabrication will be limited by 
availability of lasers. Because laser machines require large capital investment, other 
microneedle fabrication methods can facilitate inexpensive large scale fabrication of 
stainless steel microneedles. Wet etching of stainless steel is one such method. 
However, because wet etching of stainless steel, and other metals in general is isotropic 
in nature, fabricating microneedles with sharp tips may be difficult. Electrochemical 
etching enhances metal removal through use of electrical energy and provides a higher 
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degree of etch ratio (vertical to lateral etch depth). Therefore, I recommend that a 
process of electrochemical etching of stainless steel be developed to enable inexpensive 
mass fabrication of microneedles. 
 In this study, microneedles were manually bent out of plane of the metal sheet. 
However, I recommend that an automated mechanism should be developed to bend the 
microneedles out of their substrate to ensure reproducibility and to achieve vertical 
microneedles. 
 Metal microneedles have higher elastic modulus and are mechanically strong to 
pierce the skin. However, metal microneedles can still be misused for re-use, and also 
pose a disposal problem, though on a much smaller scale than hypodermic needles. 
Therefore, I recommend that alternative non-metallic materials, which are mechanically 
strong and easy to dispose, should be explored for microneedle fabrication for coating 
applications. An ideal case will be a material that dissolves in the skin along with the 
drug coated on its surface. 
  
9.1.1.2 Improvement in dip-coating 
 The microneedle dip-coating process and formulation guidelines developed in 
this research can allow coating of a broad range of drugs with different physicochemical 
properties. However, because the dip-coating devices were designed for manual dipping 
of microneedles into the coating solution, the average variation of the mass coated onto 
microneedles was 19% relative standard deviation. For many clinical applications this 
deviation must be decreased. Therefore, I recommend that the dipping process should 
be automated. This will improve coating reproducibility and lead to a tighter control on 
the mass coated on each microneedle array.  
  A further improvement to the dipping process can be made by modifying the 
coating solution holder. In its current design, the coating solution is filled into the coating 
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solution holder at the beginning of the coating process. Over time, during the coating 
process, the coating solution becomes concentrated due to solvent evaporation. 
Because small holes are used as individual dipping ports for microneedles, deposit of 
solute can start accumulating on the edges of the holes at high solute concentrations. 
Partly, this can be addressed by controlling the humidity and temperature of the coating 
environment. But a more thorough solution will require modification of the coating 
solution holder to incorporate either a gentle pulsatile movement of the fluid in the 
solution holder to enhance mixing without pushing the fluid out of the dip holes, or a 
continuous flow of the coating solution to prevent stagnation. The latter solution can also 
be designed to have provision for automated sampling and addition of new solution to 
compensate for evaporation. 
 
9.1.1.3 Prediction of mass in coatings 
 To control the mass of drug coated onto microneedles, various coating and 
microneedle parameters can be independently controlled. Because theoretical prediction 
of the mass coated onto microneedles is difficult, in this research, vitamin B2 was used 
as a model drug and its mass in the coatings was determined as function of coating and 
microneedle parameters. However, it is not practical to repeat mass characterization for 
all the different candidate drugs, especially for expensive biopharmaceuticals. Therefore, 
I recommend experiments should be performed to determine if mass in the coatings has 
a functional dependence on some measurable parameter(s) of the coating solution, for 
example molecular weight of the drug and/or its relative concentration in the coating 
solution.  When the dependence is identified, extensive data should be generated using 
model compounds and validated against a set of different compounds, including proteins 
and DNA. Results from these experiments will ultimately allow selection of coating and 
 
 161 
microneedle parameters required to produce coatings with a specified mass of drug in 
them. 
 
9.1.1.4 Assessment of coating safety prior to use in humans 
 Both CMC and F-68, the two commonly used excipients in this research, are 
approved by the FDA for parenteral injection. However, before coated microneedles can 
be used in humans, I recommend that the safety of the coatings should be evaluated in 
vitro and in vivo.  
 Some of the potential sources of concern that should be addressed are: thermal 
degradation of CMC and F-68 or other excipients during the autoclaving process; 
change in properties of drug molecules due to physical interaction between solutes and 
drug either in solution or after solidifying on the microneedle surface; long term stability 
of drug in the coatings; and pyrogenicity and irritation from coated microneedles. 
Appropriate in vitro and in vivo models should be used to address these concerns. 
 
9.1.1.5 Development of larger arrays 
 For delivery of compounds with dose in the range of few hundred micrograms, 
arrays with many hundred microneedles will be required. I recommend that research 
should be carried out in this direction to design and develop larger solid microneedle 
arrays. Corresponding modifications in the coating process and technique of array 
insertion into the skin will also need to be made. 
 
9.1.2 Application development 
9.1.2.1 Vaccination via regular antigens 
 I predict that the major impact of coated microneedles will be in the field of 
vaccination and delivery of biopharmaceuticals. I recommend that in vivo immunization 
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studies should continue to be performed to characterize the immune responses in more 
detail and to assess the long term stability of the coated antigens. Based on my 
experience, CMC and F-68 appear to be good excipients, and can be used to coat most 
antigens and DNA molecules, either for vaccination or gene therapy. 
 
9.1.2.2 Vaccination through antigens encapsulated in microparticles 
 Delivery of microparticles encapsulating antigen into the skin may allow 
combination of prime and boost effects into a single dose, eliminating the need for 
multiple doses of vaccines. In addition, microparticles can be designed to better interact 
with the Langerhans cells of the skin by controlling microparticle diameter, to produce a 
more robust immune response. Because, in this research we have already 
demonstrated the ability to coat microparticles onto microneedles and their subsequent 
delivery into the skin, I recommend that microparticle encapsulated antigen based 
delivery into the skin should be studied in greater detail. This method has potential to 
decrease the frequency of vaccine administration. 
 
9.1.2.3 Delivery of other compounds 
 Most compounds with a dose in the range of few hundred micrograms are 
available for delivery through coated microneedles. Biopharmaceuticals like growth 
hormones and peptides like desmopressin are few examples. Molten liquid formulations 
after melting the drug can also enable coating of pure drug onto microneedles, 
increasing the dose coated on a single microneedle. Further, pocketed microneedles 
provide a unique way to deliver difficult to coat materials like large particles and liquids, 
into the skin. All these techniques can be very useful and I recommend that effort should 





 Coated microneedles also offer some non clinical applications, for example, for 
tattoo formation. I hypothesize that microneedle length can be controlled to produce 
temporary or permanent tattoos. Shorter microneedle lengths because of shallow 
insertion and deposition into the epidermis may result in temporary tattoos because of 
clearance of the tattoo dye due to high turnover rate of the epidermis and the stratum 
corneum. I recommend testing of this hypothesis to ultimately develop self administrable 
temporary or permanent tattoos based on coated microneedles. 
 
9.2 MICRODERMABRASION 
 In this research, microdermabrasion was demonstrated to selectively remove the 
stratum corneum layer. I consider the main utility of this method to remove stratum 
corneum for subsequent transdermal patch application for controlled or bolus drug 
delivery. Because the stratum corneum will take a few days to grow back (maybe slower 
when it is occluded by the patch), drug delivery can occur for a longer duration. I 
recommend the following research direction for microdermabrasion. 
 
9.2.1 Process development 
9.2.1.1 Modeling of the microdermabrasion process 
 Microdermabrasion is a complex process with a number of different variables like 
particle flow rate, vacuum pressure and time of exposure. All these variables can 
independently affect the microdermabrasion process. It is important to identify which 
variables are most important in controlling the skin layer removal process and to identify 
the optimum numerical range of these variables in removing the stratum corneum 
without deeper damage to the skin. I recommend development of a detailed mechanistic 
model of microdermabrasion to aid in microdermabrasion process optimization. Such a 
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model can help guide the selection of optimum operating parameters and their levels. In 
this thesis a few parameters have been studied, however, a more detailed analysis is 
required to develop the model in detail. 
 
9.2.1.2 Decreasing heterogeneity 
 The microdermabrasion process resulted in heterogeneous tissue removal, even 
though the particle size was small compared to the treated skin area. Heterogeneity in 
stratum corneum and epidermis removal will cause variations in drug dose administered 
to different individuals. Therefore, I recommend that effort should be made to reduce the 
level of heterogeneity. One method to achieve this is by masking the treated skin with an 
abrasion-resistant mask containing smaller openings. This will allow small and targeted 
regions of the skin to be abraded. Further homogeneity can be achieved by 




9.2.2.1 Gene therapy, vaccination and biopharmaceutical delivery 
 I expect the greatest impact of microdermabrasion to be in the field of gene 
therapy and vaccination through topical delivery to the exposed epidermal keratinocytes. 
I recommend that in vivo experiments should be performed to investigate these 
applications in greater detail. In addition, biopharmaceutical delivery after 
microdermabrasion is another application with good clinical potential. Transdermal 
patches that control the release of biopharmaceutical compounds can be applied to 
microdermabraded skin. Therefore, I also recommend conducting in vivo 
pharmacokinetic studies after topical drug administration on microdermabraded skin. 
These studies can promote understanding of the change in plasma concentration 
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profiles, and to estimate the effective time for patch application before the skin starts to 
heal itself. Transepidermal water loss or skin electrical resistance measurements can 




APPENDIX A: PAIN STUDY – EXPERIMENTAL DETAILS AND PAIN DATA 
 
1) RANDOMIZATION  
 To obtain unbiased pain data, the sequence and location of insertion of different 
microneedles and controls was randomized for each human volunteer. The procedure of 
randomizations is described below: 
 
Insertion-sequence randomization: 
1. Each microneedle and control treatment, in triplicate, was given an identifier-label. 
These labels were then pre-arranged in a column in Microsoft-Excel. 
2. Random numbers, equal to the number of identifier-labels were then generated 
in an adjacent column. 
3. The two columns were next sorted in an ascending order based on the random 
numbers column. This sorting process arranged the random numbers in an 
ascending order, but led to a random shuffling of the identifier-labels column, 
resulting in a list of randomized insertion sequence. 
4. Steps 2 to 3 were repeated for each volunteer to generate different randomized 
insertion sequence lists for each volunteer. 
 
Insertion-location randomization 
 A random sequence was also generated to associate each insertion from the 
insertion sequence list to a unique but random location of insertion on the skin. 
1. A rubber stamp with grids of dots was stamped on the forearms of human 
volunteers. Each square that was formed between the dots was then assigned a 
unique address. The addresses were numbered 1 through 40 for stage-I of the 
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study (Figures A.1) and were given rectangular matrix addresses for stage-II of 
the study (for example, LA-1, LA-2, LA-3, RB-7 etc., Figure A.2). 
2. The addresses were then listed in a column in Microsoft Excel and steps 2 and 3 
of the insertion-sequence randomization process were performed to randomly 
shuffle the addresses. In this manner, randomized square-address lists were 
generated for each volunteer. 
 
 Thus, for each volunteer two randomized lists were generated, a randomized 
insertion sequence list and a randomized address list. Through a sequential pair-wise 
matching of the two lists, the sequence in which the different insertions were to be made 







1 2 3 4
5 6 7 8
9 10 11 12
37 38 39 40
13 14 15 16
17 18 19 20
21 22 23 24
25 26 27 28
29 30 31 32
33 34 35 36
 
Figure A.1. Dot pattern used in pain study stage-I. Design of the dots imprinted on the forearms of 
human volunteers in stage-I of the pain study. The address associated with each insertion square site is 
labeled. The numbers were not physically stamped and only served as a tool in randomizing the insertion 














Figure A.2. Dot pattern used in pain study stage-II. Design of the dots imprinted on the (A) left and the B) 
right forearms of human volunteers in stage-II of the pain study. The addresses associated with each 
insertion square site should be read as a matrix address. Example addresses are labeled as ‘LA-1’ and ‘LA-
2’ and the remaining addresses should be filled as a combination of the matrix column labels LA, LB, LC, 
RA, RB and RC, and the row labels 1 to 7. All dimensions are in mm. ‘Elbow’ and ‘Hand’ represent the 





2) DEPTH CONTROL OF HYPODERMIC NEEDLE 
 To reproducibly insert a 26 gage hypodermic needle 5-mm deep into the skin, a 
sleeve was fabricated that allowed just 5 mm of the hypodermic needle to protrude out 
(Figure A.3). The sleeve was fabricated by cutting an appropriate length of the tip of the 
protective sheath that encases a new hypodermic needle in its blister pack. 
 
 
Figure A.3. Depth control of a hypodermic needle. A 26 gage hypodermic needle protruding 5 mm from 
the sheath. The arrow points to the hypodermic needle hub inserted into the sheath. 
1 mm 
Depth control sleeve 
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3) RAW VAS PAIN SCORE 
 After each insertion of the microneedle or the control treatment, human 
volunteers rated the pain using a visual analog scale (VAS). The side of the scale visible 
to the human volunteers had “No pain” and “Worst pain” printed at its two ends and was 
fitted with a movable slider (Figure A.4 A). Human volunteers moved this slider between 
the two ranges based on their perception of pain after each insertion. The opposite side 
of the same scale was printed with a number scale (in millimeter units, Figure A.4 B), 
which the investigators used to numerically quantify the pain from each insertion. This 
numerical score was reported as the raw VAS pain score, and it was used for analysis of 
the pain as described in Chapter 3. Raw VAS pain scores of all the human volunteers 
from different microneedle and control treatments, in triplicate, for stages-I and -II are 
given in Tables A.1.A, A.1.B, A.2.A and A.2.B.  
 An example calculation to find normalized pain scores from triplicate raw pain 
scores is given in Table A.3. The table has four columns. The first column contains the 
labels of microneedles forming the ‘length study’ group. The second column contains 
their raw pain scores, the third column contains the average raw pain scores obtained as 
a mean of the triplicates for each microneedle length, and the fourth column contains the 
normalized pain scores obtained by dividing the mean raw pain scores of column three 
with the mean raw hypodermic needle pain score in the column and then multiplying with 
100.  The mean raw and normalized pain scores for all the ten subjects for the ‘length 




Figure A.4. Visual analog scale.  The two sides of the visual analog scale used to measure the pain 








Table A.1.A. Triplicate raw VAS pain scores for stage – I of the pain study (Volunteers 1 to 5). 
 












20°- 480μm - 1 0 0 5 5 0
20°- 480μm - 2 0 28 0 3 0
20°- 480μm - 3 0 25 0 9 0
20°- 960μm - 1 0 25 5 24 0
20°- 960μm - 2 0 18 0 3 0
20°- 960μm - 3 0 10 10 24 0
55°- 1450μm - 1 4 30 6 12 0
55°- 1450μm - 2 8 77 19 64 3
55°- 1450μm - 3 4 27 11 50 0
55°- 480μm - 1 0 0 10 2 0
55°- 480μm - 2 0 18 0 5 4
55°- 480μm - 3 0 0 0 2 0
55°- 700μm - 1 0 22 0 2 0
55°- 700μm - 2 0 0 15 7 7
55°- 700μm - 3 0 23 0 14 0
55°- 960μm - 1 6 28 5 6 21
55°- 960μm - 2 4 4 4 8 3
55°- 960μm - 3 2 51 8 45 8
90°- 480μm - 1 0 0 0 25 1
90°- 480μm - 2 4 25 8 0 0
90°- 480μm - 3 4 0 0 3 3
90°- 960μm - 1 3 49 4 9 5
90°- 960μm - 2 6 60 0 28 6
90°- 960μm - 3 0 32 60 3 0
Hypodermic - 1 6 84 10 60 46
Hypodermic - 2 7 40 73 55 20
Hypodermic - 3 9 53 84 49 46
Teflon rod - 1 0 0 0 0 0
Teflon rod - 2 0 0 0 0 0
Teflon rod - 3 0 0 0 0 0 
 
Note: Dimension pairs refer to microneedle ‘tip-angle in degrees’-‘length in microns’’. The trailing numbers -
1,-2 and -3 refer to triplicates for each insertion. Use Table 3.1 to determine the remaining microneedle 
dimensions and the appropriate groups for ‘Length study’ and ‘Tip angle study’. 
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Table A.1.B. Triplicate raw VAS pain scores for stage – I of the pain study (Volunteers 6 to 10). 
 
Skin insertion 












20°- 480μm - 1 4 0 0 0 0
20°- 480μm - 2 4 4 0 0 0
20°- 480μm - 3 3 2 0 0 0
20°- 960μm - 1 4 12 3 3 0
20°- 960μm - 2 4 28 6 0 0
20°- 960μm - 3 0 6 0 0 0
55°- 1450μm - 1 10 37 5 14 0
55°- 1450μm - 2 4 20 0 6 0
55°- 1450μm - 3 0 20 4 10 0
55°- 480μm - 1 9 0 4 0 0
55°- 480μm - 2 0 6 0 0 0
55°- 480μm - 3 3 2 0 0 0
55°- 700μm - 1 0 0 6 5 0
55°- 700μm - 2 8 0 0 0 0
55°- 700μm - 3 10 0 0 5 0
55°- 960μm - 1 4 0 4 0 0
55°- 960μm - 2 5 41 0 0 0
55°- 960μm - 3 12 23 3 5 4
90°- 480μm - 1 2 4 4 0 0
90°- 480μm - 2 0 0 0 0 0
90°- 480μm - 3 0 0 6 0 0
90°- 960μm - 1 0 7 0 0 0
90°- 960μm - 2 5 11 3 0 0
90°- 960μm - 3 10 9 3 0 0
Hypodermic - 1 35 84 10 15 20
Hypodermic - 2 72 75 5 28 36
Hypodermic - 3 52 30 11 35 8
Teflon rod - 1 0 0 0 0 0
Teflon rod - 2 0 0 0 0 0
Teflon rod - 3 0 0 0 0 0 
 
Note: Dimension pairs refer to microneedle ‘tip-angle in degrees’-‘length in microns’. The trailing numbers -
1,-2 and -3 refer to triplicates for each insertion. Use Table 3.1 to determine the remaining microneedle 
dimensions and the appropriate groups for ‘Length study’ and ‘Tip angle study’. 
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Table A.2.A. Triplicate raw VAS pain scores for stage – II of the pain study (Volunteers 1 to 5). 
 
Skin insertion 












Array 5 - 1 2 0 0 2 0
Array 5 - 2 4 0 0 4 12
Array 5 - 3 3 0 0 2 0
Array 50 - 1 3 0 0 2 11
Array 50 - 2 4 0 9 6 15
Array 50 - 3 7 0 0 7 17
Thick-100μm - 1 0 3 0 6 14
Thick-100μm - 2 3 3 8 39 9
Thick-100μm - 3 2 3 22 33 22
Thick-30μm - 1 2 4 0 35 40
Thick-30μm - 2 3 2 10 5 15
Thick-30μm - 3 0 3 28 19 15
Wide-160μm/Thick-45μm - 1 0 3 17 6 12
Wide-160μm/Thick-45μm - 2 2 3 0 4 0
Wide-160μm/Thick-45μm - 3 7 0 12 40 9
Wide-245μm - 1 0 3 35 6 27
Wide-245μm - 2 3 3 16 4 10
Wide-245μm - 3 2 0 6 39 10
Wide-465μm - 1 5 4 0 9 0
Wide-465μm - 2 2 4 0 0 9
Wide-465μm - 3 0 3 19 4 12
Hypodermic - 1 4 10 34 51 24
Hypodermic - 2 8 7 21 48 30
Hypodermic - 3 8 10 11 55 20
Teflon rod - 1 0 0 0 0 0
Teflon rod - 2 0 0 0 0 0
Teflon rod - 3 0 0 0 0 0 
 
Note: The trailing numbers -1,-2 and -3 refer to triplicates for each insertion. Use Table 3.1 to determine the 





Table A.2.B. Triplicate raw VAS pain scores for stage – II of the pain study (Volunteers 6 to 10). 
 
Skin insertion 












Array 5 - 1 0 4 4 0 0
Array 5 - 2 0 4 6 0 0
Array 5 - 3 8 0 0 0 0
Array 50 - 1 10 7 4 0 11
Array 50 - 2 19 8 6 0 0
Array 50 - 3 6 3 7 0 14
Thick-100μm - 1 0 9 6 0 15
Thick-100μm - 2 17 16 0 0 36
Thick-100μm - 3 12 3 8 6 0
Thick-30μm - 1 14 5 7 0 14
Thick-30μm - 2 6 0 6 3 15
Thick-30μm - 3 0 4 6 0 5
Wide-160μm/Thick-45μm - 1 0 7 0 5 18
Wide-160μm/Thick-45μm - 2 16 5 14 0 8
Wide-160μm/Thick-45μm - 3 0 14 6 0 15
Wide-245μm - 1 18 10 6 0 29
Wide-245μm - 2 7 9 6 0 19
Wide-245μm - 3 0 7 4 4 0
Wide-465μm - 1 0 9 8 0 9
Wide-465μm - 2 8 5 8 4 14
Wide-465μm - 3 9 9 8 0 9
Hypodermic - 1 26 28 22 6 74
Hypodermic - 2 27 20 16 11 58
Hypodermic - 3 31 29 8 0 15
Teflon rod - 1 0 0 0 0 0
Teflon rod - 2 0 0 0 0 0
Teflon rod - 3 0 0 0 0 0 
 
Note: The trailing numbers -1,-2 and -3 refer to triplicates for each insertion. Use Table 3.1 to determine the 






Table A.3. Typical calculation to determine mean normalized pain scores. 
 
  Subject 1A 
‘Length study’ 
group in triplicates 
Raw VAS 





55°- 480μm - 1 0     
55°- 480μm - 2 0     
55°- 480μm - 3 0 0.0 0.0 
55°- 700μm - 1 0     
55°- 700μm - 2 0     
55°- 700μm - 3 0 0.0 0.0 
55°- 960μm - 1 6     
55°- 960μm - 2 4     
55°- 960μm - 3 2 
Eg. (6+4+2)/3 = 
4.0
Eg. (4/7.3 x 100) = 
54.8 
55°- 1450μm - 1 4     
55°- 1450μm - 2 8     
55°- 1450μm - 3 4 5.3 72.7 
Hypodermic - 1 6     
Hypodermic - 2 7     
Hypodermic - 3 9 7.3 100.0 
Teflon rod - 1 0     
Teflon rod - 2 0     





Table A.4. Raw and normalized pain scores for ‘Length study’ group. 
 












































Subject 1A 0 0 0 0 4 55 5 73 7 100 0 0
Subject 2A 6 10 15 25 28 47 45 76 59 100 0 0
Subject 3A 3 6 5 9 6 10 12 22 56 100 0 0
Subject 4A 3 5 8 14 20 36 42 77 55 100 0 0
Subject 5A 1 4 2 6 11 29 1 3 37 100 0 0
Subject 6A 4 8 6 11 7 13 5 9 53 100 0 0
Subject 7A 3 4 0 0 21 34 26 41 63 100 0 0
Subject 8A 1 15 2 23 2 27 3 35 9 100 0 0
Subject 9A 0 0 3 13 2 6 10 38 26 100 0 0
Subject 10A 0 0 0 0 1 6 0 0 21 100 0 0





APPENDIX B: ELECTROPOLISHING PROTOCOL AND APPARATUS 
 
 Laser-cut microneedles were electropolished to remove slag and to sharpen the 
tips. The electropolishing apparatus for this purpose was designed and built in the 
laboratory, and the complete apparatus is shown in Figure B.1.  
 
Electropolishing protocol 
 Briefly, the protocol to electropolish an out-of-plane microneedle array is: 
1. Fill 250 ml of electropolishing solution in a 300 ml glass beaker by adding 150 ml 
glycerine, 25 ml DI water and filling with phosphoric acid up to the 250 ml mark. 
2. Place the beaker on the hot plate with the thermocouple dipped into the 
electropolishing solution and program the hot plate to heat the electropolishing 
solution temperature to 70 °C (Figure B.2) 
3. Place the copper cathode holder (Figure B.3 A) into the beaker by resting the 
cathode holder on the rails and screwing it in place (Figure B.2 and B.5). 
4. Clean the stainless steel sheet containing the laser-cut microneedles with 
powdered soap and water. 
5. Bend the microneedles out of the plane of the stainless steel sheet. 
6. Trim extra metal surrounding the arrays. 
7. Clamp the edge of the stainless steel sheet to the screw-and-plate clamp of the 
microneedle array holder as shown in Figure B.3 B and B.4. 
8. Place the microneedle array holder in the beaker filled with electropolishing 
solution, let the holder surface rest onto the rails as shown in Figure B.5, and 
withdraw the holder out. Measure the length and width of the stainless steel 
sheet wetted by the solution. 
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9. Find the wetted area by multiplying the wetted length and width in mm2. The 
current density required for electropolishing is 1.8 mA/mm2. Multiply the current 
density and the wetted area to determine the constant current required for 
electropolishing. 
10. Now place the microneedle array holder back into the beaker by letting its 
surface to rest on the rails. Attach the threaded connection between the 
microneedle array holder and the linear oscillator as shown in Figure B.5. Once 
both the cathode holder and the microneedle array holder are placed securely on 
the rails, they will be in close proximity as shown in Figure B.4. 
11. Start the linear oscillator by turning the power on to the power supply for linear 
oscillator (Figure B.1). 
12. Attach the positive lead of the electropolishing power supply (Figure B.1) to the 
microneedle array holder lead, and the negative lead to the cathode holder lead. 
13. Turn on the power supply for electropolishing and match the ammeter current 
reading to the current value required from step 9. 
14. Perform electropolishing for 15 min. 
15. Stop all power supplies, remove the microneedle array holder from the beaker 
and the rails, wash the microneedles thrice alternatively in 25% nitric acid and DI 
water stored in beakers, wash the microneedles under running hot water and DI 
water, dry the microneedles with pressurized air or nitrogen and store in air-tight 
containers. 
16. Repeat electropolishing for other arrays if required. A 250 ml beaker of 
electropolishing solution once prepared is good for electropolishing 4-5 stainless 




Figure B.1. Electropolishing apparatus. Photograph of the electropolishing apparatus showing all the 
components required for electropolishing. The beaker with the electropolishing solution is not shown but its 
expected location is marked with the dotted rectangle. Refer Figure B.2 for a close-up photograph of the 






Figure B.2. Electropolishing beaker on the hot plate. Photograph of the glass beaker containing 
electropolishing solution and resting on the hot plate. Thermocouple, cathode holder and the microneedle 
holder are shown resting on the rails and immersed in the electropolishing solution. The electropolishing 








Figure B.3. Cathode and microneedle holders. Photographs of (A) cathode holder and (B) microneedle 





Figure B.4. Orientation of microneedle arrays in the holder. Photograph showing the proper orientation 
of microneedle arrays after clamping to the microneedle-array holder. Microneedle arrays face the copper 
cathode and the arrays are bent at their flexible joint with the stainless steel sheet such that the 





Figure B.5. Joint between microneedle array holder and linear oscillator. Top view of the rails showing 
the cathode holder and the microneedle holder resting on the rails; and the screw joint between the 








APPENDIX C: DIP-COATING DEVICES 
 
 Novel dip-coating devices were designed and fabricated to form uniform and 
spatially controlled coatings on microneedles. Three different dip-coating devices were 
fabricated, the first to coat single microneedles (Figure C.1), the second to coat in-plane 




Figure C.1. Dip-coating device to coat single microneedles. Photograph of a dip-coating device to form 
coatings on single microneedles. A single microneedle is held on the sticky end of the cylindrical 
microneedle holder. The sticky end is formed by wrapping a double sided adhesive tape on one end of the 
cylindrical holder. At the opposite end of the device, a pipette tip filled with the coating solution is secured. 
The microneedle is then dipped in and out of the pipette tip while visually monitoring the movement under a 
stereomicroscope. Micron-scale control in the movement is achieved by the use of a micropositioner on 






Figure C.2. Dip-coating device to coat in-plane rows of microneedles. Photograph of a dip-coating 
device to coat in-plane rows. A row of microneedles is placed in a grove in the acrylic sheet and held in 
place with the aid of a tiny magnet located on the underside of the sheet. A 1-ml syringe is filled with the 
coating solution and attached to the dip-coating device to fill the coating solution reservoir. X, Y and Z 
micropositioners are next used to align the microneedles in the in-plane row to the dip holes in the coating 
reservoir. After alignment is achieved, the microneedle row is dipped in and out of the dip holes using the X-







Figure C.3 Dip-coating device to coat out-of-plane microneedle array . Photograph of a dip-coating 
device to coat out-of-plane arrays. Dip holes and the microneedle array holder are pre-aligned. A 1ml 
syringe is filled with the coating solution and attached to the coating solution reservoir to fill the reservoir. A 
microneedle array is placed on the microneedle holder where a magnet helps to keep the array secure. The 
angle plate on which the microneedle holder is mounted is then pulled down to dip the microneedles into the 
dip holes. Upon release of pressure to the angle plate, it moves up due to tension of the springs. The motion 
is repeated if multiple dips are required. The dip counter gets actuated each time the angle plate moves 
down because the magnetic switch gets actuated in the presence of the magnetic field generated by the 
magnet attached to the small cylindrical post fixed on the bread-board. This allows keeping track of the 
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